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General introduction
Chapter 1
9GENERAL INTRODUCTION TO THE TOPIC 
The liver is the largest solid organ in the human body and involved in multiple impor-
tant processes, such as metabolism of toxins and medication, synthesis of proteins and 
enzymes, and storage of glucose, vitamins, iron and copper.1 The liver is also the only 
organ with a self-regenerating capacity. In ancient Greek culture this feature was already 
recognized and appreciated in the mythological story of Prometheus; a titan who de-
fied the gods by stealing fire and giving it to humans. As a punishment, Zeus sentenced 
Prometheus to eternal torment. He was bound to a rock, where each day an eagle was sent 
to feed on his liver, which would then grow back overnight.2 
The regenerative capacity of the liver ensures that it can overcome many harmful stimuli, 
such as medication, infections and an occasional night of excessive alcohol use. However, 
upon severe, repeated, and prolonged injury the liver eventually gets damaged and scarred. 
This scarring, liver fibrosis, represents the aberrant wound healing process in response 
to persistent liver injury, and results in abnormal formation and deposition of connec-
tive tissue within the liver. The late state of fibrosis is called cirrhosis, in which normal 
hepatic architecture is distorted and regenerative nodules are formed.3 Liver fibrosis is the 
most important prognostic factor in patients with chronic liver disease as it determines 
morbidity and mortality. Patients with severe fibrosis and cirrhosis are at risk for severe 
complications such as portal hypertension with increased risk of variceal bleeding, hepatic 
encephalopathy and development of hepatocellular carcinoma.4 Causes of chronic liver 
disease and liver fibrosis are various, sometimes multi-factorial and include congenital, 
inflammatory, metabolic, and toxic aetiologies. 
MECHANISMS OF LIVER FIBROSIS 
Independent of the underlying aetiology, the formation of fibrosis is initiated and regulated 
by an interplay of multiple extracellular matrix (ECM) producing cells, with the myofibroblast 
as main driver.5 In the liver, the dominant source of myofibroblasts are the hepatic stellate 
cells (HSC), which are normally present in a quiescent state in the space of Disse, stor-
ing vitamin A in characteristic lipid droplets. When HSCs become activated (mainly upon 
inflammatory stimuli), they transform into proliferative and profibrogenic myofibroblasts, 
secreting large amounts of ECM (i.e. collagens, elastin and fibronectin). HSCs regulate deg-
radation and formation of these ECM by secretion of pro- and anti-fibrogenic cytokines and 
enzymes.6 A sustained pro-fibrogenic state leads to accumulation of ECM components, that 
mature, cross-link and distort normal liver parenchyma and vascular architecture.7 Fibrosis 
progression can escalate even when initial pro-fibrogenic stimuli are depleted, by a positive 
pro-fibrogenic feedback loop from the ECM itself.8, 9 On the other hand, fibrosis regression 
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is possible when pro-fibrogenic stimuli are withdrawn. In clinical practice, examples of 
regression are sometimes seen after treatment of underlying viral disease or cessation of 
alcohol intake.10, 11 Nonetheless, regression of fibrosis only seems possible when the point 
of no return has not yet been reached and it cannot be achieved in all patients. In which 
specific patients liver fibrosis has the ability to regress remains to be elucidated. 
DISEASE PHENOTyPES 
An estimated 844 million people worldwide have chronic liver disease, with a mortality 
rate of 2 million per year. Of all patients with chronic liver disease, 4.5-9% of patients has 
liver cirrhosis. While this could be an underestimation since most patients remain asymp-
tomatic for a long time, the risk of decompensation in cirrhotic patients is as high as 25%.12
There are many aetiologies that could lead to chronic liver disease. Viral hepatitis (B 
and C) has been the main contributor to severe liver disease in the past, but effective 
therapies will hopefully reduce morbidity and mortality in the near future.13 There are also 
auto-immune, cholestatic and drug-induced liver diseases. This thesis focuses on patients 
with non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) and Fontan-
associated liver disease (FALD), from which the phenotypes will be discussed below. 
NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease marked by lipid ac-
cumulation (steatosis).With 25% of the global population affected it is currently the most 
prevalent chronic liver disease, resulting in a tremendous global health burden.14 NAFLD 
is seen as the hepatic manifestation of the metabolic syndrome and is associated with 
obesity, metabolic syndrome and type 2 diabetes.15 Consequently, patients with NAFLD 
have an increased mortality risk, mainly from cardiovascular complications.16 NAFLD 
consists of a wide disease spectrum extending from bland steatosis to steatohepatitis 
(NASH). NASH is a risk factor for fibrosis and, depending on host related factors, may 
progress to cirrhosis, with risk of decompensation and hepatocellular carcinoma.17 
ALD
Alcoholic liver disease (ALD) is the result of excessive alcohol consumption, with hepatic 
manifestations including steatosis, inflammation and fibrosis. ALD is histological equiva-
lent to NAFLD with a similar pattern, only differing in the causal toxin, being alcohol.18 
Steatosis is seen in approximately 90% of heavy drinkers, of which a third will develop 
hepatic inflammation if they continue to drink. Also in ALD, steatohepatitis is the main 
risk factor for development of cirrhosis.19 Of all worldwide deaths attributable to liver 
cirrhosis, almost half result from ALD, representing 0.9% of deaths to any cause.20 
11
FALD
Fontan-associated liver disease refers to the spectrum of structural hepatic changes, seen 
in patients with a Fontan physiology.21 The Fontan procedure is performed in patients born 
with single-ventricle type congenital heart disease.22 The result of the Fontan procedure 
is an anastomosis between the caval veins and the pulmonary arteries, currently mainly 
performed using an extra-cardiac conduit (See Figure 1). Systemic venous blood is re-
turned to the lungs, bypassing the heart and preventing mixture with oxygen rich blood in 
the functional mono ventricle. Sufficient oxygen saturation in the systemic circulation is 
thereby secured, but since the use of a pumping right chamber is lost, a state of systemic 
venous hypertension and decreased cardiac output is induced.23 Since the first operation in 
the 1970s and several successful modifications, life expectancy of these patients improved 
significantly over the years, and most of them now reach adulthood.24 However, hepatic 
abnormalities are increasingly recognized in this population.25 Fibrosis is profoundly pres-
ent in the majority of these patients and multiple case reports of hepatocellular carcinoma 
in young adults have been published.26 
Figure 1.25 Subsequent modifications to the Fontan procedure are shown in panels A, B and C.
(A) Atriopulmonary connection: This depicts an anastomosis between the superior vena cava (SVC) 
and the right pulmonary artery (PA). Blood from the inferior vena cava (IVC) is baffled to the lungs by 
means of a patch to the pulmonary artery. (B) Lateral tunnel: Fontan with an intra-atrial conduit baffling 
blood from the inferior vena cava through the right atrium to the pulmonary artery. A bidirectional ca-
vopulmonary shunt carries blood from the superior vena cava to the pulmonary artery. (C) Extracardiac 
conduit: a cavopulmonary extracardiac conduit from the inferior vena cava to right pulmonary artery. 
The superior vena cava is anastomosed as a bidirectional cavopulmonary anastomosis. 
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EXTRA-HEPATIC RISK FACTORS FOR LIVER FIBROSIS 
Smoking
The mechanism of fibrogenesis in NAFLD is complex and still not clearly understood.27 
Advanced stages of NAFLD have been associated with risk factors such as diabetes, obesity 
and even smoking.28-30 In a large cohort study, long term smoking was significantly associ-
ated with the presence of advanced fibrosis, suggesting cigarette smoking may accelerate 
disease progression.30 However, it is not known to what degree smoking contributes to 
lobular inflammation, steatosis and hepatocellular ballooning in patients with NAFLD. 
Alcohol (cessation) 
The risk of liver damage from alcohol consumption is dose dependent in patients with al-
cohol abuse, but even when consumed in moderation, alcohol contributes to the progres-
sion of liver disease in patients with NAFLD.19, 31 Alcohol consumption in the European 
Union is the highest in the world, with an average of 27 g per adult per day, twice as high 
as the global average.32 Currently, advises on maximum intake of alcohol are becoming 
more stringent.33 Total cessation of alcohol consumption is a critical determinant in reduc-
ing mortality in alcoholic liver disease, especially when liver cirrhosis is already present.34 
However, the benefits of short-term abstinence remain largely intuitive, and scientific 
evidence of these benefits in non-dependent alcohol consumers without established liver 
disease is scarce.
Central venous pressure
The exact pathophysiology of FALD remains unknown, however similarities with that of 
congestive hepatopathy, seen in right-sided heart failure, exist.35 Due to its anatomical 
location, the liver suffers directly from elevated central venous pressure, resulting in in-
creased hepatic afterload and congestion.36 Venous congestion elicits sinusoidal dilatation, 
hepatocyte necrosis and initiates fibrogenesis, which could ultimately lead to cirrhosis, 
portal hypertensive complications and HCC.37 Also benign vascular or ”congestive” nod-
ules have been reported in these patients.38,39 It is unknown to what degree asymptomatic 
patients with a Fontan physiology have severe liver disease upon systematic screening, 
depicted by fibrosis, contrast-enhancing nodules and signs of portal hypertension. 
DIAGNOSIS AND EVALUATION OF LIVER DISEASE 
Liver biopsy
Liver biopsy is considered the gold standard for diagnosis and evaluation of severity of 
chronic liver disease. Especially in the staging of fibrosis, histological assessment of a 
13
liver biopsy specimen is key.40 The histological pattern of liver fibrosis can vary accord-
ing to aetiology, especially in the earlier stages of fibrosis.41 In viral hepatitis, fibrosis 
first becomes apparent around the portal triad and progresses by forming septa with a 
portal-to-portal bridging pattern. In alcoholic and non-alcoholic fatty liver disease fibrosis 
starts with a centrilobular or perivenular distribution and progresses along the sinusoids. 
Cirrhosis is in all cases characterised by extensive bridging between vascular structures, 
with subsequent transformation of normal lobular to pathological nodular architecture.42 
To aid pathologists in a systematic assessment of fibrosis and other histological features, 
multiple scoring systems have been developed over the years.41 Most of these scoring 
systems are disease-specific and stage fibrosis in four to six stages, roughly ranging from 
no fibrosis to mild, moderate, severe fibrosis (depending on the severity and pattern of 
bridging) and ultimately cirrhosis (See figure 2). Most of the scores have been developed 
for viral hepatitis (METAVIR, Ishak) and are widely used since.43, 44 From these, many other 
disease-specific scores have been derived. To systematically assess NAFLD, the NAFLD 
activity and fibrosis score can be used, which not only stages fibrosis, but also disease 
activity; by staging steatosis, inflammation and cellular ballooning.45,46 
Figure 2.41 Stage component of the Ishak system. *Proportion (%) of area of illustrated section show-
ing Sirius red staining for collagen (Collagen Proportionate Area). 
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Many of these semi-quantitative systems have been validated against clinical outcomes 
and have some predictive value in risk estimation of morbidity and mortality in patients 
with chronic liver disease.47,48 However, liver biopsies have many drawbacks.
LIMITATIONS OF LIVER BIOPSIES
Sampling error 
The premise of a liver biopsy is that it is able to obtain a cut of affected liver that is repre-
sentative for the pathology that actually affects the liver.49 A liver biopsy is pursued in the 
diagnostic trajectory of diffuse liver disease such as NASH or FALD with the assumption 
that the pathological lesions are distributed evenly within the liver. This is not always the 
case, as with NASH, areas of steatosis can be alternated with segments of non-steatosis.50 
In order to avoid sampling errors, a sufficient amount of liver tissue is necessary. In clinical 
practice the strategy is to use a thick needle and to perform multiple passes in order to 
collect samples with a sufficient length. Indeed, length of the biopsy and number of portal 
triads, determine the accuracy of the diagnosis.51 
Inter- and intra-observer variability
Inter- and intra-observer variability is key in the reliability of liver biopsy assessment as a 
diagnostic procedure. For example, consistency of fibrosis assessment among pathologists 
is acceptable in liver biopsy specimens of NASH patients, but the evaluation of inflam-
matory activity and hepatocyte ballooning is not.52, 53 Unfortunately, training does not 
improve inter-observer variability of histopathological observation.54 
This is partly due to the scoring systems used, which are ordinal and subjective (how 
much is much?). Digital image analysis, quantifying the amount of stained tissue (Sirius 
red stains collagen) or carrying specific features (steatotic cells) could be a solution. The 
Collagen Proportionate Area (CPA), quantifying fibrotic stained tissue digitally, becomes 
more and more integrated in research and clinical practice (See Figure 2).55 CPA de-
termines prognosis and predicts decompensation in chronic liver disease patients better 
than the semi-quantitative scoring systems.56 Steatosis assessment could furthermore be 
improved by a more quantitative approach.57 
Complications 
There is an inherent risk of complications following liver biopsy. Post-procedural pain is 
the most common finding and reported in 20% of patients depending on the definition 
used.58 The incidence of serious adverse events such as hospital admission, surgical or 
radiological procedures and mortality is lower but they do occur incidentally. Proper 
training and a higher level of experience reduce the risk of complications.59 In any case, 
15
the use of ultrasound to guide liver biopsies is helpful to mitigate the incidence of compli-
cations.60 The invasive nature makes liver biopsy an uninviting tool to monitor progression 
of chronic liver disease. 
Issues with pathological diagnosis 
The pathological diagnosis of liver disease is not straightforward. Diagnostic scores of 
most diffuse liver diseases include a number of variables that need to be recognized from 
examination of a tissue sample. For example, in case of NASH, features of typical NASH, 
such as steatosis , lobular cell inflammation, ballooning, Mallory-Denk bodies, pericel-
lular fibrosis, sinusoidal fibrosis, and giant mitochondria may not be present in all NASH 
patients and also occur in ALD.61 Features identified upon histopathological examination 
should always be interpreted in the light of clinical signs and symptoms to ascertain the 
diagnosis. 
NON-INVASIVE MARKERS 
As non-winvasive markers of liver disease severity are increasingly developed, validated 
and refined in the management of diffuse liver diseases, in particular NASH, it is unclear 
whether the advantages of obtaining a liver biopsy still outweigh the disadvantages. The 
most relevant parameter that bears prognostic value is fibrosis and the non-invasive as-
sessment of liver fibrosis is rapidly evolving.62 Non-invasive alternatives for assessment of 
fibrosis severity can be broadly categorized in (1) serum biomarkers, (2) combined scores 
and algorithms and (3) imaging techniques. 
Serum biomarkers
Sole liver biochemistry values do not predict severity of fibrosis. Hence, alternatives have 
been sought in markers that reflect fibrogenesis better. Available panels can be roughly di-
vided in those using direct and those using indirect biomarkers. Direct markers of fibrosis 
include enzymes or peptides reflecting collagen synthesis or collagen degradation. More 
routine blood tests reflecting alterations in liver function are being used as indirect mark-
ers of fibrosis, but do not directly represent extracellular matrix metabolism. Advantages of 
biomarkers include their high applicability, reproducibility and availability. However, they 
are never liver specific, can be influenced by other inflammatory processes and are often 
expensive.62 Lastly, it remains difficult to discriminate intermediate stages of fibrosis and 
validation in liver diseases other than viral hepatitis and NAFLD is warranted.  
16
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Scores and algorithms
Next to serologic panels, scores and algorithms that incorporate clinical data are emerg-
ing, especially in the NAFLD field. Many of these scores are based on indirect serum bio-
markers, such as alanine aminotransferase, aspartate aminotransferase, and platelets with 
age and BMI. The advantages are the low cost (of non-patented scores) and applicability, 
even for general practitioners and screening purposes. However, caution is warranted 
in the interpretation of a “positive” test result, as the cut-offs of these scores have been 
established by association to fibrosis staging, bypassing many important confounders.63 
Imaging techniques
Most imaging techniques are based on the rationale that increased liver stiffness or de-
creased elasticity corresponds to increasing severity of liver fibrosis. This is correct to a 
certain degree, but liver stiffness is also influenced by inflammation, congestion, steatosis 
and confounded by extra-hepatic fat content, presence of ascites or even food-intake 
shortly prior to measurement. Available techniques include 1-dimensional transient 
elastography, point or 2-dimensional shear-wave elastography and magnetic resonance 
elastography. Ultrasound techniques require proper training and experience to reduce 
intra- and interobserver variability. MR-elastography is expensive, difficult to conduct and 
is therefore predominantly applied in a research setting.64 
Non-invasive steatosis measurement
In NAFLD, severity of steatosis is increasingly being measured with non-invasive tech-
niques in addition to fibrosis. Several imaging techniques, such as specific types of mag-
netic resonance imaging (MRI-PDFF) and elastography (MRE or controlled attenuation 
parameter on Fibroscan) are quite successfully developed to quantify and stage steatosis. 
MRI techniques are probably more reliable than current histological steatosis assessment 
due to their quantitative nature.65 Nevertheless, availability, complexity, and expenses of 
MRI forestall broad application in clinical practice and usability as a screening tool in the 
rapidly expanding population of patients with NAFLD. 
17
THIS THESIS
This thesis focuses on contribution of several extra-hepatic risk factors to severe liver 
disease and fibrosis (part I), and on measures to improve diagnosis and evaluation of liver 
disease (part II). 
Clinical course and progression to severe liver fibrosis and cirrhosis remain difficult 
to predict in patients with chronic liver disease, as fibrogenesis is multi-factorial and 
patient characteristics, environmental influences and extra-hepatic stimuli contribute to 
progression. Clinical decision making is further hampered by the difficulties that arise 
from accurately diagnosing liver disease and evaluating its severity. Therefore, the main 
goals of this thesis were: 
(1) To better understand the contribution of Fontan physiology, smoking and cessation of 
alcohol on severity of liver disease.
(2) To improve the evaluation of liver fibrosis and steatosis in patients with NAFLD or FALD. 
To answer our research questions we used the following study designs: 
1. Cohort study with: 
 a. Human data (chapter 2, 3, 4) 
 b. Liver tissue data (chapter 2, 3, 6-8)
 c. Non-invasive biomarker data (chapter 2, 4, 8)
2. Intervention study (chapter 4) 
3. Systematic Review (chapter 5) 
Table 1 summarizes the addressed research questions per chapter, with the design and 
measures used to achieve this. 
18
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Table 1. Main research questions and methodology addressed in chapters of this thesis
Part I Contribution of extra-hepatic risk-factors to severe liver disease
Chapter Research question Study design Measures
2. -What is the spectrum of FALD?
-Which non-invasive measures 
correlate with histological fibrosis 
severity in this population? 
Prospective cross-
sectional patient 
cohort 
-Liver histology grading
-Blood panel (incl. 
fibrosis biomarkers) 
-Imaging (US/CT/MRI/
TE)
3. Is smoking correlated to severity 
of disease activity and fibrosis in 
patients with NAFLD? 
Retrospective cross-
sectional patient 
cohort 
-Liver histology grading
-Smoking history
4. Does one month of alcohol 
abstinence improve liver health in 
moderate consumers?
Clinical intervention 
study (1 month 
alcohol abstinence) 
with control group 
(abstainers) 
-Pre- and post- 
interventional measures: 
-Liver biochemistry, US 
and TE 
Part II Improving evaluation of liver disease
Chapter Research question Study design Measures
5. What are common components in 
histological assessment of FALD?
Systematic review of 
literature
-Systematic literature 
search (PRISMA)
-Qualitative data 
synthesis 
6. Which ECM components are related 
to inflammation and fibrosis severity 
in NAFLD?
Cross-sectional cohort 
of human liver tissue 
-Liver histology grading
-IHC & enzyme activity 
assays 
7. Does our developed DIA algorithm 
accurately and automatically 
quantify hepatic steatosis on 
histological whole slide images?
Cross-sectional cohort 
of scanned liver tissue 
slides 
-Development 
algorithm: logistic 
regression analysis 
-Validation to histology 
grading
8. Can CAUS accurately assess 
steatosis, compared to histology as 
reference standard? 
Cross-sectional cohort 
of paired US images 
and liver biopsies
-CAUS methodology
-Validation to liver 
histology grading
FALD: Fontan-associated Liver Disease. NAFLD: non-alcoholic fatty liver disease. US: ultrasound. CT: 
computer-  tomography. MRI: magnetic-resonance imaging. TE: transient elastography. ECM: extra-cel-
lular matrix. IHC: immuno-histochemical staining. DIA: digital image analysis. CAUS: Computer-aided 
ultrasound. 
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ABSTRACT
Aims
Liver fibrosis and cirrhosis are a consequence of a Fontan physiology, and determine 
prognosis. It is unclear whether non-invasive assessment of liver pathology is helpful to 
provide clinically relevant information. The aims of this study were to assess the spectrum 
of Fontan-associated liver disease (FALD) and usefulness of non-invasive methods to as-
sess biopsy confirmed liver fibrosis. 
Methods 
Hepatic screening of consecutive patients consisted of a blood panel, ultrasonography, 
elastography, contrast-enhanced MRI/CT, and liver biopsy (scored with Fontan specific fi-
brosis scores and collagen proportionate area; CPA). Fibrosis parameters, varices, ascites, 
and splenomegaly were measured on imaging. 
Results
38/49 referred patients (27 ± 6.6 years, 73.7% male) underwent the complete screening 
protocol. Liver fibrosis on biopsy was present in all patients, and classified as severe (stage 
3-4) in 68%. Median CPA was 22.5% (16.9-29.5) and correlated with individual fibrosis 
scores. ELF® and liver stiffness were elevated, but MELD-XI scores were low in all patients. 
Fibrosis severity neither correlated to ELF® and liver stiffness, nor to (semi-) quantitative 
fibrosis parameters on MRI/CT. Varices were present in 50% and hyper-enhancing nodules 
in 25% of patients, both independent of fibrosis stage, but varices were associated with 
higher CPA values.
Conclusion
The FALD spectrum includes both hepatic congestion and severe fibrosis, with signs of 
portal hypertension and hyper-enhancing nodules as significant manifestations. Routine 
imaging, transient elastography and serum biomarkers are unable to accurately assess 
severity of liver fibrosis in this cohort. Future research should focus on validating new 
diagnostic tools with biopsy as the reference standard. 
29
INTRODUCTION 
Structural hepatic changes are a recognized complication after palliative Fontan surgery 
of patients with severe congenital heart disease.1, 2 The Fontan procedure establishes a 
unique hemodynamic physiology, resulting from a direct conduit between caval veins and 
pulmonary arteries.3, 4 As a consequence, caval pressure rises resulting in elevated hepatic 
afterload, liver congestion, and increased risk of liver fibrosis.5 
Multidisciplinary consensus recommends hepatological evaluation of patients for 
Fontan-associated liver disease (FALD), however specific guidelines how to commence 
screening are lacking.8 Since liver fibrosis is mostly asymptomatic, clinical history and 
physical examination are of limited value. As in many other chronic liver diseases routine 
liver biochemistry is inaccurate to quantify Fontan-associated liver fibrosis.9-11 Several 
non-invasive tools, such as transient elastography and fibrosis biomarkers have gained 
traction to diagnose and quantify fibrosis, but have only been evaluated to a limited extent 
in this population.12-14 A liver biopsy is considered to be the gold standard for staging of 
hepatic fibrosis, and is used as the reference standard method in evaluations of biomarkers 
and non-invasive markers of liver fibrosis. However, biopsies are invasive and carry a 
certain risk of complications, in particular bleeding.16 The exact bleeding risk is unknown, 
but could be high in the Fontan population in view of the frequent use of anticoagulants.17 
There are a number of studies that have evaluated the extent of liver disease in this popula-
tion but they are hampered by retrospective design, selection bias, or the absence of 
histology as reference standard.7, 12-14, 18-24 It is unclear which investigations contribute to 
true prognostic information that changes clinical management and outcomes. 
The aims of this study were (1) to assess the clinical spectrum of FALD including 
signs of portal hypertension and hepatic nodules in asymptomatic patients with a Fontan 
physiology, and (2) to examine the usefulness of serum and image-based fibrosis markers 
to assess fibrosis, in comparison to liver biopsy as the reference standard. 
METHODS 
Study population
All consecutive patients (18 years or older) with a Fontan physiology, monitored at the 
congenital cardiology department of the Radboud university medical centre were referred 
to the hepatology department for a prospective screening programme for liver disease. In-
clusion took place from November 2015 to September 2017. The screening protocol con-
sisted of routine biochemistry testing, VO2max exercise test, cardiac and liver ultrasound, 
transient elastography, advanced imaging of the liver with MRI or CT, and liver biopsy (See 
take home figure). Patients were required to consent for the individual procedures. All pro-
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cedures were performed on the same day, while the liver biopsy procedure and advanced 
imaging were performed within a range of three months. Data from clinical evaluations 
was collected through chart review. The study was approved by the institutional review 
board of the Radboud university medical centre (no. 2015-2132). 
Clinical evaluation 
All patients were simultaneously clinically evaluated at the departments of Hepatology 
and Cardiology. Patients were evaluated for risk factors for liver disease such as alcohol 
and drug use. Physical examination included hemodynamic parameters and signs of 
Fontan failure or liver disease such as peripheral edema, ascites, spider naevi, palmar 
erythema, and jaundice. Patients underwent cardiac ultrasonography, visually assessing 
global ventricle function, and a VO2 max test. 25, 26
Liver biopsy and histological assessment 
Ultra-sound guided percutaneous liver biopsy (16G, true-cut or suction biopsy) was per-
formed under conscious sedation by experienced hepatologists (ET, JD). Liver tissue slides 
were stained with hematoxylin-eosin, elastica-Van Gieson, and picrosirius red. Slides 
were evaluated independently by two liver pathologists experienced in vascular liver 
disease (CB, TK). Adequate biopsy samples were defined as length ≥ 2cm and the presence 
of ≥ 11 portal tracts. Three fibrosis scores, previously reported to assess Fontan-associated 
liver fibrosis, were assessed: Gross architectural distortion score,19 scoring overall fibrosis 
distribution and architectural changes (ranging 0-4); A four component score,20 scoring 
portal fibrosis (0-4), sinusoidal fibrosis (0-4), sinusoidal dilation (0-3), portal inflammation 
(0-3); and the congestive heart failure fibrosis score (CHFS; 0-4).27 See supplementary files 
for exact description of scores. 
To obtain a comprehensive overview of total amount of fibrosis present, the percent-
age of total tissue area occupied by collagen (picrosirius red stain) or so-called collagen 
proportionate area (CPA) was calculated, as described before.28 Steatosis was assessed 
with NAFLD activity score (0-3).29
Laboratory evaluation
Laboratory testing included routine liver biochemistry (alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), alkaline phosphotase (ALP), gamma-glutamyl transfer-
ase (GGT), total bilirubin, and liver function tests (INR or prothrombin time, platelets, and 
albumin). Hepatitis B and C serology was tested. A commercial panel of direct fibrosis 
markers was assessed (Enhanced Liver Fibrosis Test®, Siemens, the Netherlands) consist-
ing of hyaluronic acid, PIIINP, and TIMP-1. The score has a cut-off of ≥ 7.7 for the presence 
of fibrosis.30 Furthermore the APRI, an indirect fibrosis score was calculated from AST and 
platelets.31 Von Willebrand factor (vWf) and VITRO score (VWF/platelet ratio), as surrogate 
31
markers for portal hypertension, were measured.32, 33 MELD-XI score (developed to assess 
end-stage liver disease in patients on anticoagulants by excluding INR) was calculated.34 
Liver ultrasonography and transient elastography 
Dedicated liver ultrasonography (Hitachi Preius TM) was performed, and evaluation 
focused on aspect, pattern of parenchyma and liver surface, assessment of focal lesions, 
presence of ascites, and spleen size. Standardized Doppler flow measurements were 
performed on inferior caval vein (diameter, respiratory variability), hepatic veins (diam-
eter, flow pattern), portal vein (flow direction and flow velocity), and hepatic artery (peak 
systolic flow velocity, end diastolic flow velocity, and resistance index).
Liver stiffness (in kPa) was measured by transient elastography with Fibroscan 502®, 
assessing the median of ≥10 measurements with an interquartile range/median ≤ 30%. 
Spleen diameter (mm) and platelet count were incorporated in the platelet/spleen ratio, 
with a proposed cut-off of <909 for identification of patients at risk for presence of clini-
cally relevant portal hypertension.35
Advanced imaging 
A contrast-enhanced MRI was performed (Dotarem®; gadoterate meglumine contrast, 
Siemens, 3 tesla), or in case this was not possible a multiphase liver CT-scan (iodinated 
contrast, Toshiba, slide thickness 5 mm). For clinical CT and MRI protocols see supplemen-
tary methods. Liver radiologists and a specialized vascular liver radiologist (MR) assessed 
and semi-quantitatively scored imaging characteristics of fibrosis and portal hypertension: 
liver nodularity and dysmorphy, size of liver segment 1 and 4, ascites, splenomegaly, and 
varices. Ascites was defined as the presence of any amount of free fluid in the peritoneal 
cavity. Splenomegaly was defined as a spleen diameter > 12 cm. Spleen diameter was 
calculated as the largest spleen bipolar diameter at the splenic hilum. Varices were de-
fined as the presence of dilated vessels (regardless of the size) in one of the 5 territories 
of porto-systems shunting, i.e. gasto-esophageal, spleno-renal, para-umbilical or parietal, 
mesenteric or peri-rectal, and retroperitoneal. Discrimination with systemic-pulmonary 
shunts was made following the different pathways.
A combination of liver peripheral atrophy with hyper signal intensity on T2-weigthed 
imaging and delayed enhancement (short ‘periphery’) and subcapsular intermingled 
enhanced septa (short ‘reticulation’) were scored on MRI. Apparent diffusion coefficient 
(ADC) and relative enhancement ratio (RER) were calculated on diffusion-weighted imag-
ing, as a modification of methodology described before (see supplementary methods).36 
All focal liver lesions were described and when larger than 10 mm scored on the following 
characteristics: signal T1 and T2 intensity, diffusion-weighted intensity, intensity on differ-
ent contrast-enhanced phases, washout, fat content, capsule formation, and central scar. 
Alpha-fetoprotein (AFP) was measured in patients with focal liver lesions. 
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Statistical analyses 
Continuous data are presented with mean and standard deviation (±SD), nominal data as 
count (n) and percentage (%), and ordinal or not normally distributed data with median 
and interquartile range (25th-75th percentile). Independent t-test, or non-parametric tests 
where applicable, were used to compare continuous variables. Chi-Square test was used 
to compare categorical variables and Mann-Whitney U test for ordinal variables. Correla-
tions were tested with Pearson’s correlation coefficient or Spearman’s Rho, depending 
on the level of measurement. A two-sided level of p < 0.05 was considered statistically 
significant. All statistical analyses were carried out using SPSS software (version 22; SPSS 
Inc., Chicago, Illinois, USA).
Take home figure. Prospective multimodality assessment of Fontan-asociated liver disease. 
RESULTS
Clinical characteristics 
A total of 49 patients with a Fontan physiology was referred for simultaneous cardiac and 
hepatologic screening. Eleven patients refused biopsy, so they were excluded from further 
analyses. The cohort consisted of 38 patients, prospectively assessed with the multimodal-
ity approach (see Figure 1). Mean age at time of screening was 27 ± 6.6 years, with 74% 
males. Average time after completion of the Fontan circulation was 21.4 ± 5.5 years. For 
all characteristics see Table 1. 
33
Based on cardiac ultrasound assessment, 21 (55%) of patients had good systolic 
function of the systemic ventricle, 15 patients (40%) had mild dysfunction and two (5%) 
moderate dysfunction.25 
The majority of patients were classified as NYHA I (90%) or NYHA II (10%). All patients 
had regular physical activity, but the mean VO2max, as a marker of exercise tolerance, was 
25.2 ± 5.8 ml/kg/min corresponding with 56 ± 12% of age and gender matched healthy 
individuals.26
Patients had a median BMI of 22.2 (20.3-24.6) kg/m2 and a median alcohol consump-
tion of 1 (0-4) units/week. None tested positive for hepatitis B or C. Physical examination 
of patients did not reveal any signs or symptoms suggestive for chronic liver disease. All, 
but one patient, were treated with anti-thrombotics. Eleven patients (29%) used platelet 
aggregation inhibitors, while 26/38 used oral anticoagulants (23/26 coumarin derivatives 
and 3/26 Direct Oral Anti-Coagulants). 
s   r i  ltr s  ss ss t,  ( ) f ti ts   s st li  
f ti  f t  s st i  tri l ,  ti ts ( )  il  sf ti   t  ( ) 
r t  sf ti .25 
 j rit  f ti ts r  l ssifi  s  I ( ) r  II ( ). ll ti ts 
 r l r si l ti it , t t   2 , s  r r f r is  t l r , s 
.   .  l/ / i  rr s i  it     f   r t  lt  
i i i ls.26
ti ts   i  I f .  ( . - . ) / 2   i  l l s -
ti  f  ( - ) its/ .  t st  siti  f r titis  r . si l i ti  
f ti ts i  t r l  si s r s t s s sti  f r r i  li r is s . ll, 
t  ti t, r  tr t  it  ti-t r ti s. l  ti ts ( ) s  l t l t 
r ti  i i it rs, il  /  s  r l ti l ts ( /  ri  ri ti s 
 /  ir t r l ti- l ts). 
 
PatientsÊreferredÊforÊhepatologicÊandÊcardiacÊ
screeningÊ(nÊ=Ê49)Ê
LiverÊbiopsyÊperformedÊ
(nÊ=Ê38)Ê
PatientsÊunableÊtoÊ
undergoÊbiopsyÊ
(nÊ=Ê11)Ê
UltrasoundÊÊ (nÊ=Ê38)ÊÊ
LaboratoryÊÊ (nÊ=Ê37)ÊÊ
FibroscanÊÊ (nÊ=Ê36)Ê
ELFÊÊ Ê (nÊ=Ê35)ÊÊ
MRIÊÊ Ê (nÊ=Ê30)Ê
CTÊÊ Ê (nÊ=Ê8)ÊÊÊ
Ê
Figure 1. Flowchart of number of patients referred for hepatological screening and actually screened 
by the several modalities incorporated in screening. 
Fig re . Fl c art f er f atie ts referre  f r e at l gical scree i g a  act ally scree e  
y t e several alities i c r rate  i  scree i g. 
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Table 1. Patient characteristics 
Demographics
Female gender 10/38 (26%)
Age (years)  27 ± 6.6
Body mass index (kg/m2) 22.2 (20.3-24.6) 
Congenital main diagnosis
Atresia (pulmonary/tricuspidal) 18/38 (47%)
Double-inlet Left Ventricle 11/38 (29%)
Other* 9/38 (24%)
Type of Fontan procedure 
Atriopulmonary connection 14/38 (37%)
Lateral tunnel 7/38 (18%)
Extracardiac conduit 15/38 (40%)
Kawashima, secondary connection liver veins to pulmonary system 2/38 (5%)
Age at Fontan procedure (years) 5.0 (3.0-6.3)
Fontan duration (years) 21.4 ± 5.5
Medication 
Oral anticoagulants Ɨ 26/38 (68%)
Hepatotoxic medication † 1/38 (3%)
Legend: Data are presented as mean (SD) or median (IQR) for continuous variables and as n, % for 
categorical variables. * Other cardiac main diagnosis include: hypoplastic left heart syndrome (n=4), 
double-inlet right ventricle (n=2), double-outlet right ventricle (n=2), left isomerism with univentricular 
heart (n=1). Ɨ used anticoagulants are acenocoumarol (n=17), fenprocoumon (n=6), Direct Oral Anti-
Coagulant (n=3) † one patient used amiodaron and quinapril.
Liver histology 
All patients underwent percutaneous liver biopsy without any complications defined as 
severe pain, bleeding, or any cause that required prolonged admission, additional diag-
nostic procedures, or treatment. Antithrombotic or anticoagulant medication could be 
temporarily interrupted without bridging. No thrombotic events occurred. 
All biopsies were of sufficient quality. There was substantial interobserver agreement 
on portal fibrosis score between both pathologists (kappa=0.747, 95% CI: 0.615-0.879), 
but not on sinusoidal fibrosis score (kappa=0.104, 95% CI: -0.226-0.434). 
The median gross architectural distortion score was 3 (2-4). Median score for portal 
fibrosis was 2 (2-4) and for sinusoidal fibrosis 2 (1-2). Median CHFS was 3 (2.75-4). Eleven 
(29%) of patients had stage 4; cirrhosis, on all three scores. There were no patients without 
fibrosis on any of the scores (Figure 2A). Median sinusoidal dilatation was 1 (.75-2) and 
median portal inflammation score was 0, with only three patients classified as mild to 
moderate inflammation (score 1-2). Steatosis was absent from all biopsies. Median collagen 
proportionate area (CPA) was 22.5% (16.9-29.5). CPA correlated with overall architectural 
distortion score (Rs=0.457), portal fibrosis score (Rs=0.524) and CHFS score (Rs=0.419; 
35
Figure 2. FALD histology 
Panel A: Distribution of liver histology scores 
Panel B: histological images of key pathological features of FALD 
Legend: 2A: Distribution of the assessed histological scores is displayed on the X-axis, with percentages 
of the scoring stages depicted on the Y-axis. 
2B: Exemplary photographs of histological slides from patients with FALD, were taken with a camera 
attached to a microscope and processed in a digital image analysis programme. Panel 1: mild sinusoidal 
dilatatation (stage 1). Hematoxylin-Eosin stain, objective lens 10x. Panel 2: severe sinudoidal dilatation 
(stage 3). Hematoxylin-Eosin stain, objective lens 10x. Panel 3: mild sinusoidal fibrosis, with character-
istic chicken-wire pattern of staining along the dilated sinudoids. Sirius Red stain, objective lens 20x. 
Panel 4: close-up of cirrhotic liver biopsy of patient with FALD, showing severe sinusoidal fibrosis and 
dilatation (stage 3) and gross architectural distortion (stage 4), with broad scarring and nodular regen-
eration. Sirius Red stain, objective lens 10x.
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all p<.01), but not with sinusoidal fibrosis score (Rs=0.102, p=0.541). Gross architectural 
score, portal fibrosis score and CHFS all correlated significantly with each other (Rs>.800 
and p<.001). Key histopathological features of FALD are depicted in Figure 2B. 
For further analyses, patients were divided in two groups, based on stage of fibrosis by 
gross architectural distortion score: 16 patients (42%) had mild fibrosis (stage 1-2) and 22 
(68%) had severe fibrosis (stage 3-4).
Non-invasive assessment of FALD
1) Liver biochemistry 
Liver biochemistry did not differ between patients with mild and severe fibrosis (Table 2). 
To highlight, the majority of patients in both groups had an elevated GGT (80% of patients 
with mild fibrosis vs. 86% of patients with severe fibrosis p=.670). 
Bilirubin was increased in 30% of patients (20% with mild fibrosis and 41% with se-
vere fibrosis, p=.286). Platelets (10^09/L) were within normal range in most cases (73% in 
both groups). MELD-XI scores were similar between groups and almost all within normal 
range. None of the parameters correlated with CPA (data not shown).
Table 2. Laboratory results of patients with mild vs severe fibrosis 
Mild fibrosis (n=16)† Severe fibrosis (n=22)† p-value
Median (IQR) n, % abnormal Median (IQR) n, % abnormal
ALT (IU/L) 28 (24-33) 1/15 (7%) 28 (23-37) 3/22 (14%) .915
AST (IU/L) 28 (23-33) 1/15 (7%) 28 (25-35) 5/22 (23%) .551
ALP (IU/L) 70 (54-97) 2/15 (13%) 81 (70-96) 2/22 (9%) .105
GGT (IU/L) 58 (46-104) 12/15 (80%) 62 (49-121) 19/22 (86%) .636
Bilirubin (mmol/L) 13 (11-19) 3/15 (20%) 16 (11-22) 9/22 (41%) .761
Albumin (g/L) 41 (40-43) 0/13 42 (40-44) 0/21 .529
MELD-XI score 9.44 (9.44-10.98) 1/12 (8%) 9.44 (9.44-11.08) 3/22 (14%) .873
Legend: Data are presented as median with (IQR) and n,% of patients with an abnormal result (elevated 
or diminished, in comparison to the upper or lower limit of normal) on the corresponding test. * P-
values are shown for non-parametric analyses between median values of laboratory results in patients 
with mild and severe fibrosis. †Missing data: In one patient with mild fibrosis no blood results were 
present except for ELF. MELD-XI score could not be calculated, because of missing creatinin values in 4 
patients with mild fibrosis. In 2 patients with mild fibrosis missed bilirubin and albumin. Albumin was 
missing in 1 and ELF in 3 patients with severe fibrosis. Total number of patients with available blood 
results are stated as denominator in the row showing n,% of abnormal test results. 
2) Serum fibrosis markers 
Median ELF score was above the threshold of 7.7 in all patients, suggesting the presence 
of fibrosis. Scores were similar between groups, median 9.03 (8.38-9.25) in mild and 9.20 
(8.69-9.57) in severe fibrosis (see figure 3A). APRI was also comparable between groups 
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(median 0.42 (0.35-0.53) in mild and 0.44 (0.35-0.64) in severe fibrosis (p=.531)). ELF 
and APRI did not correlate with CPA (Rs=.242, p=.161 and Rs=.100, p=.555 respectively). 
3) Ultrasonography and Elastography 
Six patients with severe fibrosis (27%; five with cirrhosis and one with stage 3 on gross 
architectural score) had a heterogeneous liver aspect of the parenchyma, compared to 
none with mild fibrosis (p=.030). Median CPA was also significantly higher in patients 
who had a heterogeneous aspect of the liver on ultrasound (35% (27-37) vs. 22% (17-24), 
p=.026). 
Portal vein flow was similar between patients with mild and severe fibrosis, see figure 
3C. Portal vein flow and spleen size showed a moderate correlation with CPA (Rs=-.442, 
p=.005 resp. Rs=.452, p=.004). Ultrasound and Doppler flow parameters are shown in 
Table 3.
Fibroscan was successful in 36/38 patients. Median liver stiffness was 22.5 (8.8- 45.7) 
kPa. Liver stiffness was similar in mild (median 21.3 (14.3-29.1) kPa) and severe fibrotic 
patients (26.0 (15.1-28.9) kPa, p=.511, see figure 3B), and did not correlate with CPA 
(Rs=-.015, p=.931). Liver stiffness did not correlate to histological grade of sinusoidal 
dilatation (Rs=.-079, p=.648). 
Figure 3. ELF, Liver stiffness and portal vein flow in mild vs severe fibrosis 
Legend: Data points in the graphs represent individual patient data, with the line representing the 
median value in patients with mild (n=16), compared to patients with severe fibrosis (n=22). Panel A 
represents ELF scores as measured in serum, Panel B liver stiffness (in kPa) as measured by Fibroscan®, 
and Panel C portal vein flow (in cm/s) as measured with Doppler flow on liver ultrasonography. Missing 
data: ELF score is missing in 3 patients with severe fibrosis. 
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Table 3. Parameters ultrasound and Doppler flow measurements 
Mild fibrosis (n=16) Severe fibrosis (n=22) p-value
Ultrasound parameters
Enhanced pattern liver 3/16 (19%) 2/22 (9%) .632
Heterogeneous aspect parenchyma 0/16 6/22 (27%) .03
Irregular liver surface 5/16 (31%) 1/22 (5%) .065
VCI compliance (<50%) 15/16 (94%) 18/20 (90%) 1.000
Spleen size (cm) 11.6 (10.3-13.0) 11.8 (10.5-13.0) .895
Doppler Flow parameters
Monophasic flow hepatic veins 2/16 (13) 3/22 (14%) n.a.
Portal vein flow (cm/s) 16.5 (14.0-24.8) 16.3 (13.1-20.0) .529
Hepatic artery flow max (cm/s) 69.4 (57.2-90.3) 65.8 (55.6-85.2) .617
End diastolic hep artery flow (cm/s) 20.7 (14.4-33.0) 19.7 (16.8-23.8) .660
Resistance Index 0.66 (0.58-0.84) 0.70 (0.64-0.79) .800
Legend: Data are presented as median (IQR) for continuous variables and as n, % for categorical vari-
ables. Missing data: VCI compliance and resistance index could not be measured in 2 patients and end 
diastolic hepatic artery flow was missing in one patient. 
4) Advanced Imaging 
Fibrosis 
In 30/38 patients we performed an MRI, and eight patients were subjected to a CT-scan. 
Nodularity was a frequently observed feature, absent only in five patients, and was evenly 
distributed between patients with mild and severe fibrosis. Other semi-quantitative fibrosis 
features were also equally present in patients with mild and severe fibrosis (see Table 4). 
The combination of specific hallmarks of cirrhosis; an enlarged caudate lobe, atrophied 
segment 4 and surface nodularity were present in five patients: two patients with severe 
fibrosis (stage 3) and three patients with mild (stage 2) fibrosis. ADC and RER were similar 
between groups, and did not correlate with CPA (Rs=-.092, p=.627 and Rs=-.006, p=.972, 
respectively). None of the other histological component scores correlated with any of the 
imaging parameters (data not shown).
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Table 4. Radiological evaluation of fibrosis characteristics compared to histology 
Mild fibrosis (n=16) Severe fibrosis (n=22) p-value
Periphery*
None
Mild
Marked
0/11
6/11 (55%)
5/11 (45%)
1/19 (5%)
10/19 (53%)
8/19 (42%)
0.740
Nodularity
None
Mild
Marked
3/16 (19%)
6/16 (38%)
7/16 (44%)
2/22 (9%)
9/22 (41%)
11/22 (50%)
0.684
Reticulation*
None
Mild
Marked
0/11
7/11 (64%)
4/11 (36%)
4/19 (21%)
7/19 (37%)
8/19 (42%)
0.179
Dysmorphy 16/16 (100%) 22/22 (100%) -
Segment 1
Atrophy
Normal
Enlarged
0/16
1/16 (6%)
15/16 (94%)
0/22
4/22 (18%)
18/22 (82%)
0.374
Segment 4
Atrophy
Normal
Enlarged
4/16 (25%)
9/16 (56%)
3/16 (19%)
3/22 (14%)
12/22 (55%)
7/22 (32%)
0.534
ADC* 1.03 (0.96-1.30) 1.0 (0.96-1.04) 0.250
RER 0.45 (0.38-0.65) 0.51 (0.41-0.61) .988
Legend: Data are presented as median (IQR) for continuous variables and as n, % for categorical vari-
ables. *ADC, Periphery and reticulation characteristics can only be assessed on MRI, therefore not 
measured in 8 patients (5 mild, 3 severe fibrosis). 
Assessment of portal hypertension 
Varices were present in 19 (50%) patients, ascites in 22 (58%) and splenomegaly in 7 
(18%) of patients. A combination of all three characteristics was found in five patients 
(see Table 5). 8/11 patients with cirrhosis (73%) had varices compared to 11/27 (41%) 
patients with a lower stage of fibrosis (p=.074). CPA was significantly higher in patients 
with varices than in patients without varices: median 24.2% (21.5-35.7) vs. 18.5% (14.2-
24.6), p=0.015. 
Liver stiffness was similar between patients with and without varices (mean 21.4 ± 
11.3 kPa and 24.1 ± 9.1 kPa, respectively; p=.391). Platelet count and platelet/spleen 
ratio were significantly lower in the group with varices (median 153 (125-175) 10^9/L 
and 1177 (892-1446), respectively) than in patients without varices (median 174 (147-
222) 10^9/L, p=.020; and 1740 (1185-2009), p=.001, respectively). Of note, none of the 
patients reported clinical events such as variceal bleeding. 
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Table 5. Signs of portal hypertension in patients with mild and severe fibrosis 
Mild fibrosis (n=16) Severe fibrosis (n=22) p-value
Varices 7/16 (44%) 12/22 (54%) 0.511
Ascites 9/16 (56%) 13/22 (59%) 0.861
Splenomegaly 3/16 (19%) 4/22 (18%) 1.000
Combination of all 3* 2/16 (13%) 3/22 (14%) n.a. 
Platelets (10^09/L) 164 (137-186) 155 (136-191) .963
Diminished platelet count (n,%) 4/15† (27%) 6/22 (27%) 1.000
Platelet/spleen ratio 1416 (1032-1763) 1297 (1123-1745) 1.000
VWF (%) 100 (100-100) 100 (100-105) .417
VITRO score 63.4 (44.6-72.7) 64.9 (46.8-84.0) .421
Legend: Data are presented as median (IQR) for continuous variables and as n, % for categorical vari-
ables. Missing data: In one patient no blood results were present, so platelet/spleen ratio and VITRO 
score could not be calculated. 
*combination of varices, ascites and splenomegaly on advanced imaging. †platelet count was missing 
in one patient with mild fibrosis. 
Hepatic nodules
Thirteen patients had several nodules smaller than 10 mm, while 13 had no nodules at all. 
Nine patients had in total 25 focal hyper-enhancing hepatic lesions larger than 10 
mm (median 1 nodule per patient, ranging from 1-7) (Table 6). The number of patients 
with nodules was comparable between patients with mild and severe fibrosis (n=3, 19% 
and n=6, 27% respectively, p=.706) and patients with or without varices (4 vs. 5 patients, 
p=1.000). Patients with severe fibrosis did have more nodules (median 4 nodules; range 
1-7) than patients with mild fibrosis (all three patients had 1 nodule, p=.047). Delayed-
phase washout was present in 9 nodules (36%) in 5 patients; one patient with cirrhosis 
(stage 4) had 4 nodules with wash-out. These lesions remained stable up to 12 months 
on follow-up. Two patients with stage 3 fibrosis had 1 and 2 nodules, respectively, and 2 
patients with stage 1 and stage 2 fibrosis had one nodule. 
None of these nodules had additional ancillary features such as hyperintensity on T2 
and DWI images or fat content. The mean AFP was low in all patients (mean AFP 3.39 ± 
1.29 ug/L).
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Table 6. Features of nodules > 10mm
25 Nodules in 9 patients 
Size (mm)
10-20 mm
>20 mm
18.0 ±6.2
19/25 (76%)
6/25 (24%)
Location
Right hemi-liver
Left hemi-liver
Caudate lobe
13/25 (52%)
11/25 (44%)
1/25 (4%)
Signal intensity (T1-weighted)
Hypo-intense
Iso-intense
Hyperintense
0 
20/25 (80%)
5/25 (20%)
Signal intensity (T2-weighted)
Hypo-intense
Iso-intense
Hyperintense
4/25 (16%)
21/25 (84%)
0
Diffusion-weighted* 
Hyperintense 0 
Arterial phase 
Hyper-intense 25/25 (100%)
Portal phase
Hypo-intense
Iso-intense
Hyperintense
0 
3/25 (12%) 
22/25 (88%)
Delayed phase
Hypo-intense
Iso-intense
Hyperintense
9/25 (36%)
11/25 (44%)
5/25 (20%)
Washout
Hypo-intense on portal phase
Hypo-intense on delayed phase
    -Hyper>iso >hypo 
    -Hyper>hyper>hypo
No washout
Hyperintense all phases
0
9/25 (36%)
 3/25 (12%)
 6/25 (24%)
13/25 (52%) 
3/25 (12%)
Other
Fat content 
Capsule
Central scar
0
5/25 (20%)
4/25 (16%)
Legend: Data are presented as mean ± SD for continuous variables and as n, % for categorical variables. 
* Diffusion-weighted images only available on MRI, missing data on 5 nodules. 
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DISCUSSION 
Key findings 
The present study demonstrates (1) the presence of severe liver fibrosis, signs of portal 
hypertension and hyperenhancing nodules in a majority of asymptomatic patients with a 
Fontan physiology, and (2) the lack of correlation between several non-invasive diagnostic 
tools and histological confirmed liver fibrosis severity. These findings indicate that non-
invasive diagnosis of/screening for severe FALD in patients with a Fontan physiology is 
ineffective to accurately assess liver fibrosis.
Screening of FALD
There is an unmet need to diagnose and assess liver fibrosis severity with non-invasive 
alternatives, as liver biopsy carries potential complications. Our data suggests that there 
is no role in clinical practice for ELF®, routine transient elastography or conventional 
MRI/CT to diagnose liver fibrosis in Fontan physiology, since it fails to correlate with 
histological fibrosis severity. Ultrasound abnormalities, such as heterogeneous aspect of 
parenchyma could be indicative for severe fibrosis, but absence of abnormalities does not 
rule out severe FALD.39-41 This highlights that experiences from patients with other forms 
of liver disease (e.g. liver cirrhosis as a result of alcohol abuse, hepatitis B and C) cannot 
be applied to the Fontan population, as interference of congestion remains an issue of 
concern in this unique physiology.39-41
Although we encountered no complications from the biopsy itself or from interruption 
of anticoagulant therapy, we acknowledge that liver biopsy is not an attractive tool to 
use for follow-up. Thus there remains an unmet need for alternatives to ease screening 
and follow-up in this population. MRI is subject to fast and major developments, and 
techniques such as T1-rho mapping, extracellular volume calculation,42 susceptibility im-
aging,43 and magnetic resonance elastography 14, 44 are promising. We do stress that new 
techniques should be validated against histology before they are adopted in daily practice. 
Pathophysiology 
Although not fully elucidated, chronic passive hepatic congestion is thought to be the 
underlying mechanism that puts patients with a Fontan physiology at risk for complica-
tions of advanced liver disease.45 In congestive hepatopathy, venous congestion elicits 
a sustained wound-healing response. Upon histological examination, this is character-
istically depicted by sinusoidal dilatation, presumably resulting from venous pressure 
elevation. Consequently fibrosis arises, with also mainly a sinusoidal pattern.46 Over time, 
injury precipitates formation of broad scars, bridging fibrosis and cirrhosis. Fibrosis is also 
generated by microthrombotic events in sinusoids and veins.47 The ubiquitous presence 
of fibrosis in all biopsies examined in this study, underlines the profound impact of the 
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Fontan physiology on the liver architecture, and contrasts with that in other aetiologies 
such as viral hepatitis, where only a minority of patients will ultimately develop liver fibro-
sis.48 The specific histological pattern of sinusoidal fibrosis in combination with sinusoidal 
dilatation can help to distinguish FALD from other liver diseases, however correlation with 
clinical information should always be made to identify the definite cause of liver injury, as 
no pattern is unique in liver pathology.49
The spectrum of FALD
The findings from our study are consistent with the spectrum of FALD ranging from mild 
congestive hepatopathy to established cirrhosis. At 21 years after surgery, the majority of 
patients have developed advanced liver disease. Some 29% had histological evidence of 
liver cirrhosis and 50% had varices. These findings are in line with those from other Fontan 
cohorts, reinforcing the concept that liver fibrosis and portal hypertension are major extra-
cardiac manifestations of Fontan physiology.19, 21, 37, 38
This reflects the ongoing continuum that starts postoperatively with hepatic vein con-
gestion, which causes liver injury resulting in ongoing fibrogenesis.5 
To address the true risk of advanced liver disease and its complications in patients 
with a Fontan physiology we need longitudinal data that associate presence and severity 
of FALD to morbidity and mortality. 18, 50,66 In other chronic liver diseases, such as viral 
hepatitis and NAFLD, fibrosis stage determines portal hypertensive complications HCC 
development and ultimately prognosis.6 If this is also the case in patients with a Fontan 
physiology needs to be further elucidated by prospective studies.
Portal hypertension
In our cohort, signs of portal hypertension were more frequently seen in patients with 
cirrhosis. Splenomegaly and portosystemic varices are uncommon in congestive hepa-
topathy, and are generally related to central venous pressure being transmitted through 
dilated hepatic sinusoids to the portal venous system. We did not perform measurements 
of the transhepatic pressure gradient, but in congestive hepatopathy and FALD values are 
usually normal.45, 46 The presence of varices may be an indication of the transformation 
from congestion to fibrosis.51 To what degree failure of Fontan physiology contributes to 
the onset of portal hypertension remains unknown.
Fontan nodules
Congestive hepatopathy is also associated with the onset of focal liver lesions. Arterialized 
large regenerative nodules or focal nodular hyperplasia (FNH) are often found in conges-
tive hepatopathy.52, 53 These lesions comprise of regions of parenchyma with compromised 
hepatic venous outflow and subsequently impaired portal inflow. Parenchymal perfusion 
thus becomes reliant on arterial flow, resulting in nodular regeneration of hepatocytes. It is 
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generally assumed that FNH have no malignant potential.54 On the other hand, cirrhosis is 
associated with an increased risk of hepatocellular carcinoma (HCC), and HCC has been 
described in young cirrhotic patients with a Fontan physiology.55, 56 Hyperenhancing nod-
ules were present in ~25% of patients from our cohort, independent of fibrosis stage, cor-
roborating previous findings.53, 57 Wash-out, in the setting of cirrhosis, is usually a specific 
feature of HCC, but in FALD may also be present in benign lesions.53 Specific guidelines 
for screening of patients with a Fontan physiology for HCC are lacking,58 but the value 
of AFP, liver-specific contrast agents, and additional ancillary features for discrimination 
between benign and potentially malignant Fontan nodules should be further explored. 
Liver function & transplantation
Finally, liver function is an issue of concern. Liver function is defined as the ability to 
maintain bilirubin metabolism and intact coagulation, and not as the increase of transami-
notransferases.59 Liver fibrosis is an important prognostic determinant in patients with other 
chronic liver diseases as it may result in impaired liver function and increased mortality.6 
It is suggested that 5-year survival in cirrhotic patients with Fontan physiology was dismal 
which in turn was due to both cardiac and liver related complications.7 Clinical follow-up 
of patients with established liver disease is facilitated by the MELD (Model of End stage 
Liver Disease) score, prioritizing patients in need of liver transplantation.60 Transplantation 
data are very limited and come from several small case series that describe combined 
heart and liver transplantation in patients with a failing Fontan physiology and liver cir-
rhosis.61-63 These show good short term results, comparable to orthotopic heart transplant. 
Nonetheless, long term results are lacking. In adjusted form, MELD-XI probably predicts 
cardiac mortality or heart transplantation better than hepatological mortality, as similar 
outcomes are observed regardless of the presence of severe fibrosis.64 In our cohort, 
MELD-XI scores were low.
Strengths & Limitations
The major strength of our study lies in the optimal identification of fibrosis in this 
population using a gold standard: histological confirmation. This allows us to interpret 
the observations as a result of either congestion, fibrosis or combined. The use of multiple 
invasive and non-invasive modalities for the same patients allows a fine comparison of 
the diagnostic value to detect congestion or fibrosis in relation to the gold standard. Previ-
ous studies investigating non-invasive alternatives to assess FALD lacked reference to the 
gold standard, hampering interpretation of results. Selection bias was limited since every 
consecutive patient was included and subjected to structural assessment. Liver fibrosis 
severity in our cohort is probably representative for the general population with Fontan 
physiology. Therefore we can answer to several important key knowledge gaps as identi-
fied by the stakeholders meeting of the American College of Cardiology in 2017.65
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Our study is limited by the relatively small number of patients, but on the other hand 
our cohort underwent systematic and deep characterisation of the phenotype. The study 
design is cross-sectional, and exposure and outcome were simultaneously assessed. 
Without the presence of longitudinal data it is not possible to establish temporal relation 
between cause (Fontan physiology) and effect (liver fibrosis and its complications) or to 
assess the value of non-invasive diagnostics in monitoring of FALD. Longitudinal assess-
ment of liver stiffness measurements has the potential to be helpful in monitoring patients 
with a Fontan physiology 44, but needs further confirmation. Future research should focus 
on assessing modalities for surveillance of these patients and on pathophysiology and risk 
factors for progression of FALD.65 
Conclusion
In conclusion, we show that cirrhosis and signs of portal hypertension are present in 
substantial proportion of patients with a Fontan physiology, and that MRI, CT, transient 
elastography, and serum biomakers are unable to accurately assess severity of liver fibrosis 
in this cohort. This emphasizes the need for prospective longitudinal follow-up studies to 
further assess morbidity and mortality risk and to search for non-invasive alternatives to 
diagnose and monitor FALD.
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SUPPLEMENTARy METHODS 
Histology
Description histological fibrosis scores : First, the gross architectural distortion score 
(modified from METAVIR) was scored, ranging from 0 (no definite fibrosis); 1 (minimal 
fibrosis: no septa or rare thin septum); 2 (mild fibrosis: occasional thin septa); 3 (moderate 
fibrosis: moderate thin septa; up to incomplete cirrhosis) to 4(cirrhosis definite or prob-
able). 
Second, the Fontan Fibrosis score , a score consisting of 4 components (portal fibrosis, 
sinusoidal fibrosis, sinusoidal dilatation, and portal inflammation), was scored . Portal 
fibrosis was scored: 0 (no fibrosis); 1 (enlarged, fibrotic portal tracts); 2 (periportal, or 
portal-portal septa but intact architecture); 3 (fibrosis with distorted architecture, but no 
obvious cirrhosis); 4 (cirrhosis, probable or definite). Sinusoidal fibrosis was scored: 0 
(no sinusoidal fibrosis); 1 (sinusoidal fibrosis in < 1/3 sinusoids); 2 (in 1/3-2/3 sinusoids); 
3 (in > 2/3 sinusoids); 4 (cardiac cirrhosis: extensive central vein-central vein bridging). 
This score also includes sinusoidal dilatation (0-3): 0 (no dilatation); 1 (dilatation in <1/3 
sinusoids); 2 (in 1/3-2/3 sinusoids); 3 (in > 2/3 sinusoids) and portal inflammation 0-3 
scale (no/mild/moderate/marked inflammation in some or all portal tracts). 
Lastly, the congestive heart failure fibrosis score (CHFS), was scored: 0 (no fibrosis); 
1 (central zone fibrosis); 2A (central zone and mild portal fibrosis, with accentuation at 
central zone); 2B (at least moderate portal fibrosis and central zone fibrosis, with ac-
centuation at portal zone); 3 (bridging fibrosis); 4 (cirrhosis). 
Magnetic resonance imaging protocol
MR imaging was performed with a 3-T imager (Siemens Prisma/Skyra, the Netherlands) 
using a phased-array surface coil after 3 hours of fasting. Buscopan (1ml iv) was adminis-
tered for anti-spasmolytic effect, previous to scanning. 
The protocol included a T2-weighted single-shot sequence, a T2-weighted fast spin-
echo sequence with spectral fat saturation, and a transverse breath-hold 3D T1-weighted 
fat-suppressed spoiled gradient-recalled echo sequence before and after dynamic injec-
tion of 0.1 mmol/kg of body weight (max 7.5 ml) of gadolinium chelates (Dotarem®; 
gadoterate meglumine) followed by a 20-mL saline solution flush at a rate of 2 mL/sec 
administered with a power injector. After the T2 haste (blanco) phases, the scanning of 
the arterial phase was initiated after bolus tracking (sufficient contrast uptake in a region 
of interest in the aorta). Arterial scanning phase lasts for 13 sec, followed after 30 seconds 
by the venous phase (also 13 sec). Delayed phase was fixed at 180 seconds after intrave-
nous contrast injection. A free-breathing fat-suppressed single-shot echoplanar DW MR 
sequence was performed before contrast injection with b values of 50, 500 and 800 sec/
mm2. Cardiac gating was not used. Sequence parameters are shown below. 
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Sequence parameters
Sequences N 
slices
TR/TE (ms) Slice thickness 
(mm)
Flip 
Angle (°)
N 
concatenations
T2-weighted haste 30 1400/87 5 160 3
T2-weighted haste with 
spectral fat saturation 
35 1600/95 5 160 4
T1-weighted vibe  72 3.97/
1.29 (TE1) 
2.52 (TE2)
3 9 1
Diffusion-weighted 35 5900/52 5 - 1
Computed tomography protocol
Contrast-enhanced four phase CT was performed on 320-slides multidetector CT scanners 
(Toshiba Aquilion). As preparation patients fasted for 3 hours and drank 900 mL Telebrix 
Gastro 45 minutes and 450 mL water 30 minutes pre-scanning. 
Unenhanced multidetector CT abdominopelvic images were initially obtained. 
Contrast-enhanced acquisitions were obtained following intravenous administration of 
Iomeprol contrast medium at 300 mg iodine per milliliter, calculated on total body weight 
(ranging 120-150 ml), through an 20-gauge catheter in a fixed time of 30 seconds (rate 4-5 
mL/sec) by a power injector, followed by a 40-mL saline solution flush. The late arterial 
phases were acquired at an empirical fixed delay of 24 seconds after bolus tracking, and 
portal venous phases after another 20 seconds (around 60-70 sec). The late phases were 
fixed at 180 seconds after contrast administration had begun. See below for the used 
scanning and reconstruction parameters: 
Scan parameters
Unenhanced Arterial Venous Late
Mode Helical Helical Helical Helical
Collimation 80 x 0.5 80 x 0.5 80 x 0.5 80 x 0.5
kV Auto Auto Auto Auto
Sure Exposure (mAs) SD 17.5 SD 17.5 SD 17.5 SD 17.5
Rotation time 0.5 0.5 0.5 0.5
Pitch Standard Standard Standard Standard
Scan direction Cranio-Caudal Cranio-Caudal Cranio-Caudal Cranio-Caudal
API Inspiration Inspiration Inspiration Inspiration
Iterative 
reconstruction
AIDR3D 
Enhanced
AIDR3D 
Enhanced
AIDR3D 
Enhanced
AIDR3D 
Enhanced
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Reconstruction parameters
 Axial 1  Volume 1  Multiview 1  
Unenhanced Body Axial 3 / 2.4 Body Volume 1 / 0.8   
Arterial Body Axial 3 / 2.4 Body Volume 1 / 0.8   
Venous Body Axial 3 / 2.4 Body Volume 1 / 0.8 MPR Coronal
MPR Sagital
3 / 2
3 / 2
Late Body Axial 3 / 2.4 Body Volume 1 / 0.8   
Calculation Relative Enhancement ratio
The relative enhancement ratio (RER) of liver pattern between pre-contrast and delayed 
phase was calculated, as a modification of the previously described method by Feier et 
al.36 This ratio is based on signal intensity (SI) of the liver and the paraspinal muscles (to 
normalize the signal) on pre-contrast and delayed (post) phase T1-weighted imaging. The 
following equation was used:
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ABSTRACT 
Objectives: To assess the influence of smoking on histological disease severity and fibrosis 
in real-world NAFLD patients. 
Material and methods: Consecutive NAFLD patients were identified with liver biopsies 
performed between 2008 and 2015. Characteristics such as smoking status and total 
number of pack years were collected. Biopsies were revised and BRUNT fibrosis and 
NAFLD activity score (NAS) determined. Patients with a high NAS (≥ 5) were compared 
to patients with a low NAS (<5) and with advanced fibrosis (stage 3-4) to patients with 
no-early fibrosis (stage 0-2). Patients with a history of smoking (current or past smoker) 
were defined ever smokers. 
Results: Fifty-six patients were included (mean age 49 ± 14.3, 68.9% males and 39.3% 
history of smoking). Ever smokers had a higher fibrosis score than never smokers; 2 (IQR 
0-3) vs. 1 (IQR 1-1.5) (p=0.040). Patients with advanced fibrosis smoked significantly 
more pack years than patients with no-early fibrosis; 10.6 (IQR 0-25.8) vs. 0 (IQR 0-7) 
(p=0.011). There is a weak to moderate correlation between fibrosis stage and number of 
pack years (Spearman’s Rho=0.341, p=0.012). There was no difference in NAS between 
never and ever smokers; 2.8 ±1.5 vs. 3.3 ±1.4 (p=0.205). Patients with NAS <5 had a 
median number of pack years of 0 (IQR 0-9) vs. a median of 10.3 pack years (IQR 0-24) 
in patients with NAS ≥5 (p=0.127). 
Conclusion: Smoking is associated with severity of NAFLD-related liver fibrosis but not 
with histological disease severity. This supports the recommendation to cease smoking for 
NAFLD patients.
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is the most expanding cause of chronic liver 
disease. NAFLD consists of a spectrum of conditions, ranging from simple steatosis to non-
alcoholic steatohepatitis (NASH) and ultimately end-stage liver cirrhosis.1 The diagnosis 
of NASH is defined by the presence and pattern of specific histological abnormalities on 
liver biopsy, such as inflammation. For this, a system of scoring the individual features of 
NAFLD, the NAFLD Activity Score (NAS) was developed.2 This score is based on three 
histological parameters, namely lobular inflammation, macroscopic steatosis and bal-
looning of hepatocytes.
Advanced stages of NAFLD have been associated with risk factors such as diabetes, 
obesity and increasing age.3-5 Whether smoking aggrevates chronic liver diseases and 
especially NAFLD has been increasingly subject of research debate.  
In obese rats, smoking increased the histological severity of NAFLD, favoring the devel-
opment of NASH by aggrevation of lobular inflammation and hepatocellular ballooning.6 
The underlying mechanisms seem to be induction of hepatocellular apoptosis, oxidative 
stress and modulation of several signaling pathways, such as ERK phosphorylation and 
AKT activation. The effect of smoking on fibrosis was less clear in this study. There was 
upregulation of several fibrogenic genes (pro-collagen α-2 and TIMP-1), but no significant 
fibrosis deposition in the animals. 
In human NAFLD, smoking seems to be associated with severe fibrosis, as shown in 
a large cohort study encompassing 1091 patients, collected from enrollment in several 
studies.7 Long term smoking was significantly associated with the presence of advanced 
fibrosis, suggesting cigarette smoking may accelerate disease progression. However in this 
study the association between smoking, NASH and the histological severity of indepen-
dent NAS components was not extensively studied. In a brief report by Yilmaz et al, no 
association was observed between smoking and severity of NAFLD.8 
Since human results are conflicting and experimental data suggest smoking can lead to 
progression from simple NAFLD to NASH, we conducted the present human cohort study. 
We aim to investigate whether there is an association between smoking and presence of 
NASH, including the individual histological disease components; lobular inflammation, 
hepatocellular ballooning, steatosis, as well as severity of fibrosis.
METHODS
Patient population 
All liver pathology reports from 2008 to 2009 in the VU University Medical Center and 
from 2010-2015 in the Radboud university medical center were screened for inclusion, 
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if the words NAFLD, NASH or steatosis were mentioned in the report. Patient details 
were included when the diagnosis non-alcoholic fatty liver disease or non-alcoholic 
steatohepatitis was made on clinical and histological grounds. Patients were excluded 
when there was concomitant liver disease. Patient characteristics such as age, sex, length, 
weight, body mass index (BMI), presence of diabetes mellitus type 2 (DM) and alcohol use 
(units/week) were assessed. This study was approved by the Institutional Review Boards 
of both hospitals. 
Liver histology
All biopsies were stained with hematoxylin-eosin and assessed for fibrosis using Masson’s 
Trichome or Elastin-Von Gieson. In each center the included biopsies were revised by a 
single liver pathologist, blinded for clinical information. Quality of biopsies was assessed 
and biopsies not meeting the following requirements were excluded: 20-25 mm long 
and/or containing more than 11 portal tracts. The stage of fibrosis was scored with the 
histological scoring system for NAFLD developed by Brunt et al.2 No or early fibrosis was 
defined as stage 1 or 2 and advanced fibrosis was defined as stages 3 or 4. The NAFLD 
Activity Score (NAS) was used to assess the severity of histological disease activity, with 
a total score between 0-8 based on individual scores for the three components; steatosis 
(0-3), lobular inflammation (0-3) and hepatocellular ballooning (0-2). A NAS of five or 
higher is defined as histological steatohepatitis.9 
Smoking history
Smoking history was obtained from chart review and when unclear from direct interview 
with patients. Patients were informed with a study information letter and afterwards 
telephoned for an interview. From the data obtained from this interview and medical 
records, the total number of pack years smoked by each patient was calculated (one pack 
year equals one pack of cigarettes each day during one year). Patients were furthermore 
classified as “never smokers” or “ever smokers”, the latter in case of current smoking or a 
history of smoking. 
Statistical analysis
Continuous data are presented with mean and standard deviation (±SD), nominal data 
as counts (n), percentages and ordinal data with medians and interquartile ranges (IQR). 
Independent t-test, or non-parametric tests where applicable, were used to compare con-
tinuous variables. Chi-Square test was used to compare categorical variables and Mann-
Whitney U test for ordinal variables. Correlations were tested with Pearson’s correlation 
coefficient or Spearman’s Rho, depending on the level of measurement. A two-sided level 
of p < 0.05 was considered statistically significant. All statistical analyses were carried out 
using SPSS software (version 22; SPSS Inc., Chicago, Illinois, USA).
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RESULTS
Patient characteristics
A total of 160 pathology reports with the words NAFLD, NASH or steatosis in the report 
were screened. Of these 76 were excluded because of a different or concomitant disease. 
Of 27 more patients no sufficient smoking data was present. Finally 4 biopsies were ex-
cluded because of bad quality. Leading to a total of 56 patients included in the analysis, 
with a mean age of 49 ± 14.3 years and 68.9% males. Of all patients, 22 (39,3%) had a 
history of smoking (named hereafter ever smokers). This group comprised of 6 subjects 
(27.3%) who still actively smoke and 16 subjects (72.7%) who ceased smoking. Mean 
number of pack years among ever smokers was 16.3 ± 10.8. Never smokers were signifi-
cantly younger than ever smokers (p 0.028), but BMI, presence of DM and alcohol use 
was not different between groups (see table 1). There was no correlation between age and 
the number of pack years smoked by ever smokers (Pearson’s R=0.169, p=0.453). 
Table 1. Patient characteristics
Never smokers
(n=34)
Ever smokers
(n=22)
p-value
Clinical features
Male 24 (70.6%) 14 (63.6%) 0.586
Age 45.7 (±14.4) 54.2 (±12.9) 0.028
BMI* 31.2 (±5.6) 29.9 (±6.3) 0.258
Obese (BMI>30)* 13 (54.2%) 5 (35.7%) 0.272
Type 2 DM* 7 (21.9%) 8 (40.0%) 0.160
Alcohol use (units/week)† 0 (IQR 0-7) 7 (IQR 0-14) 0.111
Histology 
Fibrosis score according to Brunt 1 (IQR 1-1.5) 2 (IQR 0-3) 0.040
No fibrosis (stage 0) 14 (41.2%) 6 (27.3%) 0.099
Early fibrosis (stage 1-2) 15 (44.1%) 8 (36.3%) 0.099
Advanced fibrosis (stage 3-4) 5 (14.7%) 8 (36.3%) 0.099
NAFLD activity score (NAS) (0-8) 2.8 ±1.5 3.3 ±1.4 0.205
Legend: Expressed as number and percentage for categorical variables, median (IQR) for ordinal vari-
ables and mean (±SD) for continuous variables. *BMI, Obese n=38, Type 2 DM n=52 †Median (IQR) 
is shown for alcohol use because of non-normal distribution and tested with a Mann-Whitney U Test. 
Liver histology 
The median fibrosis score according to Brunt was significantly higher in ever smokers than 
in never smokers; 2 (IQR 0-3) vs. 1 (IQR 1-1.5) (p=0.040). Whereas most never smokers 
had no or early fibrosis, subjects who ever smoked had predominantly early to advanced 
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fibrosis. This was however not significant. There was no difference in the NAS between 
never and ever smokers (p=0.205). See table 1 for details.
Number of pack years and severity of fibrosis
Overall, patients with advanced fibrosis smoked significantly more pack years than pa-
tients with no-early fibrosis; 10.6 (IQR 0-25.8) vs. 0 (IQR 0-7) (p=0.011) (figure 1A). This 
observation was not altered after exclusion of never smokers: patients with advanced 
fibrosis smoked 22.3 ± 11 pack years, whereas patients with no-early fibrosis smoked 13 
± 9.4 pack years (p=0.048) (figure 1B). There is a weak to moderate correlation between 
the stage of fibrosis and the number of pack years smoked by all included patients (Spear-
man’s Rho=0.341, p=0.012) and a similar trend for ever smokers (Spearman’s Rho=0.416, 
p=0.061).
Figure 1. Number of pack years compared between patients with no-early and advanced fibrosis
Legend: Panel A shows the difference in number of pack years (represented with boxplots with median, 
IQR and min-max value) for the whole cohort. Panel B shows the difference in number of pack years 
represented (represented as mean + standard error of the mean) for ever smokers (active and past smok-
ers). 
Possible confounders in advanced fibrosis
The mean NAS was higher in patients with advanced fibrosis compared to no-early fi-
brosis; 3.9 ± 1 vs. 2.7 ± 1.5 (p=0.003). In detail, a higher, but not significant, proportion 
of patients with advanced fibrosis had a NAS of 5 or higher compared to patients with 
no-early fibrosis (30.8% vs. 9.3%; p=0.074). Patients with advanced fibrosis were older 
(mean age 60.4 ± 9.7 years vs. 45.5 ± 13.7 years; p<0.001). No other clinical features, 
such as sex, BMI, Type 2 DM or alcohol use differed between patients with no-early 
fibrosis compared to advanced fibrosis (data not shown). 
Number of pack years and histological disease severity  
Overall, patients with NAS<5 compared to patients with NAS ≥5 had a median number 
of pack years of respectively 0 (IQR 0-9) vs. 10.3 (IQR 0-24) (p=0.127) (figure 2a). There 
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were no differences in clinical features, including age, sex, BMI, presence of DM and 
alcohol use between both groups (data not shown). Also after exclusion of never smokers, 
no statistical difference could be observed in number of pack years (NAS <5; 15.3 ± 10.6 
vs. 19.9 ± 11.7 in NAS≥5; p=0.411) (figure 2b). There was no correlation between number 
of pack years and NAS in ever smokers (Pearson’s R=0.072, p=0.752). 
Figure 2. Number of pack years in patients with a NAS < 5 compared to patients with a NAS ≥ 5
Legend: Panel A shows the difference in number of pack years (represented with boxplots with median, 
IQR and min-max value) for the whole cohort. Panel B shows the difference in number of pack years 
represented (represented as mean + standard error of the mean) for ever smokers (active and past smok-
ers).
DISCUSSION
Smoking and fatty liver disease place a heavy burden on health care systems worldwide. 
This study addresses the possible synergistic effect of smoking on histological outcomes of 
non-alcoholic fatty liver disease . 
We demonstrate in this study that NAFLD patients with advanced fibrosis smoked 
more pack years than patients with no or early fibrosis. These results corroborate the 
association between smoking and severity of NAFLD fibrosis as previously shown.7 In a 
smaller study no association between smoking and severity of fibrosis in NAFLD patients 
was observed, which may be the result of patient numbers, comorbidity and selection.8 
The underlying pathomechanisms of our observed association cannot be clarified with 
our cross-sectional cohort study design. We can only speculate through which mecha-
nisms smoking aggrevates fibrosis in NAFLD, based on previous experimental research. 
First, the presence of inflammation as a risk factor for progression to fibrosis in NAFLD 
has been widely shown.10 However, we did not find an association between smoking and 
NASH or severity of inflammation, ballooning and steatosis. An increasing number of pack 
years was not correlated with a higher NAFLD activity score (NAS). The NAS did not differ 
between never and ever smokers. Similar results were seen in other studies.7, 8 
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The heterogeneity of NAFLD could be a possible reason for this, with many environ-
mental and genetic factors influencing disease course.11 These factors could have been 
present in our study cohort and are impossible to correct for. Furthermore our cohort 
contained only a small percentage (14%) of patients with active steatohepatitis and could 
therefore be underpowered to show a possible association between smoking and histo-
logical disease severity. 
Second, also a direct effect on fibrogenesis from smoking could be postulated as an 
underlying mechanism. NAFLD is a heterogeneous disease and probably progression is 
caused by a multi-hit model.12 Smoking probably can interfere in several pro-inflammatory 
and pro-fibrotic pathways in experimental NAFLD. Chronic hypoxia, as a consequence of 
smoking, not only led to more hepatic inflammation but also an increase of pro-fibrotic 
cytokines.13, 14 Other pathways involved in fibrogenesis, such as more profound lipid ac-
cumulation, oxidative stress and insulin resistance, have been shown 15. Stimulation of the 
nicotinic acetylcholine receptors in hepatic stellate cells by nicotine in vitro suggests a 
direct effect of smoking on fibrogenesis.16 In addition, in other chronic liver diseases such 
as hepatitis C and primary biliary cholangitis, associations between smoking and fibrosis 
have been described.17-22 
It is furthermore suggested that smoking increases progression of fibrosis in other organ 
systems, including the pancreas, kidneys, lungs and heart.23-26
In our study, patients with advanced fibrosis were older than those with early fibrosis 
but the number of pack years was not correlated to the age of patients. Therefore, age 
seems to play a minor role in the association between smoking and fibrosis severity. 
Nonetheless, it endorses the advice to cease smoking for all patients, irrespective of their 
biological age. 
The retrospective set-up of a small cohort is a major limitation. With extensive chart 
review and direct questioning of patients on smoking history, we aimed to characterize the 
cohort as good as possible. However smoking data was not validated by direct measure-
ment of serum nicotine concentrations, so the possibility of bias by patients is present.
In conclusion, in this study the number of pack years is associated with severity of liver 
fibrosis but not with histological disease severity in patients with NAFLD. The observed 
data may serve as pilot for larger cohorts. These findings still emphasize the recommenda-
tion to cease smoking for all patients with NAFLD.
Disclosure of interest: The authors report no conflicts of interest.
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UNSTRUCTURED ABSTRACT 
In this study, 16 moderate alcohol consumers without structural liver disease ceased 
alcohol intake for one month and underwent liver measurements at three time points. 
Gamma-glutamyl transferase (GGT), although within the normal range, decreased signifi-
cantly after abstinence and increased after the resumption of alcohol consumption. 
SHORT SUMMARy
In this study in healthy moderate alcohol consumers, we observe that one month of al-
cohol abstinence results in decreased gamma-glutamyl transferase levels, which return to 
baseline levels after resumption of alcohol consumption. 
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INTRODUCTION
Liver steatosis and inflammation are features of the early stages of alcoholic liver disease, 
and may ultimately lead to liver fibrosis and cirrhosis. Liver steatosis is frequently present 
in the general population, particularly in those with metabolic syndrome and obesity, and 
has been labelled non-alcoholic fatty liver disease (NAFLD) (Younossi et al., 2016). The 
risk of liver damage from alcohol consumption is dose dependent (Askgaard et al., 2015), 
but even when consumed in moderation, alcohol contributes to the progression of liver 
disease in patients with NAFLD (Boyle et al., 2018). 
Alcohol consumption in the European Union is the highest in the world, with an aver-
age of 27 grams (g) per adult per day, twice as high as the global average (Laramée et al., 
2013). The UK Chief Medical Officer has recently updated the advice on alcohol intake. 
The advised maximum alcohol intake has been reduced for men from 32g/day and for 
women from 24 g/day to 112 g/week for both. The advice also recommends spreading the 
intake evenly over three or more days, and incorporating alcohol-free days into each week 
(Department of Health, United Kingdom 2016). The Health Council in the Netherlands 
has revised its advice from recommending a maximum of 140 g/week to suggesting that it 
is better not to drink at all (Health Counsil, the Netherlands 2015). 
Public and social media initiatives to raise awareness about the health risks associated 
with alcohol consumption have become increasingly popular. Dry January in the UK, 
Tournée Minérale in Belgium, and IkPas in the Netherlands are examples of public health 
campaigns challenging people to abstain from alcohol for one month. Total cessation 
of alcohol consumption is a critical determinant in reducing mortality in alcoholic liver 
disease, especially when liver cirrhosis is already present (Xie et al., 2014). However, 
the benefits of short-term abstinence remain largely intuitive, and scientific evidence of 
these benefits in non-dependent alcohol consumers without established liver disease is 
scarce. Four weeks of abstinence in patients with alcoholic liver disease has been found 
to result in a reduction in liver stiffness and improvement in liver biochemistry (Gianni et 
al., 2017). 
A recent UK study showed that Dry January resulted in a lower body weight, better 
glucose homeostasis and reduced liver stiffness in participants with an average alcohol 
intake of 252 ±13 g/week (Mehta et al., 2015). It is unclear whether beneficial effects can 
be achieved in participants with a moderate alcohol intake (well within the limits set by 
the guidelines). To this end, we investigated whether one month of alcohol abstinence 
improves liver health in moderate alcohol consumers. 
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METHODS
Design 
We performed a prospective controlled intervention study from November 2016 to Janu-
ary 2017. Approval was granted by the institutional review board (NL56238.091.15) of the 
Radboudumc, and all of the participants gave informed consent.
Study population
The intervention group consisted of 16 adult participants (10 males; 6 females), who had a 
moderate alcohol intake, with a maximum of 210 g/week. Nine adults who were teetotal-
lers (4 males; 5 females) served as a control group. We excluded patients with established 
liver disease.
Intervention
The intervention consisted of 28 days of alcohol abstinence. All of the participants un-
derwent an extensive health evaluation at three time points: before the intervention (T0), 
directly after the intervention (T4) and at four-week follow-up (T8).
Outcome parameters
Alcohol intake: The participants reported their average alcohol use in the previous month 
in standard units per week, which were converted to a mean alcohol intake in g/week. 
One standard unit was estimated at 10 g of pure alcohol. 
Liver measurements
Liver stiffness in kilopascals (kPa) was measured with two modalities: transient elastog-
raphy (Fibroscan®) and shear wave elastography (Applio 500 Toshiba®) (Friedrich-Rust 
et al., 2016). Liver fat was measured using computer-aided quantitative ultrasonography 
(CAUS ) on conventional ultrasound images. Liver fat percentage was calculated from 
residual attenuation (in decibels per centimetre per Megahertz), as previously described 
(Thijssen et al., 2008; Weijers et al., 2016). The diameter of the abdominal fat layer in 
millimetres (mm) was measured by ultrasound on the midclavicular line near the seventh 
intercostal space. Gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase (ALP) (all in U/L), ferritin (in ug/L) 
and carbohydrate deficient transferrin (CDT) (in %) were assayed on automated analysers.
Statistical analyses
As tests for normal data distribution are inaccurate in a small sample, all analyses were 
performed with parametric and non-parametric statistics. A two-sided level of p < .05 on 
both tests was considered statistically significant. Data are presented as medians with an 
71
interquartile range (IQR: 25th-75th percentile) or as numbers; percentages (n, %), and p-
values from the non-parametric tests are shown. The interaction between time and group 
in terms of liver biochemistry was tested with a multivariate general linear model for 
repeated measures. All repeated measures within groups were also tested with a paired-
samples T-test and Wilcoxon matched-pair signed rank test. Analyses were performed with 
the SPSS software (version 22; SPSS Inc; Chicago, Illinois, USA). 
RESULTS
Group characteristics 
The intervention group drank a median of 120 g (IQR: 63-120 g) alcohol/week before the 
intervention, while the control group did not drink any alcohol. The age, gender, body 
composition and demographics of the two groups were comparable (see Table 1). 
Table 1. Group characteristics baseline 
Intervention (n=16) Controls (n=9) P-value 
Gender (n, % male) 10 (62.5) 4 (44.4) NS
Age (years) 55 (42-64) 58 (26-61) NS
Alcohol (g/week) 120 (IQR: 63-120) 0 <0.001
Alcohol frequency (days/week) 3 (IQR 3-4) 0 <0.001
 -Smokers (n,% current / past ) 2 (12.5) / 10 (62.5) 0 / 4 (44.4) 
Comorbiditity (n,%) 6 (37.5) 3 (33.3) NS
 -Cardiovascular/Diabetes 3 (50.0) 2 (66.7)
 -Other 3 (50.0) 1 (33.3)
 -BMI 24.3 (IQR: 22.6-27.2 22.3 (IQR: 19.7-26.9) NS
 -Mean arterial blood pressure (mmHg) 93.7 (IQR: 86.0-98.9) 75.3 (IQR 67.8-98.8) NS
 -Body fat (%)* 27.9 (IQR: 24.1-32.6) 30.2 (21.9-36.7) NS
 -Highest education 
  (% college degree) 
13 (81.3) 9 (100) NS
 -Family situation 
   (% household with partner)
14 (87.5) 7 (77.8) NS
 -Employment 
  (% employed / retired) 
13 (81.3) / 2 (12.5) 6 (66.7) / 2 (22.2) NS
Legend: number, percentage, median and IQR (25th -75th percentile) or mean ± SD are shown. 
* measured with bio-impedance analysis. NS: not significant, p-value >0.05.   
Intervention and follow-up
All of the participants reported absolute alcohol abstinence during the intervention period. 
CDT mirrored alcohol consumption and remained unchanged in the controls (T0: 1.39% 
(1.33-1.45%) and T4 1.35% (1.32-1.48%)). CDT decreased during abstinence (T0: 1.50% 
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(1.29-1.67%) to T4 1.38% (1.22-1.46%), p=.008). During the follow-up, participants in 
the intervention group resumed alcohol consumption, averaging 138 g (IQR: 75-159 g) 
alcohol/week, a higher intake than before the intervention period. 
The liver after the intervention
The liver measurements of all of the participants at baseline were within the normal range. 
Liver stiffness (measured with both modalities) and liver fat percentage were similar be-
tween and within groups across all time points (see panels A and B, Figure 1). 
The median thickness of abdominal fat was 18.7 mm (IQR: 13.2-27.0 mm) in the 
intervention group and 16.2 mm (IQR: 11.2-22.6 mm) in the control group (p=.108). The 
median thickness remained stable within and between groups at T0, T4 and T8 (Panel C, 
Figure 1). 
The liver biochemistry values of one participant in the control group exceeded the 
upper limit of the normal range at all three time points, but the values were included in 
the final analysis. In the intervention group, GGT decreased from 24.6 U/L (IQR: 20.1-
33.1 U/L) at T0 to 21.0 U/L (IQR: 15.6-26.3 U/L) at T4 and rose again to 23.1 U/L (IQR: 
20.0-32.4 U/L)at T8 (p=.001 and p=.010, respectively). The values remained unchanged 
in the control group; 21.1 U/L (IQR: 15.2-41.1 U/L) at T0; 20.6 U/L (IQR: 15.0-38.5 U/L) 
Figure 1. Effects of alcohol abstinence 
Legend: Median values with interquartile range of measurements at T0, T4 and T8 are shown for the 
interventional group (black circles) and controls (open squares). (A) shows liver stiffness (kPa), (B) liver 
fat percentage (%), (C) thickness of abdominal fat (mm), (D) GGT levels (U/l) and (E) ferritin levels (ug/l). 
Statistically significant differences of repeated measures of GGT at T4 and T8 in interventional group are 
stated with corresponding P-values in (D).
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at T4; 22.7 U/L (IQR: 15.2-47.2 U/L) at T8 (p=.953 and p=.441, respectively; see Panel D, 
Figure 1). 
In a multivariate analysis, time and group interacted significantly with change in GGT 
at T4 (p=.011). AST, ALT and ALP did not change with the intervention, and did not differ 
between the intervention group and the control group. The laboratory values at all three 
time points are shown in Supplementary Table S1. 
The intervention group had higher ferritin levels at baseline than the controls: 106.8 
ug/L (IQR: 51.8-281.6 ug/L) vs. 55.5 ug/L (IQR: 21.4-99.9 ug/L), p=.027). The intervention 
did not change the ferritin levels. At T4, the ferritin levels were 86.2 ug/L (IQR: 52.0-307.0 
ug/L) in the intervention group, compared to 53.0 ug/L (IQR: 22.0-69.4 ug/L) in the control 
group, and remained unchanged after four weeks of resumed alcohol consumption (T8): 
120.4 ug/L (IQR: 41.0-300.1ug/L) vs. 39.7 ug/L (IQR: 25.7-78.8 ug/L); see Panel E, Figure 
1).
DISCUSSION
We found that one month of abstinence from alcohol resulted in a significant decrease in 
GGT levels in a group of moderate alcohol consumers. Resumption of moderate alcohol 
consumption resulted in a return to the values seen at baseline. All of the observed changes 
were within the range of normal values, but the effect size was larger in two participants 
with a higher alcohol intake (120 g/week). It is tempting to speculate that GGT might serve 
as a biomarker of abstinence. 
GGT is an important factor in maintaining high concentrations of glutathione –a strong 
mitochondrial anti-oxidant – in the liver tissue during oxidative stress (Whitfield, 2001). 
GGT increases with increasing alcohol intake. With the enzymatic conversion of alcohol 
to acetaldehyde, reactive oxygen species (ROS) are released in the liver (van Beek et al., 
2014). Both acetaldehyde and ROS are toxic to hepatocytes, and are associated with 
oxidative stress and cell death (Ajakaiye et al., 2011). 
The decrease in GGT observed in this study, albeit modest in absolute numbers, most 
likely reflects reduced oxidative stress. 
Measurements of liver stiffness and liver fat percentage remained unchanged after 
alcohol cessation. This contrasts with the reduction in liver stiffness found in a UK study 
(Mehta et al., 2015), although in comparison with our study, participants had a higher 
alcohol intake at baseline and a higher degree of hepatic steatosis. It is possible that 
elastography lacks the sensitivity to detect small but relevant changes in liver architecture 
that result from alcohol cessation in moderate consumers. Such early changes may be 
reflected by GGT levels (Whitfield, 2001).
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The design of this study has several limitations. First, both groups were small, and 
the number of participants and distribution of data per group differed, possibly affecting 
the statistical analyses between groups. Nonetheless, significant differences were already 
present immediately after the intervention in the small intervention group, suggesting that 
the results would withstand scrutiny in larger studies. The use of a control group with 
stable measurements at the different time points reduces the risk of measurement intravari-
ability as an explanation for the observed differences. Secondly, we could not correct 
for all possible confounders during the intervention, such as diet and lifestyle changes. 
The participants did not report changes in physical activity, but it is possible that alcohol 
abstinence is associated with an (unreported) improved life style. We did not add a third 
group that did not cease moderate drinking, as this was a pilot study. A follow-up study 
with randomisation of the intervention and larger numbers of participants is needed to 
confirm our results. Finally, alcohol intake was self-reported by the participants, possibly 
leading to recall bias. As the participants acted as their own controls in our within-subject 
repeated measures design, changes in reports may be more important than the accuracy 
of reports. 
Framing our findings from a societal perspective. The scientific evidence that alcohol 
significantly impairs health, even in low volumes, is irrefutable (Stockwell et al., 2016). 
Nonetheless, alcohol consumption remains deeply anchored within the culture of Eu-
ropean societies. More than three quarters of European citizens consume alcohol on a 
regular basis, resulting in a total annual health burden of 125 billion Euros (Laramée 
et al., 2013). The efficacy of public warning campaigns is limited, although promising 
initiatives have been launched (Hassan et al., 2018). Increasing taxes, restrictions on the 
sale of alcohol, and bans on alcohol advertising may be cost-effective measures to reduce 
alcohol consumption (Anderson et al., 2012). Lifestyle interventions such as Dry January 
have been shown to have both short-term and long-lasting effects (de Visser et al., 2016; 
de Visser et al., 2017). The positive message of the possibility of improving liver health 
through abstinence could be advocated by policy makers to meet the challenge of reduc-
ing the societal burden of alcohol consumption. 
In conclusion, we found that one month of alcohol abstinence resulted in a decrease 
in GGT (within the normal range) in moderate alcohol consumers without apparent pre-
existing liver damage. 
Acknowledgements: We would like to thank Rebecca van Veen and Denise Janssen-Bell 
for performing ultrasounds. 
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Supplementary table S1. 
T0 T4 T8 
Variable Intervention Controls Intervention Controls Intervention Controls
GGT (U/L) 24.6 
(20.1-33.1)
21.1 
(15.2-41.1)
21.0 
(15.6-26.3)**
20.6 
(15.0-38.5)
23.1 
(20.0-32.4)**
22.7 
(15.2-47.2)
AST (U/L) 23.0 
(20.0-27.0)
26.0 
(24.0-29.0)
22.0 
(19.0-26.0)
25.0 
(22.0-28.0)
23.0 
(20.0-28.0)**
28.0 
(27.0-35.0) *
ALT (U/L) 24.0
(19.0-31.0)
24.0 
(18.0-33.0)
22.5 
(19.0-28.0)
25.0 
(22.0-31.0)
22.0 
(19.0-31.0)
28.0 
(21.0-38.0)
ALP (U/L) 68.0 
(53.0-80.0)
64.0 
(52.0-87.0)
62.5 
(52.0-74.0)
65.0 
(55.0-84.0)
65.5 
(53.0-81.0)
68.0 
(56.0-94.0)
Legend: Median and interquartile range (25th-75th) percentile are shown. 
* p<.05 and ** p=<.01 in univariate repeated measures analyses within group. In a multivariate analysis 
time and group interacted significantly with change in GGT at T4 (p=.011). Changes in ALT, AST and 
ALP were not statistically significant in a multivariate analysis.  
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ABSTRACT 
Background
Fontan-associated liver disease (FALD) is a severe comorbidity in patients with a Fontan 
circulation. FALD encompasses a wide clinical spectrum and currently we are unable to 
predict who is at risk for severe liver fibrosis and complications. Liver histology is the gold 
standard for assessment of fibrosis, but it is unknown whether the histological features of 
FALD are reported in a standardized way. 
Aims
To identify common themes and components in the histological assessment of FALD 
across literature to allow development of a unified reporting system. 
Methods
Pubmed, Web of Science, and Embase were systematically searched in adherence to 
PRISMA, to identify all articles published up to May 2018 on liver histology in patients 
with a Fontan circulation. Components of the reported histological assessment were ex-
tracted using a building block approach, to uncover mutual themes across studies.   
Results
From 1071 identified articles, 62 were included. In 27/62 (44%) articles, methodology of 
histological assessment was specified and components of reporting were further analysed. 
Six major building blocks were identified; gross fibrosis (n=27, 100%), sinusoidal fibrosis 
(n=19, 70%), quantitative fibrosis (n=3, 11%), sinusoidal dilatation (n=12, 44%), inflam-
mation (n=17, 63%) and miscellaneous features (n=8, 30%). The used histological grading 
systems were very heterogeneous, as most were not used again in subsequent studies.   
Conclusion
There is a major inconsistency in reporting of histological FALD across studies. The 
identified building blocks could aid in constituting a standardized system for reporting 
histological findings, to serve future research focused on pathophysiology, prevalence, 
and prognosis of FALD.  
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INTRODUCTION 
The Fontan procedure is used to re-establish appropriate circulation in patients with 
congenital heart disease resulting in a single functional ventricle. Fontan-associated liver 
disease (FALD), is an increasingly recognized source of (liver) morbidity and mortality.1-3 
FALD encompasses a wide clinical spectrum and ranges from isolated elevation of liver 
enzymes to decompensated liver cirrhosis. FALD affects populations of all age and pa-
tients may develop serious complications, such as hepatocellular carcinoma (HCC).4,5 The 
progression rate of FALD and ultimate prognosis of patients are not known. Currently, we 
are unable (1) to predict who will develop severe FALD and (2) chart the clinical course 
with respect to liver-related complications.  
Liver fibrosis severity is the most important prognostic factor for development of liver 
related complications, regardless of cause of liver disease.6,7 It is reasonable to hypothesize 
that liver fibrosis is a major contributor to (liver-related) morbidity and mortality in patients 
with a Fontan circulation. The gold standard to determine severity of fibrosis is histological 
assessment of a liver biopsy specimen.8 Other liver diseases, for example viral hepatitis, 
have established grading systems such as METAVIR to assess liver histology.9 These scoring 
systems appreciate the disease-specific histopathological patterns of fibrosis and other 
elements, such as inflammation, that contribute to fibrogenesis. Standardized appraisal of 
histology has greatly facilitated longitudinal outcome studies assessing disease course and 
morbidity and mortality risk in patients with a chronic liver disease.10,11 A similar uniform 
reporting of histological features of FALD would be valued aid in accurate assessment 
of prevalence and prognosis of FALD. Apart from fibrosis, liver congestion is a relevant 
finding, as it is thought to be the driving initiator of fibrogenesis in FALD.12,13 Nonetheless, 
the contribution of these separate elements to the histological picture of FALD are largely 
unexplored. Studies that describe liver histopathology data in FALD typically report pres-
ence of liver fibrosis and sinusoidal dilatation as feature of congestion, without hepatic 
inflammation.14-16 There is an unmet need for uniform reporting on liver histology, as this 
could support the development of a cohesive concept for FALD.
As a first step forward, we sought to (1) determine which histological descriptions of 
FALD have been reported in literature and (2) identify common themes and components as-
sessed across studies to allow development of a consensus on histological reporting of FALD. 
METHODS 
Literature search 
A systematic search of Medline (PubMed), EMBASE and Web of Science was conducted 
in collaboration with a research librarian, using the key words ‘Fontan’ AND ‘Liver’ or 
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variants of these terms. The complete search grid is shown in Supplementary Table 1. 
‘Histology’ (and related terms to this concept) were not included in the search strategy 
to ensure that articles reviewing liver histology not as a primary aim or only in a propor-
tion of patients were not missed. The search was conducted according to the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-analysis) guideline 17. There 
were no restrictions in the search on study design, date of publication, number of patients 
or language. The final search was performed on 02/05/2018. Reference lists of included 
studies were thoroughly examined to identify additional studies of potential interest.  
In- and exclusion criteria/Study selection 
Two reviewers (IM and FUtC) independently screened titles and abstracts, and evaluated 
full-text articles if deemed potentially relevant or if suitability of a study was uncertain. 
This systematic review was performed with an inductive approach. Studies were included 
if they were: (1) peer-reviewed, (2) reported on liver histology assessment (i.e. by biopsy, 
autopsy or surgical resection), (3) in patients with a Fontan circulation. Studies were 
excluded if they: (1) did not report on the outcomes of the histological assessment, (2) 
did not contain original data (i.e. reviews, letters, editorials), (3) full-text was written in 
a language other than English. Disagreement upon selection was resolved with mutual 
discussion and if necessary, consensus was reached upon consultation of a third reviewer 
(ET). 
Data extraction
Data were independently extracted by two reviewers (IM and FUtC). Discrepancies were 
also mutually resolved. When no consensus could be achieved, a third reviewer (ET) 
made the final decision. A standardized form was used to ensure consistency of the data 
extraction. The following data were extracted for all included studies: (1) general study in-
formation (i.e. 1st author, study location, year of publication); (2) study characteristics (i.e. 
study purpose and design); (3) population characteristics (i.e. total sample size, sample 
with liver histology, age of population and cardiac status); (4) histological assessment 
characteristics (i.e. specification of histological assessment in methods section, indication 
for liver histological assessment, type of histology, and type of stains used); (5) reported 
histology assessment (i.e. description of histology outcome present (Y/N) and transcrip-
tions of the histology description itself).
Data synthesis and analysis using the building block approach 
All extracted data were organized in tabular form and qualitative assessment of histology 
descriptions was performed. We hypothesised that if we could dissect the reporting of liver 
histology assessment into smaller components of useful information, we might be able to 
discover patterns among the different histological assessment methods to identify useful 
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components and grading systems. This concept has previously been described 18,19. In 
short, the building block approach successively pares down a definition or description to 
its constituent pieces or ‘building blocks’. We adapted this method to analyse the reported 
histological assessment of FALD. 
We conducted a two-step approach to identify relevant studies for the building block 
approach. First, only studies reporting on fibrosis as an outcome were included, since 
this is the most important component of histological assessment. Second, only studies 
describing in the methods section how histology was assessed were further analysed, as 
their systematic assessment made subdivision of components feasible. 
From these articles, descriptions of reported histology components and grading systems 
were further analysed to examine whether they could be incorporated into encompassing 
building blocks, aiming to uncover relevant patterns in reporting across studies.
RESULTS
Identification of the literature 
After removal of 1044 duplicates, we screened 1071 records on title and abstract. We 
excluded 830 articles as they did not meet selection criteria. We reviewed 182 full-text 
reviewed records and 62 articles entered the data-extraction stage (references are shown 
in Supplementary File 1). Figure 1 provides the PRISMA flow diagram with specified 
reasons for full-text exclusion. 
Description of histological assessment 
Seven studies (11%) reported histological results of biopsied nodules, but not of surround-
ing liver architecture or fibrosis. In 28 articles (45%) the outcome of histology was reported, 
but without a clear description how histology was assessed or how abnormalities were 
defined (See Figure 2). For example, several studies reported that the liver biopsy “showed 
cirrhosis” or “was abnormal”, but did not offer further specification. Fibrosis severity was, 
when mentioned, not defined. Qualitative descriptions such as “bridging fibrosis is pres-
ent” or “there was grade 4 fibrosis” were reported, without identification of the process 
that led to this description or which grading systems were used (See Supplementary Table 
2 for all reported descriptions). There were 27 articles (44%), who performed histological 
assessment with a pre-specified protocol, definition or grading system mentioned in the 
methods section. These articles served as input for analysis to identify patterns among 
reported components and grading systems of FALD. 
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Study and population characteristics
All 27 articles were published between 2005 and 2018, and 60% were published after 
2015. Thirteen studies (48%) were retrospective by nature, while 14 (52%) carried a pro-
spective design. In 11/27 studies (41%) the primary aim of the study could be interpreted 
as characterisation of histopathological liver features in patients with a Fontan circulation. 
Eight studies (30%) included only adult patients, two (7%) only pediatric patients, and 
56% was mixed. Cardiac status widely differed across studies; ranging from asymptomatic 
patients (33%), to patients with a failing Fontan (15%). See Supplementary Table 3 for 
study and population characteristics. 
Figure 1. PRISMA Flow Diagram 
Legend: The flow diagram depicts the process from identification to selection of articles.
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Reporting of histological components of FALD
In total, 38 histological components were reported in the 27 included papers (See 
Supplementary Table 4 for an overview). These 38 components could be clustered into 
6 major building blocks of histological assessment: (1) overall fibrotic and architectural 
changes (GROSS FIBROSIS), (2) sinusoidal fibrotic changes (SINUSOIDAL FIBROSIS), (3) 
quantification of amount of fibrosis by digital image analysis of a suitably stained section 
(QUANTITATIVE FIBROSIS) (4) dilatation of sinusoids or congestive changes (SINUSOI-
DAL DILATATION), (5) Inflammatory/necrotic foci or infiltrates (INFLAMMATION), (6) 
other histological features, such as steatosis, cholestasis, and iron deposition (MISCEL-
LANEOUS). Figure 3 depicts examples of the liver histology in FALD. Assessment of gross 
fibrosis was, to some extent, reported in all papers. Sinusoidal fibrosis was reported in 
70%, quantitative fibrosis in 11%, sinusoidal dilatation in 44%, inflammation in 63%, 
and 30% of papers reported on miscellaneous features. Reporting of building blocks 1-4 
was done in 10/27 (37%) of studies (See figure 4 for patterns across studies in reporting 
the building blocks). 
Figure 2. Description histology assessment in included articles
Legend: Piechart depicting percentages of studies only reporting on liver nodules and not assessing 
surrounding liver architecture (n=7, 11%), studies without predefined methodology for histological as-
sessment (n=28, 45%), and of studies with a defined protocol for histolocigal assessment (n=27, 44%). 
These studies were included in the building block approach. 
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Figure 3. Histopathological features of FALD  
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Legend: Exemplary photographs of histological slides from patients with FALD, monitored at the Radboud university 
medical centre, were taken with a camera attached to a microscope and processed in a digital image analysis programme. 
Panel A: overview of cirrhotic liver biopsy (gross fibrosis stage 4), with broad scars, bridging fibrosis, sinusoidal fibrosis and 
nodular regeneration. Sirius red stain, objective lens 5x. Panel B: close-up of liver biopsy, showing sinusoidal fibrosis 
(“chicken-wire pattern”), with collagen staining along the dilated sinusoids (stage 2), objective lens 20x. Panel C: overview 
of liver biopsy with severe sinusoidal dilatation (stage 3), Hematoxylin-Eosin stain, objective lens 5x. Panel D: close-up of 
severe sinusoidal dilatation (stage 3), H-E, objective lens 20x.  
 
Use of semi-quantitative grading systems  
In most cases (85%), gross fibrosis severity was assessed using a semi-quantitative grading system 
(2/27 used descriptive and 2/27 employed a sole quantitative measurement). Reported grading 
systems were very heterogeneous between studies, and a total of 14 different scores were used. 
Many of the scores are derived from scores previously used in other aetiologies (such as METAVIR), 
but with unique modifications and interpretations, and most of these bespoke systems have not 
been evaluated in subsequent studies. For sinusoidal fibrosis, a system scoring the proportion of 
sinusoids being fibrotic, was most commonly used (n=12, 63%). However, in half of cases the score, 
instead of ranging 0-3, had an additional fourth stage defined as “cardiac cirrhosis”. Sinusoidal 
dilatation was most commonly scored (ranging 0-3) as the proportion of sinusoids being dilated (n=5, 
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biopsy with severe sinusoidal dilatation (stage 3), Hematoxylin-Eosin stain, objective lens 5x. Panel D: 
close-up of severe sinusoidal dilatation (stage 3), H-E, objective lens 20x. 
Use of semi-quantitative grading systems 
In most cases (85%), gross fibrosis severity was assessed using a semi-quantitative grad-
ing system (2/27 used descriptive and 2/27 employed a sole q antitative measurement). 
Reported grading systems were very heterogeneous between studies, and a total of 14 
different scores were used. Many of the scores are derived from scores previously used in 
other aetiologies (such as METAVIR), but with unique modifications and interpretations, 
and most of these bespoke systems have not been evaluated in subsequent studies. For 
sinusoidal fibrosis, a system scoring the proportion of sinusoids being fibrotic, was most 
commonly used (n=12, 63%). However, in half of cases the score, instead of ranging 0-3, 
had an additional fourth stage defined as “cardiac cirrhosis”. Sinusoidal dilatation was 
most commonly scored (ranging 0-3) as the proportion of sinusoids being dilated (n=5, 
50%). Reporting of inflammation grading was heterogeneous, with differences in location 
of inflammation or range of the scoring system used (See Supplementary Table 4 for all 
grading systems used). 
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Figure 4. Overview of building blocks used in histological assessment of FALD
Legend: Reference numbers are derived from supplementary file 1. Dark grey building blocks represent 
studies reporting the building block using a grading system, light grey blocks refer to a descriptive man-
ner of reporting. †N depicts number of patients with histology per included study. ‡ Miscellaneous com-
ponents are steatosis, hepatocellular damage or necrosis, plate twinning, orcein, or lipofuscin positivity, 
cholestasis, iron, ductular proliferation, megamitochondria and core fragmentation.
DISCUSSION 
The present systematic review demonstrates major heterogeneity in scientific reporting 
of histopathological components of FALD. We identified 3 major issues. First, more than 
half of the papers did not define methods that specify how liver histology was assessed. 
Second, even if assessment was defined, studies differed greatly in choice of histological 
components they reported. Finally, studies used a wide range of different grading systems 
to assess similar components. Even for the most important and uniformly reported com-
ponent, fibrosis, numerous staging methods were reported. This identified heterogeneity 
carries great clinical impact, as it hampers interpretation of, and comparison between, 
reported fibrosis prevalence, severity, and prognosis in this population.20-24 
Fundamentally, we lack a uniform definition of the pattern of Fontan-associated fibro-
sis and there is no consensus how it should be staged. From a histopathological view, the 
pattern of fibrosis has always been linked to the underlying aetiology and scored as such.25 
For example, in viral hepatitis, fibrosis first becomes apparent around portal triads, and 
then progresses by forming septa with a portal-to-portal progressive bridging pattern. To 
assess severity, the portal-based METAVIR score was formulated, incorporating in the score 
this specific portal-based pattern allied with the extent of fibrosis.9 In NAFLD, bridging 
fibrosis tends to expand from one central vein to another, accompanied by characteristic 
“chicken-wire” sinusoidal fibrosis. This is reflected in the specific NAFLD fibrosis score.26 
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In patients with a Fontan circulation, both portal and pericentral sinusoidal fibrosis can be 
present and are therefore often scored separately.14 The difficulty arising from a simultane-
ous use of two different scores within one disease entity is to decide which severity or 
staging has the most value. Cirrhosis ’derived’ from the sinusoidal score is thereby implied 
to differ from a cirrhosis that it is portal derived. However, cirrhosis should be seen as 
a pathological stage asserted to specific architectural changes that includes extensive 
bridging from one vascular structure to the other, and the subsequent transformation 
of a lobular to a nodular liver architecture, independent of the presence or absence of 
sinusoidal fibrosis.27 Cardiac or Fontan cirrhosis may therefore be the equivalent to any 
other form of cirrhosis, for instance alcoholic cirrhosis, with a similar histopathological 
appearance, but with an alternate clinical cause (cardiac or Fontan failure). 
We suggest that assessment of fibrosis in FALD should be made using a grading system 
that evaluates the overall fibrosis and architectural changes in a manner common to evalu-
ation of all other chronic liver disease. Most Fontan studies did assess gross fibrosis to 
some degree, however the diversity in scoring systems is wide. Several reported scores 
were derived from scores such as METAVIR and Ishak, but modified to make it Fontan-
specific.14,15,28,29 These adjustments and differences between the various scores, although 
mostly subtle, do cause ambiguity for clinicians to interpret and compare reported out-
comes. By uniformly reporting an equal gross fibrosis staging system in future research 
and clinical practice, comparison between patients with FALD is assured, and fibrosis 
severity in this population could be compared to other chronic liver diseases. 
In addition to semi-quantitative staging, digital quantitative measurement of fibrosis 
(by digital image analysis of the Sirius Red stained tissue area %, commonly referred 
to as collagen proportionate area) could aid to increase accuracy of assessment.30,31 It 
produces a continuous outcome,e and lacks intra- and inter-observer variability often seen 
in histological staging.32 However, CPA does not take architectural distribution into ac-
count, and cirrhosis cannot be defined merely on the extent of fibrotic changes. Although 
digital pathology research is rapidly growing, application in clinical practice it is still in 
its infancy. 
It is thought that fibrogenesis in FALD is the result of congestion, instead of being 
inflammation-driven as in most other chronic liver diseases (viral hepatitis, NAFLD, alco-
hol).12,33-35 With the Fontan circulation, systemic venous pressure rises significantly, and 
is transferred to the hepatic veins, causing sinusoidal dilatation at the level of the liver 
lobule.36 This is underscored by the few studies that systematically assessed histological 
FALD, showing inflammation only in a minority and sinusoidal dilatation in the majority 
of patients.15,16,20 How congestion initiates accumulation of fibrosis is not understood. 
An experimental murine model of congestive hepatopathy showed that congestion leads 
to sinusoidal thrombosis, strain, activation of hepatic stellate cells (HSCs) and increased 
Sirius Red deposition.37 However, this model is far from the complex situation present in 
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the Fontan circulation, in which many more contributors may be present. The presumed 
clinical correlations of sinusoidal dilatation severity, systemic venous pressure or duration 
of Fontan circulation, with severity of fibrosis, all remain unconfirmed.2,38,39 Hitherto, we 
lack a good disease-specific experimental model to study mechanisms of fibrogenesis in 
FALD. Future research should focus on finding alternatives to study these mechanisms. 
Exploration of HSC activation and the extracellular matrix composition of FALD liver tis-
sue, by simple immunohistochemical staining with alpha-smooth actin, or more advanced 
techniques as mass spectrometry to examine the proteomic profile, are examples of this.40 
There are some limitations to the systematic review we performed. First, when compo-
nents were not reported, we assumed they were also not assessed. However, there could 
have been reporting bias, since every histopathological assessment presumably consists of 
standard scoring of features such as inflammation. Nonetheless, by not reporting (although 
assessing) components, there remains uncertainty about the prevalence and contribution 
of specific histological features to the spectrum of FALD. Secondly, we did not perform a 
formal risk of bias assessment of the included studies; since our primary aim was to give 
an overview of reporting, and not to grade or compare the differently used methods, we 
regarded this beyond the scope of this review. Nonetheless, it is clear that most studies are 
at risk for population bias, as they consisted of retrospective cohorts with limited number 
of patients. Only a small number of studies did assess FALD histology in a prospective, 
consecutive and systematic manner, and these possibly reflect true prevalence of FALD 
in the population.16,41 Future reviews aiming at comparing methods or at assessing preva-
lence should include such a quality assessment. 
In conclusion, this systematic review shows that there is a major heterogeneity in 
reporting of histological FALD across studies. To facilitate much-needed research on the 
prevalence, prognosis and mechanisms of this severe comorbidity in the growing Fontan 
population we propose to come to a uniform reporting of histological features, including 
fibrosis, sinusoidal dilatation, inflammation, and standard histological features. 
92
C
ha
pt
er
 5
REFERENCES
 1. Rychik J, Veldtman G, Rand E, et al. The 
precarious state of the liver after a Fontan 
operation: summary of a multidisci-
plinary symposium. Pediatric cardiology. 
2012;33(7):1001-1012.
 2. Goldberg DJ, Surrey LF, Glatz AC, et al. 
Hepatic Fibrosis Is Universal Following 
Fontan Operation, and Severity is As-
sociated With Time From Surgery: A Liver 
Biopsy and Hemodynamic Study. Journal 
of the American Heart Association. 
2017;6(5).
 3. Bradley E, Hendrickson B, Daniels C. 
Fontan Liver Disease: Review of an 
Emerging Epidemic and Management 
Options. Curr Treat Options Cardiovasc 
Med. 2015;17(11):1-15.
 4. Tellez L, Rodriguez-Santiago E, Albillos 
A. Fontan-Associated Liver Disease: A 
Review. Ann Hepatol. 2018;17(2):192-
204.
 5. Wu FM, Ukomadu C, Odze RD, Valente 
AM, Mayer JE, Jr., Earing MG. Liver dis-
ease in the patient with Fontan circula-
tion. Congenit Heart Dis. 2011;6(3):190-
201.
 6. Huo T-I, Lee S-D, Lin H-C. Select-
ing an optimal prognostic system for 
liver cirrhosis: the model for end-stage 
liver disease and beyond. Liver Int. 
2008;28(5):606-613.
 7. Angulo P, Kleiner DE, Dam-Larsen S, et 
al. Liver Fibrosis, but No Other Histologic 
Features, Is Associated With Long-term 
Outcomes of Patients With Nonalcoholic 
Fatty Liver Disease. Gastroenterology. 
2015;149(2):389-397.e310.
 8. Germani G, Hytiroglou P, Fotiadu A, 
Burroughs AK, Dhillon AP. Assessment of 
Fibrosis and Cirrhosis in Liver Biopsies: 
An Update. Seminars in liver disease. 
2011;31(01):082-090.
 9. Bedossa P, Poynard T. An algorithm for 
the grading of activity in chronic hepa-
titis C. The METAVIR Cooperative Study 
Group Hepatology. 1996;24.
 10. Dulai PS, Singh S, Patel J, et al. Increased 
risk of mortality by fibrosis stage in non-
alcoholic fatty liver disease: Systematic 
review and meta-analysis. Hepatology. 
2017;65(5):1557-1565.
 11. Everhart JE, Wright EC, Goodman ZD, 
et al. Prognostic value of Ishak fibrosis 
stage: findings from the hepatitis C antivi-
ral long-term treatment against cirrhosis 
trial. Hepatology. 2010;51(2):585-594.
 12. Asrani SK, Asrani NS, Freese DK, et al. 
Congenital heart disease and the liver. 
Hepatology. 2012;56(3):1160-1169.
 13. Myers RP, Cerini R, Sayegh R, et al. Cardi-
ac hepatopathy: clinical, hemodynamic, 
and histologic characteristics and cor-
relations. Hepatology. 2003;37(2):393-
400.
 14. Schwartz MC, Sullivan LM, Glatz AC, et 
al. Portal and sinusoidal fibrosis are com-
mon on liver biopsy after Fontan surgery. 
Pediatric cardiology. 2013;34(1):135-
142.
 15. Kendall TJ, Stedman B, Hacking N, et al. 
Hepatic fibrosis and cirrhosis in the Fon-
tan circulation: a detailed morphological 
study. J Clin Pathol. 2008;61(4):504-508.
 16. Surrey LF, Russo P, Rychik J, et al. Preva-
lence and characterization of fibrosis in 
surveillance liver biopsies of patients 
with Fontan circulation. Hum Pathol. 
2016;57:106-115.
 17. Moher D, Liberati A, Tetzlaff J, Altman 
DG, The PG. Preferred Reporting Items 
for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS 
Med. 2009;6(7):e1000097.
 18. Udink ten Cate FE, Hannes T, Germund I, 
et al. Towards a proposal for a universal 
diagnostic definition of protein-losing en-
teropathy in Fontan patients: a systematic 
review. Heart. 2016;102(14):1115-1119.
93
 19. Getting PA. Emerging Principles Govern-
ing the Operation of Neural Networks. 
Annu Rev Neurosci. 1989;12(1):185-
204.
 20. Wu FM, Jonas MM, Opotowsky AR, 
et al. Portal and centrilobular hepatic 
fibrosis in Fontan circulation and clini-
cal outcomes. J Heart Lung Transplant. 
2015;34(7):883-891.
 21. Simpson KE, Esmaeeli A, Khanna G, et 
al. Liver cirrhosis in Fontan patients does 
not affect 1-year post-heart transplant 
mortality or markers of liver function. J 
Heart Lung Transplant. 2014;33(2):170-
177.
 22. Hilscher MB, Johnson JN, Cetta F, et al. 
Surveillance for liver complications after 
the Fontan procedure. Congenit Heart 
Dis. 2017:n/a-n/a.
 23. Ohuchi H. Adult patients with Fontan 
circulation: What we know and how to 
manage adults with Fontan circulation? J 
Cardiol. 2016;68(3):181-189.
 24. Greenway SC, Crossland DS, Hudson 
M, et al. Fontan-associated liver disease: 
Implications for heart transplantation. J 
Heart Lung Transplant. 2016;35(1):26-
33.
 25. Standish RA, Cholongitas E, Dhillon A, 
Burroughs AK, Dhillon AP. An appraisal 
of the histopathological assessment of 
liver fibrosis. Gut. 2006;55(4):569-578.
 26. Kleiner DE, Brunt EM, Van Natta M, et al. 
Design and validation of a histological 
scoring system for nonalcoholic fatty liver 
disease. Hepatology. 2005;41(6):1313-
1321.
 27. Germani G, Burroughs AK, Dhillon AP. 
The relationship between liver disease 
stage and liver fibrosis: a tangled web. 
Histopathology. 2010;57(6):773-784.
 28. Wu FM, Earing MG, Aboulhosn JA, et al. 
Predictive value of biomarkers of hepatic 
fibrosis in adult Fontan patients. J Heart 
Lung Transplant. 2017;36(2):211-219.
 29. Johnson JA, Cetta F, Graham RP, et al. 
Identifying predictors of hepatic disease 
in patients after the Fontan operation: 
a postmortem analysis. The Journal of 
thoracic and cardiovascular surgery. 
2013;146(1):140-145.
 30. Calvaruso V, Burroughs AK, Standish R, 
et al. Computer-assisted image analysis 
of liver collagen: relationship to Ishak 
scoring and hepatic venous pressure 
gradient. Hepatology. 2009;49(4):1236-
1244.
 31. Tsochatzis E, Bruno S, Isgro G, et al. 
Collagen proportionate area is superior 
to other histological methods for sub-
classifying cirrhosis and determining 
prognosis. Journal of hepatology. 
2014;60(5):948-954.
 32. Rousselet MC, Michalak S, Dupre F, et 
al. Sources of variability in histological 
scoring of chronic viral hepatitis. Hepa-
tology. 2005;41(2):257-264.
 33. Wells ML, Venkatesh SK. Congestive 
hepatopathy. Abdominal Radiology. 
2017.
 34. Marra F, Aleffi S, Bertolani C, Petrai I, 
Vizzutti F. Review article: the pathogen-
esis of fibrosis in non-alcoholic steato-
hepatitis. Alimentary pharmacology & 
therapeutics. 2005;22 Suppl 2:44-47.
 35. Wallace MC, Friedman SL, Mann 
DA. Emerging and disease-specific 
mechanisms of hepatic stellate cell 
activation. Seminars in liver disease. 
2015;35(2):107-118.
 36. Shah H, Kuehl K, Sherker AH. Liver 
disease after the Fontan procedure: what 
the hepatologist needs to know. J Clin 
Gastroenterol. 2010;44(6):428-431.
 37. Simonetto DA, Yang H-y, Yin M, et al. 
Chronic Passive Venous Congestion 
drives Hepatic Fibrogenesis via Sinusoi-
dal Thrombosis and Mechanical Forces. 
Hepatology. 2015;61(2):648-659.
 38. Kutty SS, Peng Q, Danford DA, et al. 
Increased hepatic stiffness as conse-
94
C
ha
pt
er
 5
quence of high hepatic afterload in the 
Fontan circulation: a vascular Doppler 
and elastography study. Hepatology. 
2014;59(1):251-260.
 39. Evans WN, Winn BJ, Yumiaco NS, et al. 
Transvenous hepatic biopsy in stable 
Fontan patients undergoing cardiac 
catheterization. Pediatric cardiology. 
2014;35(7):1273-1278.
 40. I.D. M, T. K, N. K, et al. Extracellular 
matrix components indicate remodelling 
activity in different fibrosis stages of 
human non‐alcoholic fatty liver disease. 
Histopathology.0(ja).
 41. Evans WN, Acherman RJ, Ciccolo ML, et 
al. MELD-XI Scores Correlate with Post-
Fontan Hepatic Biopsy Fibrosis Scores. 
Pediatric cardiology. 2016;37(7):1274-
1277.
95
SUPPLEMENTARy TABLES 
Supplementary Table 1. Search grids for searched databases 
Database Search grid No. of 
items 
found 
PUBMED (“Fontan Procedure”[Mesh] OR “Heart Ventricles/surgery”[Mesh] OR 
Cavopulmonary [tiab] OR Fontan [tiab]) 
AND  
(((“Liver Cirrhosis”[Mesh]) OR (((“Liver Diseases”[Mesh] OR liver[tiab] 
OR livers[tiab] OR hepato[tiab] OR hepatoc*[tiab] OR hepati*[tiab]))))) 
OR cirrho*[tiab]
 507
EMBASE 1
(Heart Ventricle* or Single Ventricle* or Cavopulmonary or Glenn 
Procedure* or Glenn Shunt* or Fontan or Norwood Operation* or 
Norwood Procedure*).ab,kw,ti.
2 Fontan procedure/
3 Norwood procedure/
4 exp heart ventricle/su [Surgery]
5 exp liver disease/
6 (liver or livers or hepato or hepatoc* or hepati*).ab,kw,ti.
7 5 or 6
8 1 or 2 or 3 or 4 
9 7 and 8 1053
WEB OF 
SCIENCE
TS=(Fontan OR “Single Ventricle*” OR Cavopulmonary) AND TS=(liver 
OR livers OR hepato OR hepatoc* OR hepati* OR cirrho*) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan=All years
555
Footnotes: The complete search grids for the searched databases are shown, with all used search terms 
and number of studies found. 
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Supplementary Table 2. Study outcome descriptions from studies without predefined histology assess-
ment 
Author year Description outcome histology assessment: 
Agarwal 2017 liver disease
Agnoletti 2016 cirrhosis
Asrani 2013 HCC, nom description of fibrosis
Babaoglu 2010 severe cirrhosis & hepatocell adenoma (NB stage Laennec not mentioned) 
Bae 2016 sinusoidal fibrosis, bridging-fibrosis and cirrhosis
Baek 2010
inconclusive: non-neoplastic liver parenchyma with focal sinusoidal 
dilatation
Bulut 2013
1: mild yet bridging fibrosis, 2: more extensive blue staining of fibrotic 
bands
Conroy 2017 poorly differentiated HCC, no description fibrosis
Dorsey 2016 fibrolamellar HCC
Duong 2017 extensive broad sclerotic fibrous bands, surrounding small nodules
Egbe 2018 cirrhosis defined by stage 4 on histology
Elder 2013 congestive hepatopathy and bridging fibrosis
Hollander 2013 nodular hepatic fibrosis 
Horai 2011 cirrhosis with signs of portal hypertension
Izumi 2017 liver fibrosis 
Kwon 2015
HCC, surrounding tissue showed centri-zonal + periportal+ perivenular 
fibrosis, sinusoidal dilatation, hemorraghe, hepatocytic dropout
Lemmer 1983
all central zones fibrotic, irregular bands from central-central zone and to 
portal tracts
Martinez-
Quintana
2011 sinus dilatation, portal fibrosis, areas of bridging
Matsuda 1988 all centrilobular necrosis, congestion, intrahepatic bile stasis
Melero-Ferrer 2014 grade 4 fibrosis
Mizuno 2016
Liver cirrhosis, irregular reticular fibrosis extended throughout the whole 
lobes
Navaratnam 2016 portal-to-portal bridging fibrosis
Ofei 2015 portal fibrosis/bridging fibrosis/cirrhosis
Oh 2016 HCC, no description of fibrosis
Poterucha 2015
centrilobular sinusoidal dilation and regions of patchy, dense, 
centrilobular perisinusoidal fibrosis, consistent hepatic fibrosis and venous 
outflow impairment. No HCC 
Pundi 2016 abnormal/cirrhosis
Saliba 2010 HCC, no description fibrosis
Serai 2014 metavir stage 3 fibrosis
SosaLozano 2011 stage 3 fibrosis 
Takuma 2016 liver cirrhosis and bridging fibrosis
Vallabhajosyula 2013 central-to-portal bridging fibrosis
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Supplementary Table 2. Study outcome descriptions from studies without predefined histology assess-
ment  (continued)
Author year Description outcome histology assessment: 
Velpula 2011
Irregular fibrosis, perisinusoidal pattern in areas, gross fibrous septa. Patchy 
sinusoidal dilatation. Marked cholestasis. Mild inflammation.
Wells 2017 type of nodules described, no description of fibrosis
Weyker 2014 HCC, no description of fibrosis
yamada 2015 HCC and cardiac cirrhosis
Footnotes: Transcriptions of histological outcomes reported in the articles are shown. These studies were 
not included in the building block approach, since they lacked a predefined methodology to histologi-
cal assessment.  
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Supplementary Table 4 Overview all histological components and grading systems of FALD reported
Components Variants of components  Specification of used grading 
systems 
References
Definitions: 
Cirrhosis Cardiac cirrhosis present: yes-no
Laennec score (4A-4C subclass 
cirrhosis) 
Gross architectural distortion 
score stage 4 
Both portal and sinusoidal 
fibrosis stage 4 defined as 
cirrhosis
Based on Metavir stage 4 (+ on 
CHFS stage 4*)
Both Scheuer and Ishak last stage 
defined as cirrhosis 
Last stage newly developed 
fibrosis score
21
29
7, 23, 28
15-20,46
33, 58, 59, 
*51
27, 41, 45
11, 30, 48, 
60, 61
Fibrosis 
components: 
Gross staging 
fibrosis  
Grading of severity and 
pattern of overall fibrosis /
Grading of portal based 
fibrosis /
Grading of bridging / 
Gross architectural 
distortion (GAD) / % 
collagen deposition
Metavir score F0-F4
Ishak score 0-6 + Scheuer score 
0-4
Congestive Hepatopathy Fibrosis 
Score 
Portal fibrosis score (by Schwartz 
et al, mod. Scheuer) 
Fibrosis score 0-4 (no, mild, 
moderate, severe, cirrhosis) 
Fibrosis score 0-5 (mod. Metavir, 
4=evolving, 5=established 
cirrhosis)
Fibrosis score 0-5 (mod. Kendall 
et al, + stage 5, cirrhosis not in 
score)
Overall fibrosis score 0-8 (sum 
portal + sinusoidal fibrosis score) 
Overall fibrosis score 0-14 (sum 
of Ishak, Scheuer and sin fib 
score)
GAD: score 0-4 (no, minimal, 
mild, moderate, cirrhosis, mod. 
Metavir)
% collagen deposition (digitally 
measured % sirius red stain)
Location bridging scored: CV-
CV;CV-PT;PT-PT
33, 51, 58, 
59 
27, 41, 45
51
46, 15, 18, 
20
48,
60, 61
49
15-20
41
7, 28
22, 51, 53
51, 58, 59
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Supplementary Table 4 Overview all histological components and grading systems of FALD reported 
(continued)
Components Variants of components  Specification of used grading 
systems 
References
Sinusoidal fibrosis Central / central 
vein / centrilobular / 
perisinusoidal/ Space of 
disse fibrosis 
Sinusoidal fibrosis score 0-3 (no, 
<1/3, 1/3-2/3, >2/3 sinusoids)
Sinusoidal fibrosis score 0-4 (+ 
stage 4 added: cardiac cirrhosis)
Central fibrosis score 0-4
Central vein fibrosis scored 
yes-no
7, 28, 30, 51, 
60, 61
15, 20, 27, 
41, 45, 46
58, 59
27
Injury components: 
Sinusoidal 
dilatation 
Venous outflow 
obstruction/
Hepatic sinusoidal 
congestion/ Chronic passive 
congestion /
Portal venous congestion 
Sinusoidal dilation score 0-3 (no, 
<1/3, 1/3-2/3, >2/3 sinusoids)
Sinusoidal dilation score 0-4 (nfs) 
Chronic passive congestion score 
0-4 (nfs) 
Portal venous congestion score 
0-3 (nfs)
7, 28, 30, 46, 
51 61
58, 59
21
27
Inflammation Lobular / Portal 
inflammation /
Focal lobular necrosis 
(FLN) /
Centrilobular necrosis 
(CLN) 
Location not further specified: 
Scored as yes-no, score 0-4 (nfs)*
Lobular: score 0-1, absent-
present 
Portal: score 0-3 (no, mild, 
moderate, severe), yes-no *
FLN: score 0-3 (necro-
inflammatory foci per lobule: 
absent, <1, 1, >1) 
CLN: score 0-4 (nfs), yes-no*
15, 16, 19, 
29, *58, *59
7, 28, 51
30, 45, 46, 
*51
61
21, *27
Steatosis Scored as absent-present 
Score 0-3 (absent, <25%, 25-
50%, >50% steatosis) 
Score 0-4 (not further specified) 
51  
61
58, 59
Miscellaneous: 
Orcein positivity Score 0-3 (none of the fibrotic 
matrix has orcein positive 
staining, <1/3, 1/3-2/3, >2/3) 
7, 28
Ductular 
proliferation 
Ductular reaction / Bile 
duct reaction 
Ductular proliferation score 0-3 
(no, mild, moderate, severe) 
Ductular reaction score 0-3 (no, 
<25%, 25-75%, >75% of portal 
tracts)
Bile duct reaction: scored as 
absent-present
7, 28
61
51
Cholestasis Score 0-1 (absent - present) 7, 28, 51, 59
Iron deposition Score 0-1 (absent - present)
Score 0-3 (trace,1+,2+,3+)
7, 28
61
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Supplementary Table 4 Overview all histological components and grading systems of FALD reported 
(continued)
Components Variants of components  Specification of used grading 
systems 
References
Hepatocellular 
damage 
Hepatocellular necrosis
Hepatocellular ballooning
Hepatocyte atrophy/plate 
twinning 
Hepatocellular damage score 0-4 
(nfs), absent-present*
Score 0-1 (ballooning, necrosis 
or apoptosis absent or present)
Not specified how these features 
were scored
58, 59, *51
7, 28
29
Lipofuscin Score 0-2 (absent, minimal/focal, 
>minimal/focal) 
Scored as absent-present
61
59
Piecemeal necrosis Score 0-3 (alteration of periportal 
plate in portal tracts: absent, 
focal, diffuse in some, diffuse 
in all)
61
Megamitochondria Scored as absent-present 59
Core fragmentation Score 0-4 (not further specified) 59
Footnotes: Reference numbers are derived from Supplementary File 1. 
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ABSTRACT
Aims
The composition of several important extracellular matrix components (ECM) has not yet 
been elucidated in human non-alcoholic fatty liver disease (NAFLD). We aim to investigate 
the proportion of hepatic stellate cells (HSCs) and activity of matrix metalloproteinases 
(MMPs) and tissue inhibitors of MMPs (TIMPs) in human NAFLD liver tissue with respect 
to severity of inflammation and fibrosis. 
Methods and results
Histopathological features were quantified by NAFLD activity score and grading as-
signment. The collagen proportionate area (CPA) was measured. Slides were stained 
with alpha-smooth muscle actin (α-SMA), as a marker of activated HSCs, and α-SMA 
was quantified digitally. Zymography was performed to measure the proteolytic activity 
of MMP-2 and MMP-9. TIMP-1 and TIMP-2 protein concentration was measured with 
enzyme-linked immunosorbent assay (ELISA). α-SMA was higher in severe fibrosis (6.3%, 
interquartile range, 2.9–13.1) than mild and no fibrosis (median, 1.1 and 0.9%, P < 0.001) 
and correlated strongly with CPA (Rs = 0.870, P < 0.001). ProMMP-2 activity in severe 
(4.1% IQR, 2.6–16.2) and mild fibrosis (2.7% IQR, 1.9–3.9) was higher than in no fibrosis 
(1.5% (IQR, 0.95–2.1); P = 0.001 and P = 0.046) and showed a moderate positive cor-
relation with CPA (Rs = 0.495, P = 0.001). TIMP-1 and TIMP-2 were significantly higher 
in severe fibrosis than mild or no fibrosis. Both showed moderate correlation with CPA 
(TIMP-1: Rs = 0.471, P = 0.002 and TIMP-2: Rs = 0.325, P = 0.036). MMP-9 correlated as 
the only ECM component to inflammation severity. 
Conclusions
Advanced human NAFLD-fibrosis has a distinct ECM composition with increased HSCs 
and increased TIMP inhibition, but there is also ongoing remodelling activity of MMP-2. 
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease marked by fat ac-
cumulation. Prevalence is increasing, and this disease now affects approximately 25% 
of the global population.1 NAFLD consists of a wide disease spectrum, extending from 
simple steatosis to non-alcoholic steatohepatitis (NASH). NASH is a risk factor for fibrosis, 
and depending on host-related factors may progress to cirrhosis and even hepatocellular 
carcinoma.2
The role of the extracellular matrix (ECM) in fibrosis progression in NAFLD is complex 
and dynamic, and our understanding is incomplete.3,4 The onset of inflammation in a stea-
totic liver triggers a cascade that results eventually in liver fibrosis. Inflammatory injury 
activates hepatic stellate cells (HSCs) to differentiate into a proliferative and profibrogenic 
phenotype, and to secrete several fibrotic components (collagens, proteoglycans and 
elastin), profibrogenic enzymes and cytokines.5 
The histopathological pattern of fibrosis in NAFLD has a typical distribution, usually 
starting in the pericentral, zone 3, region.6 It is believed that as fibrosis progresses, ac-
cumulated ECM components mature, cross-link and destroy normal liver architecture.7 A 
recent study, however, shows that even in advanced NAFLD cases, there is active fibrosis 
matrix remodelling signalling the possibility of reversibility of fibrosis.8
Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are involved in the 
turnover of fibrosis and play an important role in ECM homeostasis.9 TIMP-1 and -2 are 
secreted by HSCs, and are abundantly present in the human liver. Blocking MMPs, such 
as MMP-2 and -9, prevents degradation of fibrosis. Investigation in experimental models 
of liver fibrosis suggests that an imbalance between TIMP and MMP drives fibrogenesis. 
Specifically, the increase of TIMPs and blocked MMP activity advances fibrosis.10,11
Although these model systems have allowed us to gain a deeper understanding of 
the complexity of liver inflammation and repair, the composition of the ECM in human 
NAFLD is less well studied.12 A number of studies have attempted to shed light on this 
issue. One study found that MMP-9 mRNA expression, but not MMP-2, was up-regulated 
in liver tissue from NASH patients.13 Another study saw that MMP-2 mRNA and serum 
levels were up-regulated in NASH, but a third study could not confirm this and found only 
increased TIMP-1 serum levels.14,15 Human data on pro- and antifibrotic ECM components 
in relation to fibrosis stage or inflammation grade are lacking. Exploring this balance could 
lead to clearer insight into the activity of ECM remodelling. Therefore, we embarked upon 
a study to investigate the tissue activity of HSCs, MMP-2, MMP-9, TIMP-1 and TIMP-2 in 
relation to NAFLD fibrosis and disease severity. 
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METHODS 
Study design
We performed a cross-sectional study using biopsy material from patients with non-alco-
holic fatty liver disease. Patients with evidence of alternative or coexistent liver disease 
(viral hepatitis, autoimmune hepatitis, Wilson’s disease, haemochromatosis or alpha-1-
antitrypsin deficiency) during standard work-up were excluded. Patients who consumed 
more than 210 g of alcohol per week for males and 140 g for females were also excluded. 
Biopsies were collected between 2011 and 2016. Immediately after collection, liver 
tissue was divided in two parts: one formalin-fixed and paraffin-embedded (FFPE) for 
histopathological scoring and a second part snap-frozen in liquid nitrogen and stored at 
–80°C until activity assays [zymography, enzyme-linked immunosorbent assay (ELISA)] 
were performed (for the Biospecimen Reporting for Improved Study Quality (BRISQ) TIER-
1 list), see Supporting information, Table S1. The study was approved by the Institutional 
Review Board of the Radboud University Medical Centre (no. 2016-2823) and patient 
material was used according to the Code of Conduct for Responsible Use of Human Tissue 
and Medical Research.16 Clinical data and laboratory results up to 3 months prior to liver 
biopsy were obtained through chart review. 
Histology
Histopathological scoring was performed on FFPE slides. Slides were stained with a 
haematoxylin and eosin and picrosirius red stain and reviewed by experienced liver 
pathologists. Staging of fibrosis (0–4) was assessed using the ordinal scale associated with 
the NAFLD activity score, and patients were grouped into no fibrosis (stage 0); mild (stages 
1–2) and severe fibrosis (stages 3–4).17 Furthermore, the collagen proportionate area (CPA; 
the tissue percentage occupied by collagen, as stained with picrosirius red) was assessed 
digitally, as described previously.18 Disease activity was graded with NAFLD activity score 
(NAS; 0–8) by summing the scores of steatosis (0–3), lobular inflammation (0–3) and hepa-
tocyte ballooning (0–2). Histological NASH was determined with the fatty liver inhibition 
of progression (FLIP) algorithm, in which at least 1 point for ballooning and inflammation, 
in addition to steatosis, has to be present to define histological NASH.19 Groups were also 
divided into patients with a total NAS of 0–2, NAS of 3–4 and NAS ≥ 5.17 Tissue sections 
were cut consecutively and immunostained with antibody against α-SMA (1:3200, clone 
1A4; Sigma-Aldrich, St Louis, MO, USA). Of the slides, 10 pictures were taken randomly 
at ×20 magnitude (Zeiss microscope, AxioVision version 2.0 software; Carl Zeiss Ltd, 
Cambridge, UK, attached to a personal computer), and images were quantified digitally 
(after exclusion of artefacts and blood vessels) with use of a colour deconvolution plugin 
in the ImageJ processing program (fiji).20
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A mean α-SMA proportionate area in % (area positive α-SMA staining/total area of the 
biopsy specimen) was calculated for each slide. 
Gelatin zymography
Protein extraction from snap-frozen liver tissue, determination of protein concentrations 
and gelatin zymography were performed as described previously;21 see Supporting infor-
mation. In short, gelatinolytic activity of pro- and active forms of MMP-2 and MMP-9 were 
determined on a gelatin-impregnated sodium dodecyl sulphate-polyacrylamide gel (SDS-
PAGE). Samples were loaded with a fixed amount of protein in duplo. An internal standard 
was included as a reference for quantification of proteolytic activity. After electrophoresis 
and incubation, gels were stained with Coomassie Blue. Quantification of proteinase ac-
tivity, which is expressed as relative percentage to the reference standard, was performed 
with computerised densitometry. The mean of duplicates is presented. For the layout of the 
gels and positions of the pro- and active forms of MMP-2 and MMP-9 see Figure 1. 
Figure 1. Zymography (layout). Proteolytic matrix metalloproteinase (MMP) activity in human liver 
tissue extracts detected by quantitative zymography. Proteolytic activity was measured with Total 
Lab Quant, in which the intensity of the bands was measured as a relative percentage of the internal 
standard. NC = sample buffer was loaded as a negative control on position 15. Position 5 remained 
blank. Active MMP-9, located at 82 kDa and active MMP-2 at 62 kDa are not identifiable by eye in 
these tissue extracts.10
ELISA
TIMP-1 and -2 concentrations were measured in the supernatant of the snap-frozen liver 
tissue using sandwich ELISA (R&D Systems, Minneapolis, MN, USA), according to the 
manufacturer’s instructions. Absorbance was read at 450 nm on an Infinite200PRO plate 
reader (Tecan, Zürich, Switzerland). TIMP-1 and TIMP-2 concentrations (in pg/µg protein) 
were calculated using the Magellan program.
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Statistical analysis
Categorical variables (gender) are expressed in number and percentage and analysed 
by Fisher’s exact test. Continuous data are presented as mean with standard deviation 
(SD) or median with interquartile range (IQR, 25th–75th percentile) and analysed with 
an independent-samples t-test or Mann–Whitney U-test, one-way analysis of variance 
(anova) or Kruskal–Wallis test, Pearson’s or Spearman’s rank correlation coefficient, ac-
cording to distribution. A two-sided level of P < 0.05 is considered statistically significant. 
Statistics are performed using spss statistical software package (version 22.0; SPSS Inc., 
Chicago, IL, USA). Figures are created using Graphpad Prism (version 5.03; Graphpad 
Software Inc., La Jolla, CA, USA).
RESULTS
Clinicopathological characteristics
The total cohort consisted of 42 patients with a clinical and histological diagnosis of 
NAFLD or NASH. The mean age was 51 ± 11 years and 55% were male. Median NAS was 
4 (IQR = 3–5), and 16 (38%) patients had histological evidence of NASH, as indicated 
by NAS ≥ 5. Based on the FLIP algorithm, 28 (67%) patients had histological NASH. 
Characteristics of patients with and without histological NASH are shown in Table 1. 
Table 1. Characteristics of patients with and without histological NASH
No NASH (n=14) Histological NASH† (n=28) p-value
Demographics
Age (years) 50.6 ± 12.1 50.6 ± 10.8 .985
Male gender 7 (50.0%) 16 (57.1%) .661
Diabetes Mellitus type 2 3 (21.4%) 9 (32.1%) .719
BMI (kg/m2) 28.3 ± 2.6 32.7 ± 5.7 .020
Laboratory results 
Alanine transaminase (IU/L) 66 (47-103) n=13* 77 (59-139) n=24 .422
Aspartase transaminase (IU/L) 36 (30-53) n=12 54 (42-78) n=21 .030
Alkaline Phosphotase (IU/L) 86 (65-125) n=12 109 (82-131) n=21 .187
Gamma-glutamyltransferase (IU/L) 135 (53-335) 102 (59-260) n=23 .922
Bilirubin (umol/L) 10 (6-11) n=12 10 (7-16) n=21 .518
C-Reactive protein (mg/L) 1 (1-8) n=5 9 (5-45) n=7 .073
Ferritin (ug/L) 258 (205-553) n=6 214 (96-804) n=16 .590
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Patients with histological NASH had significantly higher aspartate transaminase (AST) 
levels compared to those without NASH (see Table 1). AST was 144 (IQR = 63–155) U/l in 
severe (NAS 2) inflammation and 75 (IQR = 50–134) U/l in mild (NAS 0–1) inflammation 
(P = 0.020). Alanine transaminase (ALT) was 67 (IQR = 48–101) U/l in severe compared to 
42 (IQR = 33–54) U/l in patients with mild inflammation (P = 0.028).
Fibrosis was absent from the liver biopsy in nine patients, while 22 patients had mild 
fibrosis (15 stage 1, seven stage 2), and 11 patients had severe fibrosis (six stage 3, five 
stage 4). Median CPA in the whole cohort was 4.2% (IQR = 2.3–10.6), and CPA correlated 
strongly with the histopathologically determined fibrosis stage (Rs = 0.749, P < 0.001). See 
Table 2 for characteristics of the fibrosis groups. 
Correlation extracellular matrix components and fibrosis staging
The area of α-SMA staining was significantly higher in samples with severe fibrosis com-
pared to samples with mild or absent fibrosis, and there was a strong correlation of α-SMA 
with CPA (Rs = 0.870, P < 0.001, see Table 2 and Figure 2A,B). The gelatinolytic activity 
of proforms of both MMPs was increased compared to the active forms regardless of 
stage; median proMMP-2: 2.7% (IQR = 1.7–4.1), proMMP-9: 36.2% (IQR = 23.3–61.0), 
actMMP-2: 0.4% (IQR = 0.2–0.8) and actMMP-9: 0.2% (IQR = 0.1–0.3).
Median proMMP-2 activity was significantly higher in severe and mild fibrosis 
compared to samples without fibrosis, and showed a moderate positive correlation with 
CPA (Rs = 0.495, P = 0.001). The activity of actMMP-2 was not statistically significantly 
different between groups (see Table 2 and Figure 3A). Both forms of MMP-9 were distrib-
uted similarly among different fibrosis groups (see Table 2 and Supporting information, 
Figure 1), and were not correlated with CPA (see Table 3 for all correlations on ECM 
components and fibrosis staging).
Table 1. Characteristics of patients with and without histological NASH (continued)
No NASH (n=14) Histological NASH† (n=28) p-value
ECM components
α -SMA (%) 1.2 (0.7-2.4) 1.8 (0.7-6.0) .272
ProMMP-2 (relative %) 2.0 (1.4-2.8) 2.8 (1.8-4.3) .147
ActMMP-2 (relative %) 0.4 (0.2-0.9) 0.4 (0.2-0.8) .927
ProMMP-9 (relative %) 40.5 (23.2-71.1) 34.0 (23.0-62.5) .626
ActMMP-9 (relative %) 0.2 (0.1-0.4) 0.2 (0.1-0.3) .607
TIMP-1 (pg/µg) 2.4 (2.1-2.8) 2.7 (2.0-3.4) .607
TIMP-2 (pg/µg) 3.2 (2.8-3.6) 3.4 (2.7-3.9) .589
Legend: Results are shown as count and percentage (n,%), mean with standard deviation or median and 
interquartile range (25th-75th percentile). *Number of patients with laboratory results within 3 months 
prior to liver biopsy, are specified in the columns. †Histological NASH, based on FLIP algorithm 19. 
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TIMP-1 and TIMP-2 (in pg/µg protein) levels were significantly higher in severe fibrosis 
than mild or absent fibrosis (see Table 2 and Figure 3B). Both TIMP-1 and TIMP-2 levels 
correlated with CPA (TIMP-1: Rs = 0.471, P = 0.002 and TIMP-2: Rs = 0.325, P = 0.036; 
see Table 3).
Correlation extracellular matrix components and disease activity/inflammation
Median α-SMA in patients with histological NASH was comparable to that of patients 
without histological NASH (see Table 1). α-SMA did not correlate with total NAS grade 
or individual components of NAS grading (steatosis, ballooning or inflammation; see 
Table 3). ProMMP-9 levels were higher in patients with severe inflammation (58.0% 
IQR = 29.2–85.5) compared to mild inflammation (30.1% IQR = 21.8–44.7, P = 0.035). 
ActMMP-9 was similar in mild and severe inflammation (see Supporting information, 
Figure 1). Both actMMP-9 and proMMP-9 were similar between patients with and without 
histological NASH (see Table 1). α-SMA and MMP-9 showed no correlation to ALT or AST 
levels (data not shown). 
Table 2. Characteristics of patients within fibrosis groups 
No fibrosis 
F0 (n=9)
Mild fibrosis 
F1-2 (n=22)
Severe fibrosis 
F3-4 (n=11)
p-value
Demographics 
Age (years) 48.9 ± 10.0 47.1 ± 10.3 58.9 ± 9.8 .011
Male gender 6 (66.7%) 13 (59.1%) 4 (36.4%) .335
Diabetes Mellitus type 2 1 (11.1%) 5 (22.7%) 6 (54.5%) .069
BMI (kg/m2) 30.6 ± 4.1 32.1 ± 5.6 30.0 ± 7.1 .570
Histology
Collagen Proportionate Area 1.54 (0.91-2.59) 4.07 (2.56-5.86) 13.02 (10.46-17.84) <.001
NAFLD Activity Score 0-2 5 (55.6%) 4 (18.2%) 0 .005
NAFLD Activity Score 3-4 4 (44.4%) 6 (27.3%) 7 (63.6%) .005
NAFLD Activity Score ≥5 0 12 (54.5%) 4 (36.4%) .005
Histological NASH* 2 (22.2%) 17 (77.3%) 9 (81.8%) .006
ECM components
α-SMA (%) 0.9 (0.5-2.1) 1.1 (0.6-1.9) 6.3 (2.9-13.1) <.001
ProMMP-2 (relative %) 1.5 (1.0-2.1) 2.8 (1.9-3.9) 4.2 (2.6-16.2) <.001
ActMMP-2 (relative %) 0.4 (0.2-0.7) 0.3 (0.1-0.7) 0.7 (0.2.2.0) .278
ProMMP-9 (relative %) 36.9 (16.7-78-.1) 36.8 (24.5-69.6) 34.0 (28.0-46.1) .848
ActMMP-9 (relative %) 0.2 (0.1-0.5) 0.1 (0.1-0.2) 0.2 (0.1-0.5) .286
TIMP-1 (pg/µg) 2.4 (1.9-2.6) 2.3 (2.0-3.1) 3.4 (2.9-5.0) .007
TIMP-2 (pg/µg) 3.0 (2.8-3.4) 3.3 (2.3-3.6) 4.1 (3.5-4.6) .007
Legend: Results are shown as count and percentage (n, %), mean ± standard deviation or median and 
interquartile range (25th-75th percentile). * Histological NASH, based on FLIP algorithm 19. 
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A
B
Figure 2. A, Example of alpha-smooth muscle actin (α-SMA) and collagen proportionate area (CPA) 
staining. Detail of a biopsy from a cirrhotic liver stained with Sirius red on the left and α-SMA in the 
right panel. Stains were quantified with digital image analysis. B, More activated hepatic stellate cells 
in severe fibrosis compared to mild or no fibrosis. α-SMA percentages were analysed between fibrosis 
groups with the Kruskal–Wallis test on the left; *P < 0.01; **P < 0.001. On the right, correlation between 
α-SMA and CPA is shown with Spearman’s correlation coefficient; Rs = 0.870; P < 0.001.
Table 3. Correlations of ECM components and fibrosis staging and NAS grading 
CPA (%) Fibrosis stage
(0-4)
NAS grade 
(0-8)
Steatosis 
(0-3)
Ballooning 
(0-2)
Inflammation 
(0-3)
α-SMA Rs=.720**
p=.000
.667**
.000
.086
.587
.032
.841
.182
.248
-.011
.943
proMMP-2 4.95**
.001
.647**
.000
.191
.226
.1741
.280
.112
.480
.108
.495
actMMP-2 .180
.253
.198
.209
-.004
.979
-.024
.880
.124
.434
-.041
.796
proMMP-9 -.088
.579
.001
.996
.040
.804
-.043
.788
-.078
.624
.211
.180
actMMP-9 .033
.837
.041
.794
-.193
.221
-.113
.477
-.104
.511
-.104
.349
TIMP-1 .471**
.002
.400**
.009
.027
.866
-.129
.414
.132
.405
.145
.358
TIMP-2 .325*
.036
.482**
.001
.071
.866
-.015
.923
.031
.848
.143
.365
Legend: Spearman’s Rank (Rs) correlation coefficients and p-values are shown for correlations between 
ECM components and fibrosis staging and NAS grading. *Correlation is significant < .05 level, ** cor-
relation is significant <.01 level. 
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Figure 3. Matrix metalloproteinase (MMP)-2 and tissue inhibitors of MMPs (TIMPs) in fibrosis groups. 
A, ProMMP-2 and actMMP-2 levels (in relative % to reference standard) with group median (line) are 
shown for three fibrosis groups: no fibrosis, mild fibrosis and severe fibrosis. B, TIMP-1 and TIMP-2 
levels (in pg/lg protein) with group median (line) are shown for three fibrosis groups. Analyses were 
performed with the Kruskal–Wallis test; *P < 0.05; **P < 0.01.
DISCUSSION
This study documents that liver biopsy samples from patients with advanced NAFLD-
associated fibrosis possess a distinct ECM composition, with increased levels of α-SMA, 
proMMP-2 and both TIMP-1 and -2. These results suggest that advancing fibrosis in NAFLD 
is driven by activated HSCs, creating an environment which permits inhibition of matrix 
degradation and contributes to fibrosis accumulation. Increased activation of HSCs in the 
context of severe fibrosis in human NAFLD has been reported previously,22 but data on 
MMP and TIMP activity were lacking. Increase of proMMP-2, TIMP-1 and TIMP-2 activity 
in NASH fibrosis is consistent with data obtained for other chronic liver diseases.11,23–25 
The increase of proMMP-2 and, to a lesser extent, of active MMP-2, suggests there is 
still active matrix turnover in advanced NAFLD fibrosis. This is consistent with another 
study that quantified hepatic fibrogenesis flux rates in liver tissue and blood from NAFLD 
patients.8 In experimental models, the early phase of liver injury resulted in increased 
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levels of MMP-3, MMP-13 and, to a lesser extent, MMP-2. During the later phase of HSC 
activation, expression of MMP-2, TIMP-1 and TIMP-2 increased.26 The protein concen-
tration of TIMPs appears to be critical for the actual proteolytic activity of MMPs. Low 
concentrations of TIMPs mediate activation of MMP-2, while higher TIMP levels inhibit 
MMP-2 activation.27 MMP-2 degrades collagen type IV (present in the basal membrane 
in normal liver), but MMP-2 also possesses elastase and collagenase activity in vitro.9 
Furthermore, there is evidence that MMP-2 and MT1-MMP (a membrane type MMP) 
work synergistically to degrade fibrillar collagens, and that their combination is poorly 
inhibited by TIMP-1.28,29 Although we were not able to measure the activity of MT1-MMP 
and specific collagen subtypes, it can be speculated that MMP-2 could also have a role in 
degrading mature fibrosis, which consists of collagen type I, III and elastin. 
In clinical practice, it is important to stratify NAFLD patients based on fibrosis stage, in 
view of the 10–40 times fold increase in liver-related mortality among patients with pro-
gressing stages of fibrosis.30 There is evidence to suggest that advanced fibrosis or cirrhosis 
may still be reversible after removal of the causal agent (hepatitis C treatment, reduction 
of hepatic steatosis through weight loss in NAFLD and alcohol cessation in alcoholic liver 
disease). Profiling ECM composition may be used to stratify patients according to fibrosis 
remodelling capacity. Compounds targeting ECM components could be explored further 
as new antifibrotic strategies in NAFLD.31,32 
The absence of correlation between proportion of activated HSCs and AST, ALT or 
NASH in our study could imply that fibrogenesis is maintained independently of inflam-
matory stimuli. HSCs display several collagen receptors, such as integrins, that receive cy-
tokine signals [notably transforming growth factor (TGF)-‐] from ECM components, which 
induce differentiation and proliferation of HSCs to maintain a profibrogenic phenotype.3,7 
TIMPs have the ability to inhibit programmed cell death of HSCs.33 A positive feedback 
loop with ECM components that affect HSCs promotes fibrosis progression. Conversely, 
this model is possibly an (over)simplification of the pathogenesis of fibrosis. NASH is a 
heterogeneous and multifactorial disease and insulin resistance, alcohol use, presence of 
other toxins, virus or cholestasis all contribute to fibrosis progression. 
ProMMP-9 was the only ECM component increased in inflamed tissue. Other studies 
co-localised MMP-9 with inflammatory cells, such as Küpffer cells, macrophages and 
neutrophils.34,35 Proinflammatory cytokines C-X-C motif chemokine ligand 8 (CXCL-8), 
interleukin (IL)-1‐ and tumour necrosis factor (TNF)-α are known substrates for MMP-9. 
MMP-9 increases the biological activity of these cytokines, leading to an exacerbation of 
inflammation. The composition of inflammatory cells was beyond the scope of this study, 
but further research on the interaction of immune cells, MMP-9 and fibrosis in human 
NAFLD may elucidate this.
Our study comes with several strengths: we had access to a well-defined cohort of 
NAFLD patients, encompassing the whole spectrum of NAFLD activity and fibrosis. Zy-
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mography allowed us to measure gelatinolytic activity, which resembles true proteolytic 
ability. Active matrix turnover in tissue is reflected more clearly with this assay than with 
mRNA expression or serum markers. We performed computer-aided quantitative measure-
ments of immunohistochemical staining, minimising possible interobserver variability and 
lack of power to discriminate between stages, inherent to grouping and scoring. The cor-
relation of ECM components not only to fibrosis stage, but also to the quantitative amount 
of collagen (CPA) strengthens our conclusions.
However, this study design also brings limitations. We could only examine two MMPs, 
as no assays are available to measure proteolytic activity of other MMPs, such as MMP-12, 
MMP-13, MMP-3 and MT1-MMP.36 We could not correct for all possible confounders 
involved in the multifactorial fibrogenesis in NAFLD. The lack of follow-up biopsies in our 
cohort did not allow us to assess the predictive role of ECM components in progression or 
regression of fibrosis. 
In conclusion, in this study the severity of human NAFLD liver fibrosis is associated with 
increasing α-SMA, proMMP-2 and TIMP-1 and -2. ProMMP-9 correlates with the severity 
of inflammation. The changed ECM composition in advanced NAFLD fibrosis suggests 
that inhibition of matrix degradation is maintained by activated HSCs secreting exceeding 
amounts of TIMPs, favouring fibrosis accumulation. MMP-2 activity in advanced fibrosis 
stages suggests that there is still active matrix turnover and could signal the possibility of 
reversibility, which should be assessed further in longitudinal follow-up studies. 
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SUPPORTING FILES 
SUPPORTING METHODS 
Sample preparation and protein determination 
Snap frozen liver tissue samples were cooled in liquid nitrogen and mechanically ho-
mogenised with a Micro-Dismembrator at 1500 RPM for 10 seconds. After 24 hours of 
freeze-drying, pulverised samples were extracted in buffer (200ul/mg tissue; 0.5 M Tris, 
0.2 M NaCl, 10 mM CaCl2 and 1% Triton X-100) and freeze-thawed trice. After centrifu-
gation (13000 RPM, 25 minutes, 4°C), the supernatant was dialysed twice overnight to 
remove the Triton X-100 (dialysis buffer: 5 mM CaCl2, 50 mM Tris-HCl and 0.2 M NaCl). 
Samples were stored at -80 °C until use. 
Protein concentration in the supernatant was determined with BCA (bicinchoninic 
acid) method from Pierce BCA Protein Assay Kit (Thermofisher Scientific, Waltham, USA). 
Bovine serum albumin was used as a standard. Samples were diluted ten times before 
protein measurement. All measurements were performed in duplicate. Samples and Work-
ing Reagent (bicinchoninic acid, 4% cupric sulfate) were added in a ratio of 1:8 into a 
96-well micro titer plate. After incubation at 37 °C for 30 minutes absorbance was read 
at 562 nm on an Infinite200PRO plate reader (Tecan Mannedorf, Switzerland). Protein 
concentration (µg/ml) was calculated using Magellan software.
Gelatin zymography
Gelatin zymography was performed with use of SDS-PAGE gels (7.45% bisacrylamide) 
containing 2mg/ml gelatin as an enzyme substrate. Gels were overlaid with 15 wells 
stacking gels (3.87% acrylamide). Samples were diluted 1:1 with sample buffer (0.125 
M Tris/HCl, pH=6.8, 20% (v/v) glycerol, 4% SDS, 0.05% bromophenol blue, water) and 
heated for 20 minutes at 60°C, to denaturize proteins. Of each sample a fixed amount 
of protein was loaded in duplo. As an internal standard Collagenase type VII from Clos-
tridium hystoliticum (Sigma-Aldrich) was included in duplo on each gel, to compare the 
values of samples obtained on different gels. This specific collagenase was chosen for its 
stability in zymography. Purified enzymes proMMP-2 (PF037, Calbiochem, San Diego, 
USA) (1ng/lane) and proMMP-9 (PF038, Calbiochem, San Diego, USA) (0.5 ng/lane) were 
used as positive controls for identification of MMP-2 and -9 bands from the samples. Gels 
were run in 0.19 M Glycine, 0.024 M Tris, 3.5 mM SDS at room temperature, at 100 V 
until bromophenol blue dye reached the bottom of the gel. After electrophoresis SDS 
was removed by washing the gels in 2.5 % Triton X-100 three times at room temperature 
on a plate shaker for 10 minutes. After washing the gels twice in 50 mM Tris/HCl pH= 
7.8, 5 mM CaCl2, 0.1 % Triton X-100, gels were incubated overnight in the same buffer 
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at 37°C. Afterwards, the gels were stained for 45 minutes at 60°C with staining solution 
(40% Methanol, 10 % acetic acid containing 0.25% (w/v) Coomassie Brilliant Blue).Gels 
were then destained for one hour in destaining solution (5% methanol, 7.5% acetic acid). 
The degraded areas of gelatin were visualized as clear bands against a blue background. 
Gels were scanned using the Proxima C16 Phi+ Imaging system (Isogen Life Science, De 
Meern, The Netherlands). Gelatinolytic activity was quantified in the program Total Lab 
Quant (TotalLab, Newcastle, England). Digested areas of gelatine, corresponding to bands 
of the pro- and active MMPs and internal standard were defined manually. Background 
subtraction of the gel from each lane was performed in order to quantify the intensity 
of each band. The lower band of the internal standard was selected, set to 100 and the 
intensity of the other bands was recalculated as a relative % to this band.
Supporting Table 1. Core BRISQ Tier 1 items to report 
1. Biospecimen type Biopsy tissue: divided into snap frozen part and 
paraffine embedded block of which FFPE slides 
cut
2. Anatomical site 
(Organ of origin)
Liver
3. Disease status of patients
(Controls or individuals with the disease of 
interest)
Patients 
4. Clinical characteristics of patients
(Available medical information known or 
believed to be pertinent to the condition of the 
biospecimens)
Age and gender reported. 
5. Vital state of patients
(Alive or deceased patient when biospecimens 
were obtained)
Alive
6. Clinical diagnosis of patients
(Patient clinical diagnoses (determined by medical 
history, physical examination, and analyses of the 
biospecimen) pertinent to the study)
NAFLD
7. Pathology diagnosis
(Patient pathology diagnoses (determined by 
macro and/or microscopic valuation of the 
biospecimen at the time of diagnosis and/or 
prior to research use) pertinent to the study. 
The classification system and criteriashould be 
specified, as should the review process)
Performed on FFPE slides. Fibrosis grading by 
BRUNT score (0-4) and digital image analysis: 
collagen proportionate area. 
NAFLD activity score for staging disease activity, 
by summing the scores of steatosis (0-3), lobular 
inflammation (0-3) and hepatocyte ballooning 
(0-2). A NAS of 5 or more is defined as 
histological steatohepatitis. 
8. Collection mechanism
(How the biospecimens were obtained)
during routine liver biopsy: 16G
9. Type of stabilization
(The initial process by which biospecimens were 
stabilized during collection)
 Direct collection in liquid nitrogen (snap 
frozen) and for histopathology collection in 
formalin collector. 
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Supporting Table 1. Core BRISQ Tier 1 items to report 
10. Type of long-term preservation
(The process by which the biospecimens were 
sustained after collection (e.g formalin fixation, 
freezing)
Snap frozen samples stored at -80°C in freezer 
and histopathology samples formalin fixated 
after which paraffin embedment. 
11. Constitution of preservative
(The make-up of any formulation used to maintain 
the biospecimens in a non-reactive state)
See above. 
12. Storage temperature In freezer at 80°C and paraffin embedded 
samples at room temperature. 
13. Storage duration Up to five years. 
14. Shipping temperature Not applicable. 
15. Nature of documentation of all items and 
especially 9 through 14 inclusive Biobank log file 
16. Composition assessment and selection
(Parameters used to choose biospecimens for the 
study)
-Clinicial and histopathological diagnosis of 
NAFLD
-No concomitant liver disease
-Sufficient tissue material (both snap frozen as 
paraffin) for all analyses  
127
Supporting Figure 1. MMP-9 in fibrosis and inflammation 
Legend: In Panel A proMMP-9 and actMMP-9 levels (in relative % to reference standard) with group 
median (line) are shown for three fibrosis groups: no fibrosis, mild fibrosis and severe fibrosis. Panel 
B shows proMMP-9 and actMMP-9 (in relative % to reference standard) with group median (line) for 
mild inflammation (NAS 0-1) and severe inflammation (NAS 2). Analyses were performed with Kruskal-
Wallis test or Mann-Whitney U-test, * p<.05. 
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ABSTRACT 
Background
Accurate assessment of hepatic steatosis is key to grade disease severity in non-alcoholic 
fatty liver disease (NAFLD). We developed a digital automated quantification of steatosis 
on whole slide images (WSI) of liver tissue and performed a validation study. 
Methods
Hematoxylin-eosin stained liver tissue slides were digitally scanned and steatotic areas 
were manually annotated. We identified thresholds for size and roundness parameters by 
logistic regression to discriminate steatosis from surrounding liver tissue. The resulting al-
gorithm produces a steatosis proportionate area (SPA; ratio of steatotic area to total tissue 
area described as percentage). The software can be implemented as a Java plug-in in FIJI, 
in which digital WSI can be processed automatically using the Pathomation extension. 
Results
We obtained liver tissue specimens from 61 NAFLD patients and 18 controls. The area 
under the curve of correctly classified steatosis by the algorithm was 0.970 (95% CI 0.968-
0.973), p<.001. Accuracy of the algorithm was 91.9%, with a classification error of 8.1%. 
SPA correlated significantly with steatosis grade (Rs=.845, CI: .749-.902, p<.001) and 
increased significantly with each individual steatosis grade, except between grade 2 and 3. 
Conclusion
We have developed a novel digital analysis algorithm that accurately quantifies steatosis 
on WSI of liver tissue. This algorithm can be incorporated when quantification of steatosis 
is warranted, such as in clinical trials studying efficacy of new therapeutic interventions 
in NAFLD. 
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD), defined as the abnormal accumulation of fat 
in the liver, has a spectrum that ranges from steatosis to progressive inflammation (steato-
hepatitis), and eventually fibrosis and cirrhosis.1 NAFLD is seen as the hepatic manifesta-
tion of the metabolic syndrome and is associated with an increased mortality risk, mainly 
from cardiovascular complications.2 Approximately a quarter of the general population 
is affected by NAFLD, which constitutes a global health problem.3 Severity of steatosis is 
associated with progression to steatohepatitis and fibrosis.4, 5 Early recognition of severe 
steatosis is thus imperative to prevent progression of disease. Accurate assessment of 
steatosis severity bears relevance to other disease states such as in viral hepatitis and liver 
transplantation, since progressive disease or graft failure is associated with the degree of 
steatosis.6-10 Histological grading of steatosis, together with inflammation, ballooning and 
fibrosis, is a frequently used endpoint in clinical trials investigating novel therapies.11 The 
NAFLD activity score (NAS) is the most commonly used semi-quantitative grading system, 
and it grades steatosis as an interval-percentage upon visual examination of histological 
liver tissue slides.12 This score, as many other grading systems, is subject to inter- and intra-
observer variability and prone to inaccuracy.13, 14 More precise measurement of steatosis 
(reduction) will increase power to test efficacy of new drugs. Current research focuses 
on development of non-invasive tools to quantify steatosis such as MR-spectroscopy or 
elastography, but validation is still hampered by a subjective and semi-quantitative gold 
standard.15 
Digital image analysis (DIA) is a promising method for accurate histological steatosis 
assessment, as it does not suffer from observer variability, possesses high reproducibility 
and produces a continuous outcome measure which may be compared to established 
standards.14 There are a number of digital algorithms and tools to quantify steatosis, but 
these still include features such as manual correction or field selection.13, 16-20 
In the present study we aimed to develop and evaluate a fully automated steatosis 
quantification algorithm for whole slide image analysis, excluding any inter- and intra-
observer variability. 
MATERIAL AND METHODS 
Tissue samples
Tissue slides from liver biopsies were selected from the Radboudumc histopathology 
archives from the period 2012-2016. All specimens with a minimum of 11 portal fields 
were considered for inclusion. To represent the full range of steatosis severity, slides from 
NAFLD patients, representing each NAS steatosis grade (1: 5-33% steatosis / 2: 34-66% 
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steatosis / 3: more than 66% steatosis) were selected on basis of original pathology report, 
as well as slides of patients without any abnormalities or steatosis that served as controls 
(grade 0: <5% steatosis). All slides were stained with a Hematoxylin-Eosin stain according 
to standard practice. Steatosis and fibrosis grade were revised according to the NAS and 
Brunt fibrosis score12 by an experienced liver pathologist, blinded for the outcome of the 
initial evaluation. Requirement for ethical approval was waived by the institutional review 
board (no. 2016-2763). All tissue sections were fully digitized, producing whole slide 
images (WSI), using a P250 Flash digital slide scanner (3DHISTECH, Hungary). WSI were 
produced using a 20x objective lens (specimen level pixel size 0.24x0.24µm2) and JPEG 
compressed using quality factor 80. 
Handling of whole-slide images
The steatosis quantification algorithm was implemented as a Java plug-in for the Fiji im-
age analysis platform.21 In order to handle complete WSI, the plug-in uses the PMA.start 
whole-slide image-viewer (Pathomation, Belgium).22 A WSI containing the entire slide was 
loaded in Fiji at reduced resolution and a square region containing all tissue was selected 
manually (See Figure 1A).This greatly reduces computation time as a large part of the WSI 
generally consists of background.
To allow execution of the software on an office grade computer, the selected area 
is automatically subdivided into consecutive non-overlapping patches of 3000 by 3000 
pixels (729.28 by 729.28 µm at full zoom) (See Figure 1B). The automated steatosis detec-
tion and area measurements are consecutively performed on each individual patch. A 
foreground detection algorithm is run on every patch to detect if there is any tissue present 
at all.23 To reduce the analysis time, the patch is not processed if no tissue is detected. 
Steatosis measurements
Steatotic hepatocytes are typically characterized by 1) a white colour, 2) a specific size 
range, and 3) a round shape. The steatosis quantification algorithm detects potential 
steatotic hepatocytes and distinguish these from similar objects (e.g. blood vessels, bile 
ducts and tissue tearing) on the basis of these features. The algorithm first establishes a set 
of potential steatotic hepatocytes in the image by applying a threshold to the saturation 
channel of the HSB color space. We found that a threshold that optimally distinguishes 
between white steatotic hepatocytes and more pinkish areas (e.g. cytoplasm within the 
hepatocyte) is relatively high and will underestimate the surface area of the hepatocytes 
(See Figure 2). We therefore first applied a less conservative threshold to identify steatotic 
hepatocytes with the correct surface area after which the stricter, optimal threshold is used 
to confirm that the area is indeed a good candidate. 
To distinguish between true steatotic hepatocytes and other white areas detected by 
the procedure described above, we used the size and roundness of detected objects. 
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As a first step, we removed very large (tears in the tissue and non-tissue background parts 
of the WSI) and very small (e.g. vacuoles within a hepatocyte, interstitial spaces) objects, 
while taking care not to remove any true steatotic hepatocytes. To perform a granular 
separation between steatotic hepatocytes and other objects remaining after the previous 
steps, we constructed a statistical classifier using logistic regression analysis (SPSS, version 
22 Chicago, Illinois, USA). The classifier used measures expressing the size and roundness 
of objects, as expressed in the following quantitative features:
Circularity: 
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The classifier was constructed using manually classified objects in representative areas from 
20 biopsies (five from each NAS grade of steatosis: 0-3). The dataset was split up in a training 
and test set (50-50%). The classifier resulting from logistic regression analysis was used for 
the final discrimination, applying a threshold of 0.5 on the classifier output. 
After applying the above procedure, the summed surface area of all detected steatotic 
hepatocytes as well as the total tissue area were calculated. These sums were aggregated 
over all image patches in a WSI and the steatosis proportionate area (SPA) per WSI (the ratio 
of the steatotic area to the total tissue area described as a percentage) was calculated. 
 
Figure 2. Color saturation thresholding 
 
Legend: A part of a whole-slide image that contains a lot of small lightly colored areas that are not steatosic (A). Without a 
minimum size, all these areas will be classified as either steatosis or normal tissue and must be corrected manually (B). By 
introducing a minimum-size threshold the smaller sized objects are automatically judged to be non-steatotic tissue and no 
longer need correction (C). 
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The classifier was constructed using manually classified objects in representative areas 
from 20 biopsies (five from each NAS grade of steatosis: 0-3). The dataset was split up in 
a training and test set (50-50%). The classifier resulting from logistic regression analysis 
wa  used for the final disc imination, applying a thre hold of 0.5 on th  classifier output.
Figure 1. Selection of tissue region and subdivision in patches 
Legend: Panel A: Manual demarcation (green rectangle) to restrict high-resolution analysis of whole 
slide images to the region containing the tissue sections. Panel B: automatic subdivision of WSI in-
dividual patches (3000x3000 pixels). With foreground detection patches without tissue are excluded 
from tissue analysis. To illustrate this first 7 red squares are excluded, analysis starts at first blue square 
containing tissue.
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After applying the above procedure, the summed surface area of all detected steatotic 
hepatocytes as well as the total tissue area were calculated. These sums were aggregated 
over all image patches in a WSI and the steatosis proportionate area (SPA) per WSI (the 
ratio of the steatotic area to the total tissue area described as a percentage) was calculated.
Figure 2. Color saturation thresholding 
Legend: A part of a whole-slide image that contains a lot of small lightly colored areas that are not ste-
atosic (A). Without a minimum size, all these areas will be classified as either steatosis or normal tissue 
and must be corrected manually (B). By introducing a minimum-size threshold the smaller sized objects 
are automatically judged to be non-steatotic tissue and no longer need correction (C).
Correlation to NAS grading 
Biopsies were revised by an experienced pathologist, assessing steatosis grade and fibrosis 
stage.12 Correlation between steatosis proportionate area, resulting from the algorithm and 
NAS grade by the pathologist, was analyzed with Spearman Rank correlation coefficient 
and independent-samples Kruskall-Wallis test with post-hoc analyses to test significance 
of differences between independent grades. Distribution of SPA (interquartile range), fat 
droplet size (in um2) and number of droplets (per patch and per um2) were analyzed to 
assess heterogeneity of steatosis within slides and per steatosis grade. 
RESULTS 
Identification and classification parameters
Candidate steatotic hepatocytes were identified by application of two thresholds in the 
saturation channel after transforming the image from an RGB to HSB colour representa-
tion. The threshold values were established based on visual effect estimation of applying 
up to 10 different threshold cut-offs in a random selection of WSI samples. In a comparable 
manner, we established feature value thresholds to filter out obvious non-steatotic areas 
on the basis of their size (See Table 1).
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Table 1. Feature thresholds 
Feature Threshold
Saturation for correct surface area 29 (of 256)
Saturation for optimal separation of steatosis 15 (of 256)
Minimal size for optimal separation of steatosis 12 µm²
Minimum area size 25 µm²
Maximum area size 6000 µm²
Results logistic regression
Feature coefficients for roundness parameters and size were calculated using logistic 
regression analysis, resulting in the following classifier: 
l  . t r  t r s l s 
t r r s l
t r ti  f r rr t s rf  r  ( f )
t r ti  f r ti l s r ti  f st t sis  ( f )
i i l si  f r ti l s r ti  f st t sis  ²
i i  r  si  ²
i  r  si  ²
l  l i i  i
t r  ffi i t  f r r  r t r   i  r  l l t  i  l i ti  
r r i  l i , r lti  i  t  f ll i  l ifi r: 
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Feature Threshold 
Saturation for correct surface area 29 (of 256) 
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Maximum area size 6000 µm² 
 
 Results logistic regression 
Feature coefficients for roundness parameters and size were calculated using logistic 
regression analysis, resulting in the following classifier:  
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙(. ) =  −16.2 + .00272 ∗ size_µm2 +  5.81 ∗ circularity +  7.054
∗ roundness + 10.3 ∗ solidity 
The area under the curve (AUC) of correctly classified steatosis by the algorithm on WSI in 
the test set was 0.970 (95% CI 0.968-0.973), p<0.001 (See Figure 3). For the present study, 
an operating point of 0.5 was applied, yielding an accuracy of 91.9%, with a classification 
error of 8.1%. This accuracy shows the performance of the classifier on numbers of objects 
within the set of pre-selected candidates. As we are interested in the SPA rather than the 
numbers of objects, we also calculated the error in summed steatotic cells areas as a result 
of false positives and false negatives. From the areas calculated on the test set (see Table 2) 
we can calculate the relative area of false positives as 167779 / 3561981 * 100% = 4.71% 
and that of false negatives as 94011 / 3561981 * 100% = 2.64%. 
Figure 3. AUC for classification of steatosis 
Legend: Cut-offs of included size and roundness parameters were determined by logistic regression 
analysis on the test set.
 r  r t  r  ( ) f rr tl  l ifi  t t i   t  l rit   I i  
t  t t t  .  (  I . - . ), .  (  i r  ). r t  r t t , 
 r ti  i t f .   li , i l i   r  f . , it   l ifi ti  
rr r f . . i  r   t  rf r  f t  l ifi r  r  f j t  
it i  t  t f r - l t  i t .   r  i t r t  i  t   r t r t  t  
r  f j t ,  l  l l t  t  rr r i   t t ti  ll  r    r lt 
f f l  iti   f l  ti . r  t  r  l l t   t  t t t (  l  ) 
  l l t  t  r l ti  r  f f l  iti    /     .  
 t t f f l  ti    /     . . 
i r  .  f r l ssifi ti  f st t sis 
: t- ffs f i l  si   r ss r t rs r  t r i   l isti  r r ssi  
l sis  t  t st s t.
136
C
ha
pt
er
 7
 
Table 2. Classification results in both number of areas and in total surface area 
Classification Number of areas Total measured area (in µm²)
True positive 16612 3561981
False negative 585 94011
False positive 850 167779
Correlation between SPA and steatosis grading 
A total of 79 biopsies were included in the correlation between SPA and steatosis grade 
(61 patients with NAFLD and 18 controls without hepatic steatosis). The median SPA for 
grade 0 steatosis was 1.41% (IQR 1.03-1.80%), in grade 1: 4.99% (IQR 2.97-9.31%), in 
grade 2: 13.65% (IQR 10.90-16.10%), and in grade 3: 16.34% (IQR 14.48-20.54%) (see 
Table 3). A strong and significant positive correlation was observed between SPA and 
steatosis grading (Rs=0.845, CI: 0.749-0.902, p<0.001). The SPA also differed significantly 
between steatosis grades in overall analysis (p<.001) and in post-hoc analysis between 
individual grades, except between grade 2 and 3 (See figure 4). In a subgroup analysis 
(n=26) of patients with severe fibrosis (BRUNT fibrosis stage ≥ 2) the SPA also correlated 
significantly with steatosis grading (Rs=.821, p<.001). 
Patch distribution of steatosis 
We found a significant correlation between IQR of the SPA and steatosis grade (Rs=.822, 
P<.001). Similarly, droplet size (in um2) and total number of droplets per slide cor-
related significantly with steatosis grade (Rs=.723, p<.001 and Rs=.689, p<.001, 
respectively). Number of droplets per um2 remained equal in all steatosis grades (See 
Table 3). This results in an increasing heterogeneity in distribution of SPA with pro-
gressing steatosis grades, despite the equal number of droplets per um2 in all grades. 
Table 3. Results of automated image analysis for each grade of steatosis 
Steatosis 
grade
N SPA (%) IQR of SPA No. of droplets 
per mm2
Droplet size 
(um2)
IQR of 
Droplet Size
0 18 1.41 (1.03-1.80) 1.22 (.82-1.53) 179.5 (151.9-
243.6)
108 (94-124) 40 (35-55)
1 25 4.99 (2.97-9.31) 4.04 (2.62-
7.42)
169.5 (131.9-
278.6)
170 (158-
233)
105 (90-226)
2 25 13.65 (10.90-
16.10)
8.58 (7.51-
11.12)
169.4 (119.7-
288.9)
249 (218-
309)
279 (239-
336)
3 11 16.34 (14.48-
20.54)
9.26 (8.84-
13.09)
169.8 (136.1-
304.2)
226 (207-
321)
265 (206-
406)
Legend: N=number of biopsies analyzed. Median values + IQR (25-75th percentile) are shown. 
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Figure 5. Distribution of total fat percentage per patch
Legend: Histograms are shown for a representative WSI of each NAS steatosis grade (0-1-2-3). 
On the X-axis the SPA % per patch is shown, on the Y-axis the number of patches in the representative 
WSI. 
Figure 4. SPA per NAS grade
Legend: SPA differs significantly in all post-hoc analyses between grades (grade 0 vs. 1; 0 vs. 2; 0 vs. 3; 
1 vs. 2; 1 vs. 3) with p<0.01, except between grade 2 and 3 (p=1.000).
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Since every tissue slide is divided in hundreds of smaller patches for measurement pur-
poses the measured SPA per patch differs greatly, as is shown by the heterogeneity of 
individual patch SPA percentages in a randomly chosen tissue slide for every grade of 
steatosis (See Figure 5). 
DISCUSSION 
We describe the development of a novel automated digital analysis algorithm that quan-
tifies liver steatosis on whole slide images as a steatosis proportionate area (SPA). The 
algorithm shows good accuracy for discrimination between steatosis and non-steatotic 
tissue. 
There is an unmet need for an objective quantification of hepatic steatosis. Therapeu-
tical drug trials include reduction of steatosis as study outcome. In the transplantation 
setting, donor livers with moderate to severe steatosis (approximately exceeding 30%) are 
considered low quality grafts.24, 25 Quantitative analysis can increase reliability of steatosis 
assessment and truly determine the clinico-pathological correlations between severity of 
steatosis and graft failure. 
Several attempts have been made to establish DIA for this goal but thresholds showed 
to be insufficient to facilitate fully automated discrimination, as these required an ad-
ditional manual correction.13, 20, 26, 27 By identifying and combining optimal thresholds for 
several roundness and size parameters with logistic regression, we were able to accurately 
and automatically quantify steatosis. An additional benefit of this algorithm is its ability 
to process whole slide images. Tools that rely on (random) selection of fragments of the 
whole slide are at risk for over- or underestimation of steatosis.13, 16, 26-29 This is particularly 
relevant as steatosis is heterogeneously distributed, which further increases as the amount 
of steatosis rises.27 
The digitally quantified SPA showed to correlate well with NAS steatosis grading, how-
ever SPA was in all cases lower than the percentage range resembled by the pathologists 
grade. This observation, as well as the absolute percentages measured with our algorithm, 
corroborate findings from the other DIA methods quantifying steatosis.13, 16, 19, 20, 27, 30 Al-
though scoring by the pathologist is currently the gold standard, it suffers from inter- and 
intra-observer variability.14 Steatotic hepatocytes are identified as white droplets upon 
histological examination of hematoxylin-eosin stained liver specimens.31 Nonetheless, 
accurately estimating total percentage of steatosis has been shown to be difficult for pa-
thologists.32 Ideally, the pathologist visually estimates the relative percentage of steatotic 
hepatocytes compared to all hepatocytes present. However, individual hepatocytes are 
too small, numerous, and indistinctive to be counted at low magnification. Furthermore, 
visual overestimation of steatosis tends to increase with progressing severity.13 A possible 
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explanation for such overestimation is proposed by Rawlins et al., and comes from psycho-
logical studies that investigated how people judge quantity. When there is a high number 
of identical items arranged in an area, as is the case with many steatotic hepatocytes in 
liver parenchyma, people tend to overestimate quantity.20, 33, 34 Currently, thresholds for no, 
mild, moderate and severe steatosis are based upon the NAS score. As a result of the much 
lower steatosis percentages measured with DIA, such thresholds need to be re-established 
before used in the clinical setting.
There are some limitations to our algorithm. First, visual examination by pathologists 
allows detection and grading of more abnormalities than only steatosis. We therefore 
suggest this algorithm to be supplemental to a pathologist’s assessment. 
A second limitation of the algorithm comes from the automated division of the slide 
image in smaller patches. Steatotic hepatocytes aligned at the edge of the patch will be 
cleaved, affecting area size and roundness features, possibly causing misclassification. 
Nevertheless, in our cohort misclassification (false positives and negatives) led to only a 
small fractional error on total SPA. 
Lastly, with establishing thresholds, we only incorporated clear-cut features such as 
colour, size, and roundness in a logistic regression analysis. We cannot exclude that in the 
future other features will turn to be clinically relevant. More advanced techniques such as 
deep learning, may contribute to future algorithms investigating multiple histopathologi-
cal features at once. 
To conclude, we present a novel automated digital analysis algorithm that accurately 
and objectively quantifies liver steatosis on whole slide images, and has the potential to 
be incorporated as an addition to visual examination by pathologists. 
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ABSTRACT 
Prevalence of nonalcoholic fatty liver disease (NAFLD) is rapidly increasing, extending 
equally with the global incidence of obesity and metabolic syndrome. Accumulation of 
lipids in the liver, i.e. hepatic steatosis, is at the base of this disease. Hepatic steatosis is 
reversible but may progress to nonalcoholic steatohepatitis (NASH) and fibrosis. In order 
to monitor or screen for steatosis in a non-invasive ultrasonographic manner and without 
the need of specialized equipment, the authors developed a computer aided ultrasound 
(CAUS) protocol. This CAUS method was prospectively performed to estimate the di-
agnostic accuracy for the detection of steatosis in a substantial patient cohort (n=196) 
paralleled by liver biopsy. The diagnostic accuracy using qualitative liver grading as a 
reference for the presence of steatosis was high, with an Area under ROC curve (AUROC) 
of 97%; sensitivity of 85%; and specificity of 96%. When using a quantitative histology 
steatosis grading tool which determines the steatosis proportional area (as a %), the results 
further improved to 99%; 96%; 94%, respectively. Mean inter-observer correlation of all 
CAUS parameters was 0.94 (min:0.88 max:0.99). In 87% of all patients with steatosis 
also fibrosis present. However, no significant interference of fibrosis with the detection of 
steatosis was found. 
Conclusion
CAUS is able to detect and stage steatosis accurately, independent of interobserver varia-
tions, and is not corrupted by the presence of fibrosis. So conventional ultrasound image 
analysis using the CAUS protocol may be a suitable alternative to percutaneous biopsies 
for staging steatosis.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) forms a major health care challenge with a global 
prevalence of approximately 25%, but values up to 90% are reported in high-risk groups 
with severe obesity and type 2 diabetes mellitus.1-4 Patients with NAFLD have an increased 
overall mortality, for which the most common cause is cardiovascular disease. NAFLD is 
increasingly recognized as the liver disease component of the metabolic syndrome.4-10
NAFLD represents a spectrum of disorders and starts with lipid accumulation in the liver 
(pathological if ≥ 5% steatosis), but may progress to nonalcoholic steatohepatitis (NASH), 
characterized by inflammation with hepatocyte injury (ballooning) with or without fibrosis, 
which may eventually result in cirrhosis.4, 6 A liver biopsy still is the current gold standard 
for staging steatosis.6 The NAFLD Activity Score (NAS) is the most commonly used semi-
quantitative grading system, and grades steatosis as an interval-percentage upon visual 
examination of histological liver tissue slides by a pathologist. However, biopsies are 
invasive and complications such as bleeding and infection may occur.11 Furthermore, his-
tological grading is subject to inter- and intra-observer variability and prone to inaccuracy. 
Consequently, this raises the threshold for its general use as screening tool for NAFLD.12, 13 
Non-invasive imaging techniques, such as magnetic resonance imaging proton density fat 
fraction and magnetic resonance spectroscopy are accurate and increasingly proposed, 
however, these methods are expensive, time-consuming and may not be easily suitable 
for screening purposes. There remains an unmet need for a noninvasive, low-cost, robust, 
fast, and accurate method that can clinically assess steatosis for diagnosis and monitoring 
of patients. 
We developed and tested a computer aided ultrasound (CAUS) protocol for the as-
sessment of steatosis14-18, using conventional ultrasound B-mode images, acquired with a 
fixed and calibrated imaging preset19. We chose to perform analysis on conventional B-
mode images since all modern ultrasound equipment supports export (i.e. screen dumps) 
of B-mode images using a lossless digital image format like DICOM (Digital Image and 
Communication in Medicine). CAUS can thus be applied everywhere, offline, without the 
need for additional hard-ware. CAUS showed high predictive values (AUROC up to 0.95) 
of liver fat content in cows16-18, and a human pilot study confirmed similar performance 
of CAUS for the detection of steatosis, compared to magnetic resonance spectroscopy.15 
The aim of this study was to test the diagnostic accuracy and precision of CAUS in 
staging and quantifying steatosis, validated against the reference standard of qualitative 
histology grading, as well as to a quantitatively determined steatosis proportional area 
derived automatically from digitized scanned Hematoxylin-Eosin (HE) slides. 
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METHODS
Study population
Liver histology slides and ultrasound images from simultaneously performed investigations 
were collected from all patients who underwent liver biopsy for various clinical indica-
tions in the Radboud university medical center during the period 2012-2016. Indication 
for liver biopsy and final diagnosis were derived from electronic patient records. Data 
collection was approved and individual patient consent was waived by the institutional 
review board (no. 2016-2763). Patient material was used according to the ‘’Code of Con-
duct for Responsible use of Human Tissue and Medical Research”.20
Clinical ultrasound protocol 
Ultrasound examination (Siemens Acuson X150; Siemens Healthcare GmbH, Erlangen, 
Germany, with CH5-2 transducer) was routinely performed in all patients prior to a liver 
biopsy, for determination of the biopsy location. During this procedure, a minimum of 
five independent B-mode images of the biopsy region (liver right lobe) were acquired 
at intercostal application during breath-holding, using a fixed imaging preset of the US 
equipment. Large vessels, bile ducts and shadowing effects were avoided from the central 
zone of the image sector if possible. Imaging preset settings were; depth: 15cm; in-plane 
focus: 8cm; TGC sliders: central position; contrast: 40 dB; frequency: 3.6MHz; Persist: 0. 
The 3.6MHz setting was chosen in order to obtain reasonable penetration in combination 
with diffuse image texture (speckle pattern due to dominant small structure back scatter-
ing) obtained when using frequencies of 2.5 MHz and other above mentioned settings.21
Quantitative Ultrasound protocol
For the CAUS analysis, the five best B-mode images (most bright and avoiding large blood 
vessels in the central part of the image sector) were selected and analyzed by two observ-
ers. The CAUS method was previously described extensively by the authors.14-18 A brief 
summary of the CAUS protocol including the effect of the applied post-processing steps 
on the CAUS parameter correlations with histology were added as supplemental material.
CAUS parameters
From the final corrected and segmented region of interest (ROI), quantitative ultrasound his-
togram and texture parameters were obtained: histogram parameters were estimated both 
on average and as function of depth (indicated as: slope ‘s’ of applied linear fit): mean echo 
level (MU, MUs [dB]), were MUs further is called the residual attenuation coefficient (RAC) 
since normal attenuation was compensated in the ‘automatic gain correction’ pre-processing 
step (14); standard deviation of the echo levels (SD, SDs [dB]); signal-to-noise ratio of echo 
level (SNR, estimated as MU/SD, SNRs). We chose to express the RAC in [dB·cm-1·MHz-1] 
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in order to obtain equipment independent expression of the attenuation coefficient, by 
division of the RAC [dB/cm] with the probes central frequency [MHz] (determined as the 
average frequency of the specified bandwidth provided by the manufacturer). The axial and 
lateral speckle size (AX & LAT [mm]) parameters were estimated parametrically, as well as 
the standard deviations of AX and LAT (AXsd, LATsd [mm]). The parametric texture approach 
is an addition of the CAUS protocol and is explained in the supplementary material. 
The average thickness of the superficial tissue layers (FATL: containing skin, muscle 
and subcutaneous fat layer) was used as CAUS parameter too. An example of image 
analysis is shown in figure 1. 
Histology assessment 
Biopsies were routinely stained with Hematoxylin-Eosin, Elastin-von Gieson and Sirius 
Red stains. Slides were collected from the pathology archives and for all included biop-
sies, grade of steatosis was reviewed by an experienced liver pathologist, using the NAFLD 
activity score. This score semi-quantitatively grades steatosis (STEAT), percentage count 
of hepatocytes with infiltrated macrovesicular fat droplets, as follows: grade S0 = 0-5% ; 
grade S1 = 5-33%, grade S2 = 33-66%; grade S3 = >66% 22. Disease-specific scores were 
used to assess fibrosis stage (i.e. Metavir, Ishak, Roenigk and BRUNT). For purpose of 
analyses, fibrosis stages were grouped, ranging 0-4.
Quantitative histology 
A fully automated digital image analysis tool which analyses the steatosis proportional 
area (SPA; ratio of steatotic area to total tissue area described as percentage) of digitally 
scanned HE slides was used as quantitative steatosis reference (further called QSPA).23 
This method is able to classify steatosis with an AUC of 0.97 and 95% confidence interval 
(CI) of 0.968-0.973 and shows a good correlation with steatosis grading (R=.845, 95-CI: 
.749-.902, p<.001). The software can be implemented as a Java plugin in FIJI, in which 
digital whole slide images can be processed automatically using the Pathomation exten-
sion, and produces a continuous steatosis scale which enables linear regression with the 
CAUS parameters. Thresholds corresponding to the STEAT grade threshold were found to 
be: 3.21%; 9.73% and 15.63% respectively.
Statistics
The median value of all CAUS parameters derived from the five analyzed images was 
used for further statistical analyses. To demonstrate the effect of the CAUS pre-processing 
modules on the CAUS parameter correlations to STEAT, repeated correlation estimates 
with increasing number of CAUS pre-processing steps applied were performed. Descrip-
tive statistics (mean and standard deviation) of all CAUS parameters per STEAT grade 
were estimated. Box plots (with 95% confidence intervals) were derived to visualize the 
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Figure 1. CAUS pre- and post-processed B-mode examples of a normal (left) and a fatty liver
Legend: Column 1: normal liver, column 2: NAS grade 3 liver. | Row 1: Original B-mode images with 
applied look-up-table correction | Row 2: with applied post-processing steps: back-scan conversion; 
automatic gain correction; superficial tissue layer correction; automatic segmentation; residual attenu-
ation correction. | Row 3: parametric overlay image of axial speckle size | Row 4: parametric overlay 
image of lateral speckle size
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CAUS parameters as a function of steatosis and fibrosis for the two CAUS parameters with 
highest correlation to steatosis. Inter-observer analysis was performed by two observers in 
order to validate the variability of both image selection and analysis in CAUS using the 
intra-class-correlation (ICC) analysis. A control group of patients who had no fibrosis nor 
steatosis, was composed and served as reference group for statistical analysis. In order to 
study the effect of the CAUS parameters to fibrosis (FIB), a pure fibrosis (FIBpure: patients 
with positive steatosis grades excluded, and using healthy indicated patients only) refer-
ence group was selected to detect possible CAUS parameters with interfering correlations. 
CAUS parameters were univariately correlated with STEAT, QSPA and FIB of the whole 
cohort as well as of the pure fibrosis subgroup using Pearson’s correlation coefficients. 
Core analysis
The data were divided into a training and a validation set (50-50%, odd-even distribu-
tion after sorting on QSPA), in order to independently train and validate the regression 
models for diagnostic accuracy estimation. On the training-set univariate logistics regres-
sion analysis (LogR, using the RAC parameters only) and multivariate logistic regression 
analyses (MLogR) were performed to obtain the regression formulas for stratification of 
the ordinal STEAT grades for each risk group (multivariate thresholds: S0 vs. S1-3; S0-1 vs. 
S2-3; S2 = S0-2 vs. S3, further indicated with: S0; S1; S2 univariate names: SRAC0, SRAC1, SRAC2). 
For the QSPA reference one linear regression formula (LinR, using the RAC parameter 
only), and one multiple linear regression analysis (MLinR, forward method) was performed 
since two continuous scales are compared here. The corresponding QSPA threshold were 
(multivariate: Q0 = 3.21%, Q1 = 9.73%, Q2 = 15.63%; univariate names: QRAC0, QRAC1, 
QRAC2). The fibrosis stage also was fed to the multiple regression methods, to check for 
confounding of fibrosis on steatosis. The obtained regression formulas then where ap-
plied to the validation-set, followed by ROC analysis to access diagnostic accuracy for 
all thresholds and regression types described by the following ROC-parameters: Area 
under the ROC curve (AUROC), sensitivity (SN) and specificity (SP) determined using the 
Youden-index, positive predictive value (PPV) and negative predictive value (NPV) using 
the cohort’s own prevalence for steatosis. All statistics were performed using SPSS (Version 
24, SPSS Inc Chicago, Il, USA).
RESULTS
Baseline characteristics 
Of 224 patients with both ultrasound images and liver histology, 195 patients with valid 
CAUS measurements, as well as qualitative and quantitative histopathological results, 
were included. Twenty-eight patients were excluded due to: inappropriate ultrasound 
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settings (n=5), failed/invalid biopsies (n=5), or invalid/unknown underlying liver etiology 
(n=18) (Figure 1). In 87 out of the 195 patients some degree of steatosis (STEAT ≥ 1) was 
found, mainly caused by NASH (n=55), drug or substance-induced liver injuries (n=14) 
and NAFLD (n=9), which corresponds with an overall prevalence of 45% for steatosis in 
this cohort. Fibrosis prevalence was found to 68% (128 out of 195 patients). As a reference 
48 out of the 195 patients were selected who had no steatosis nor fi brosis (Figure 2). 
Between the STEAT and the FIB references no signifi cant correlation was found (R=0.01, 
p=.85). Descriptive statistics of all CAUS parameters per STEAT grade (S0, S1, S2 & S3) 
were given in table 1. Inter STEAT grades T-tests of the CAUS parameters showed highly 
signifi cance (p<0.01) for the MU, RAC and SNRs parameters between all grades, except 
between the STEAT grades 2 & 3 (see Table 1).
Fig 2. Flowchart of cohort with reference groups and disease categories
Legend: FLD: fatty liver disease | NAFLD: non-alcoholic fatty liver disease | NASH: non-alcoholic ste-
atohepatitis. ASH: alcoholic steatohepatitis | Viral hepatitis: consisted of patients with hepatitis B, C or E 
| Auto-immune: with auto-immune hepatitis, primary sclerosing cholangitis and primary biliary cholan-
gitis. | Toxic-medic: included drug- or substance-induced liver injuries. | ECI: no conclusive diagnosis 
was made based on histology. | Other: gluten-ind hep; alpha 1 defi ciency.
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Table 1: CAUS parameters per steatosis grade and inter STEAT grades t-tests 
STEAT grades S0 n=48 S1 n=43 S2 n=30 S3 n=14
CAUS
param. unit mu sd mu sd mu sd mu sd 0
-1 0-
2
0-
3
1-
2
1-
3
2-
3
FATL mm 1.35 0.45 5.25 3.56 13.59 4.74 17.41 6.01 ** ** ** ns ns ns
MU dB 26.81 4.70 31.58 5.77 31.32 6.78 31.65 6.19 ** ** ** ** ** ns
RAC dB/(cm·MHz) 0.21 0.13 0.49 0.16 0.63 0.13 0.68 0.11 ** ** ** ** ** ns
SD dB 23.22 1.54 22.22 1.16 22.26 1.19 22.31 1.18 ** ** ns ns ns ns
SDs dB/cm 0.03 0.06 0.03 0.05 0.01 0.04 0.01 0.05 ns ns ns * ns ns
SNR 7.36 0.95 9.05 0.99 9.92 0.84 9.59 0.69 ** ** ** ** ns ns
SNRs SNR/cm -0.24 0.20 -0.53 0.18 -0.63 0.14 -0.67 0.08 ** ** ** * ** ns
AX mm 0.40 0.02 0.42 0.01 0.42 0.01 0.42 0.01 ** ** ** ** ** ns
AXsd mm 0.10 0.01 0.10 0.01 0.10 0.01 0.10 0.01 ns ns ns ns ns ns
LAT mm 1.68 0.06 1.74 0.04 1.76 0.04 1.76 0.03 ** ** ** ns ns ns
LATsd mm 0.51 0.02 0.50 0.02 0.49 0.01 0.49 0.01 ** ** ** * ns ns
Legend: FATL: average thickness of superficial tissue layers; MU: average relative echo level; RAC: 
residual attenuation coefficient; SD: standard deviation of echo levels; SDs: slope of linear fit though 
SD-profile; SNR: signal-noise ratio (MU/SD); SNRs: slope of linear fit though SNR-profile; AX: average 
parametric axial speckle size; AXsd; standard deviation of AX; LAT= average lateral speckle size; LATsd; 
standard deviation of LAT. * significant at the p<0.05 level, ** significant at the p<0.01 level.
Univariate correlation analysis
Univariate Pearson correlation analysis revealed highly significant correlations for 9 out 
of 11 CAUS parameters to both STEAT and QSPA (Table 2), except for SDs and AXsd. The 
RAC showed the strongest correlation (R=0.77; 0.76; 0.77, p<0.01) to STEAT and QSPA. 
Table 2. Correlations of CAUS parameters with histology
n FATL MU RAC SD SDs SNR SNRs AX AXsd LAT LATsd
STEAT 195 0.30** 0.71** 0.77** -0.26** -0.08 0.69** -0.67** 0.52** 0.15* 0.48** -0.37**
QSPA 195 0.28** 0.70** 0.77** -0.25** -0.15* 0.67** -0.64** 0.51** 0.17* 0.47** -0.40**
FIB 195 0.02 0.17* 0.13 0.07 -0.13 0.10 -0.06 -0.06 -0.04 -0.02 -0.09
FIBpure 75 -0.09 0.30** 0.13 0.16 -0.19 0.12 -0.01 -0.18 -0.13 -0.09 -0.06
Legend: STEAT: control group + positive STEAT grades; QSPA: quantitative steatosis proportional area; 
FIB: all data grouped by fibrosis stages; FIBpure: control group + positive fibrosis stages (steatosis ex-
cluded); FATL: thickness of superficial tissue layers; MU: mean echo level; RAC=depth dependence of 
MU i.e., residual attenuation coefficient; SD: standard deviation of echo levels; SDs: slope of linear fit 
though SD-profile; SNR: signal-noise ratio (MU/SD); SNRs: slope of linear fit though SNR-profile; AX: 
average parametric axial -3dB axial speckle height; AXsd; standard deviation of parametric AX; LAT: 
average lateral speckle size (-3dB lvl); LATsd: standard deviation of parametric LAT. (* significant at the 
p<0.05 level, ** significant at the p<0.01 level)
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Boxplots with p5-95 intervals, and ANOVA significance between the STEAT grades of 
the two best correlating parameters (RAC, R=0.77**; MU, R=0.70**), with and without 
applied CAUS post-processing, are shown in figure 3. Three of the four texture parameters 
also showed highly significant (p<0.01) correlations to STEAT (AX, R=0.52; LAT, R=0.48; 
LATsd, R=-0.37). The only parameter that showed a significant but weak correlation with 
fibrosis is the MU (R=0.17, p=0.019). The AX and LAT show opposite correlations between 
fibrosis and steatosis references, which indicates not only the potential differential power 
for discrimination of fibrotic vs fatty livers based on texture analysis, but also between 
healthy and fibrotic tissue. Almost identical correlations for all CAUS parameters were 
found when using QSPA instead of the STEAT reference (See Table 4).
   Pre-processing    Post-processing
Figure 3. box-plots of CAUS parameters RAC & MU
Legend: Boxplots of the CAUS parameters mean echo level (MU) and (residual) attenuation coefficient 
(RAC) vs. NAS grades without applied CAUS postprocessing steps (A&C) and after applied CAUS post-
processing steps (B&D).
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Regression analysis and predictive values
Multiple logistic regression analysis on the training-set showed optimal correlations for 
S0 (R2=0.76, S0 vs. S1-3) and Q0 (R2=0.62, QSPA<>3.21%), where RAC was selected 
first in both cases. In logistic regression also the SNR parameter was selected, where 
in linear regression MU was an additional contributing parameter (See Table 3). In the 
corresponding validation-set the AUROC, SN and NPV values for STEAT0 and QSPA0 were 
97%; 85%; 89% and 99%; 96%; 96% respectively (See Table 3 and Figure 4). The QSPA 
thus shows improved detection of steatosis presence compared to STEAT. The predictive 
performance of the higher steatosis grades gradually reduces more in STEAT (AUROC: 97 
> 79%) compared to QSPA (AUROC: 99 > 92%). Even in univariate regression analysis 
using the RAC parameter, the predictive performance remains reasonable for STEAT and 
QSPA reference groups (See Table 3, and Figure 4). 
Figure 4. ROC curves of multivariate regression models 
Legend: CAUS ROC curves of multivariate regression models. a) QSPA with thresholds: 3.21% (blue); 
9.73%(black); 15.63%(red), corresponding to NAS thresholds with AUROC values: 97; 94 and 92% 
respectively. b) Qualitative NAS grade with thresholds: <>S1 (blue); <>S2 (black) and <>S3 (red), and 
AUROC values: 97; 88 and 79% respectively. 
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DISCUSSION
The present study demonstrates that the CAUS method reveals a high diagnostic accuracy 
in detection and grading of steatosis, compared to the histological reference standard, 
which indicates that CAUS may provide a valuable alternative to percutaneous liver 
biopsies. 
When using the quantitative steatosis as a reference the performance is even further 
improved, especially for the detection of higher steatosis thresholds, compared to quali-
tatively scored steatosis. This finding pleads for a quantitative histology approach which 
doesn’t hassle with course classifications, and thus is less prone to misclassification, since 
it produces a continuous scale outcome and works fully automatic analysis thus is user 
independent.
With the CAUS protocol in combination with quantitative histology we obtained 
higher predictive values than all other studies based on ultrasound methods: conventional 
B-mode images scored quantitatively or qualitatively24-33, radio-frequency (RF) based 
ultrasound analysis26, 28, 29, 34-37, or the controlled attenuation parameter (CAP)38-42. A huge 
benefit of the CAUS method is the usage of conventional B-mode images, which enables 
worldwide offline application without additional hardware prerequisites. 
When comparing current CAUS results to published results of the CAP technique it can 
be concluded that we found the optimal predictive performance for steatosis detection at 
the clinically most relevant lower threshold (5%), whereas CAP values show it’s optimal 
performance around 10%, or higher, cutoffs.38, 42 This also is in contrast to statements 
that ultrasound is insensitive to small amounts of fat.43 We believe that the performance 
improvement of CAUS compared to CAP studies, are obtained due to: 1) analysis of a 
relative large part of the liver instead of single image line analysis, 2) multiparameter ap-
proach of CAUS, 3) automatic segmentation of the liver parenchyma to avoid disturbance 
on the CAUS parameters by excluding large blood vessels and bile duct from the analysis. 
It can be concluded that accuracy of steatosis detection with CAUS does not suffer from 
the presence of fibrosis, since only a very low correlation of MU with fibrosis was found, 
and fibrosis itself was not selected as a contributing parameter in the regression analysis. 
Although liver biopsies are the gold standard for steatosis quantification, sampling 
errors and complications such as bleeding and infection may occur, making liver biopsy 
less suitable for longitudinal studies and clinical follow-up.44-46 11 Biopsies also are subject 
to inter- and intra-observer variability and prone to inaccuracy, however using digital 
techniques such as the quantitative SPA, these issues can be overcome. 
With the growing epidemic that NAFLD is becoming, we are in need of an easy ap-
plicable and safe diagnostic measure to screen patients for presence of steatosis. Accurate 
quantification of steatosis is furthermore warranted to assess risk of disease progression 
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and to use as an outcome in clinical trials investigating new therapeutically drugs for 
NAFLD.15 
MRI-PDFF has convincingly shown its accuracy in quantifying hepatic steatosis over 
the entire liver.47, 48 Therefore it might be superior to other non-invasive techniques and 
even to histological assessment of steatosis, but considering availability, complexity, 
intensity and expenses of MRI, the use of CAUS might also be considered in the context 
of clinical trials.
In this cohort besides NAFLD patients, also patients with other disease etiologies were 
included, allowing generalizability of results to a broader population.
Limitations
First, CAUS only quantifies steatosis, but is so far not suitable for detection or quantifica-
tion of other abnormalities such as inflammation and fibrosis. Therefore, CAUS should be 
seen as an addition to ultrasound examination performed by radiologists. 
Second, CAUS is still an offline image analysis tool, and thus real-time measurements 
cannot be obtained until the method will be incorporated in US modalities. Furthermore 
before using CAUS, a one-time calibration of a fixed imaging preset is required using a 
tissue mimicking phantom. This calibration is needed in order to obtain the conversion 
factor for recoding the echo level (gray levels) into decibels19, and to extract the beam pro-
file which is used for automatic gain correction.14, 16 Calibration does ensure comparable 
results between and within subjects. 
Last, validation of CAUS was performed in a selected population of patients, who had 
an indication for liver biopsy, this means there were no true healthy controls present.
Conclusion
Concerning the very good predictive performance in steatosis detection, in combination 
with its offline applicability to all ultrasound equipment containing a digital image export, 
CAUS may serve as a non-invasive screening and monitoring tool for steatosis. 
159
REFERENCES
 1. Williamson RM, Price JF, Glancy S, Perry 
E, Nee LD, Hayes PC, Frier BM, Van Look 
LA, Johnston GI, Reynolds RM, Strachan 
MW, Edinburgh Type 2 Diabetes Study I. 
Prevalence of and risk factors for hepatic 
steatosis and nonalcoholic Fatty liver 
disease in people with type 2 diabetes: 
the Edinburgh Type 2 Diabetes Study. 
Diabetes Care 2011;34(5):1139-44.
 2. Browning JD, Szczepaniak LS, Dobbins 
R, Nuremberg P, Horton JD, Cohen JC, 
Grundy SM, Hobbs HH. Prevalence of 
hepatic steatosis in an urban population 
in the United States: impact of ethnicity. 
Hepatology 2004;40(6):1387-95.
 3. Vernon G, Baranova A, Younossi ZM. 
Systematic review: the epidemiology and 
natural history of non-alcoholic fatty liver 
disease and non-alcoholic steatohepatitis 
in adults. Alimentary pharmacology & 
therapeutics 2011;34(3):274-85.
 4. Younossi ZM, Koenig AB, Abdelatif D, 
Fazel Y, Henry L, Wymer M. Global 
epidemiology of nonalcoholic fatty 
liver disease-Meta-analytic assessment 
of prevalence, incidence, and outcomes. 
Hepatology 2016;64(1):73-84.
 5. Bhatia LS, Curzen NP, Calder PC, Byrne 
CD. Non-alcoholic fatty liver disease: a 
new and important cardiovascular risk 
factor? Eur Heart J 2012;33(10):1190-
200.
 6. Chalasani N, Younossi Z, Lavine JE, Diehl 
AM, Brunt EM, Cusi K, Charlton M, San-
yal AJ. The diagnosis and management of 
non-alcoholic fatty liver disease: practice 
Guideline by the American Association 
for the Study of Liver Diseases, American 
College of Gastroenterology, and the 
American Gastroenterological Associa-
tion. Hepatology 2012;55(6):2005-23.
 7. Dunn W, Xu R, Wingard DL, Rogers C, 
Angulo P, Younossi ZM, Schwimmer JB. 
Suspected nonalcoholic fatty liver disease 
and mortality risk in a population-based 
cohort study. The American journal of 
gastroenterology 2008;103(9):2263-71.
 8. Edens MA, Kuipers F, Stolk RP. Non-
alcoholic fatty liver disease is associated 
with cardiovascular disease risk markers. 
Obesity reviews : an official journal of the 
International Association for the Study of 
Obesity 2009;10(4):412-9.
 9. Ekstedt M, Franzen LE, Mathiesen UL, 
Thorelius L, Holmqvist M, Bodemar G, 
Kechagias S. Long-term follow-up of 
patients with NAFLD and elevated liver 
enzymes. Hepatology 2006;44(4):865-
73.
 10. Soderberg C, Stal P, Askling J, Glaumann 
H, Lindberg G, Marmur J, Hultcrantz R. 
Decreased survival of subjects with ele-
vated liver function tests during a 28-year 
follow-up. Hepatology 2010;51(2):595-
602.
 11. Smith EH. Complications of percutaneous 
abdominal fine-needle biopsy. Review. 
Radiology 1991;178(1):253-8.
 12. El-Badry AM, Breitenstein S, Jochum W, 
Washington K, Paradis V, Rubbia-Brandt L, 
Puhan MA, Slankamenac K, Graf R, Cla-
vien PA. Assessment of hepatic steatosis 
by expert pathologists: the end of a gold 
standard. Ann Surg 2009;250(5):691-7.
 13. Hall AR, Dhillon AP, Green AC, Ferrell L, 
Crawford JM, Alves V, Balabaud C, Bha-
thal P, Bioulac-Sage P, Guido M, Hytiro-
glou P, Nakanuma Y, Paradis V, Quaglia 
A, Snover D, Theise N, Thung S, Tsui 
W, van Leeuwen DJ. Hepatic steatosis 
estimated microscopically versus digital 
image analysis. Liver Int 2013;33(6):926-
35.
 14. Thijssen JM, Starke A, Weijers G, Hau-
dum A, Herzog K, Wohlsein P, Rehage 
J, de Korte CL. Computer-aided B-mode 
ultrasound diagnosis of hepatic steatosis: 
a feasibility study. IEEE TransUltrasonFer-
160
C
ha
pt
er
 8
 
roelectrFreqControl 2008;55(6):1343-
1354.
 15. Weijers G, Wanten G, Thijssen JM, van 
der Graaf M, de Korte CL. Quantita-
tive Ultrasound for Staging of Hepatic 
Steatosis in Patients on Home Paren-
teral Nutrition Validated with Magnetic 
Resonance Spectroscopy: A Feasibility 
Study. Ultrasound in medicine & biology 
2016;42(3):637-44.
 16. Weijers G, Starke A, Thijssen JM, Haudum 
A, Wohlsein P, Rehage J, de Korte CL. 
Transcutaneous vs. Intraoperative Quan-
titative Ultrasound for Staging Bovine He-
patic Steatosis. Ultrasound in Medicine 
&amp; Biology 2012;38(8):1404-1413.
 17. Weijers G, Starke A, Haudum A, Thijssen 
JM, Rehage J, de Korte CL. Interactive vs. 
automatic ultrasound image segmenta-
tion methods for staging hepatic lipidosis. 
UltrasonImaging 2010;32(3):143-153.
 18. Starke A, Haudum A, Weijers G, Herzog 
K, Wohlsein P, Beyerbach M, de Korte 
CL, Thijssen JM, Rehage J. Noninvasive 
detection of hepatic lipidosis in dairy 
cows with calibrated ultrasonographic 
image analysis. Journal of dairy science 
2010;93(7):2952-65.
 19. Thijssen JM, Weijers G, de Korte CL. 
Objective performance testing and 
quality assurance of medical ultra-
sound equipment. Ultrasound MedBiol 
2007;33(3):460-471.
 20. Organisation F. Code of Conduct for 
responsible use of Human Tissue and 
Medical Research 2011.
 21. Wagner RF, Insana MF, Smith SW. Fun-
damental correlation lengths of coherent 
speckle in medical ultrasonic images. IEEE 
transactions on ultrasonics, ferroelectrics, 
and frequency control 1988;35(1):34-44.
 22. Kleiner DE, Brunt EM, Van Natta M, 
Behling C, Contos MJ, Cummings OW, 
Ferrell LD, Liu YC, Torbenson MS, Unalp-
Arida A, Yeh M, McCullough AJ, Sanyal 
AJ, Nonalcoholic Steatohepatitis Clinical 
Research N. Design and validation of a 
histological scoring system for nonal-
coholic fatty liver disease. Hepatology 
2005;41(6):1313-21.
 23. Munsterman ID, van Erp M, Weijers G, 
Bronkhorst C, de Korte CL, Drenth JPH, 
van der Laak JAWM, ETTL. A novel au-
tomatic digital algorithm that accurately 
quantifies steatosis in NAFLD on histo-
pathological whole slide images. United 
European Gastroenterology Journal 
2018;6(8_suppl):A748-A787.
 24. Oosterveld BJ, Thijssen JM, Hartman P, 
Rosenbusch G. Attenuation and texture 
analysis of invivi B-mode liver scans. 
Ultrason Imaging 1987;9(1):65-65.
 25. Gaitini D, Baruch Y, Ghersin E, Veitsman 
E, Kerner H, Shalem B, Yaniv G, Sarfaty C, 
Azhari H. Feasibility study of ultrasonic 
fatty liver biopsy: texture vs. attenuation 
and backscatter. Ultrasound MedBiol 
2004;30(10):1321-1327.
 26. Garra BS, Insana MF, Shawker TH, Rus-
sell MA. Quantitative estimation of at-
tenuation and echogenicity: normal state 
versus diffuse liver disease. Radiology 
1987;162:61-67.
 27. Acorda JA, Yamada H, Ghamsari SM. 
Evaluation of Fatty Infiltration of the Liver 
in Dairy-Cattle through Digital Analysis 
of Hepatic Ultrasonograms. Vet Radiol 
Ultrasoun 1994;35(2):120-123.
 28. Kuc R, Taylor KJ. Variation of acoustic at-
tenuation coefficient slope estimates for 
in vivo liver. Ultrasound in medicine & 
biology 1982;8(4):403-12.
 29. Garra BS, Shawker TH, Nassi M, Russell 
MA. Ultrasound attenuation measure-
ments of the liver in vivo using a com-
mercial sector scanner. Ultrason Imaging 
1984;6(4):396-407.
 30. Maklad NF, Ophir J, Balsara V. Attenu-
ation of ultrasound in normal liver and 
diffuse liver disease in vivo. Ultrason 
Imaging 1984;6(2):117-25.
161
 31. Nagy G, Munteanu M, Gordan M, Chira 
R, Iancu M, Crisan D, Mircea PA. Com-
puterized ultrasound image analysis for 
noninvasive evaluation of hepatic steato-
sis. Med Ultrason 2015;17(4):431-6.
 32. Edens MA, van Ooijen PM, Post WJ, 
Haagmans MJ, Kristanto W, Sijens PE, 
van der Jagt EJ, Stolk RP. Ultrasonography 
to quantify hepatic fat content: validation 
by 1H magnetic resonance spectroscopy. 
Obesity 2009;17(12):2239-44.
 33. Foster KJ, Dewbury KC, Griffith AH, 
Wright R. The accuracy of ultrasound in 
the detection of fatty infiltration of the 
liver. Br J Radiol 1980;53(629):440-2.
 34. Oosterveld BJ, Thijssen JM, Hartman PC, 
Romijn RL, Rosenbusch GJE. Ultrasound 
attenuation and texture analysis of diffuse 
liver disease, methods and preliminary 
results. Physics in Medicine and Biology 
1991;36(8):1039-1064.
 35. Fink M, Hottier F, Cardoso JF. Ultrasonic 
signal processing for in vivo attenuation 
measurement: short time Fourier analysis. 
Ultrason Imaging 1983;5(2):117-35.
 36. Graif M, Yanuka M, Baraz M, Blank A, 
Moshkovitz M, Kessler A, Gilat T, Weiss 
J, Walach E, Amazeen P, Irving CS. 
Quantitative estimation of attenuation 
in ultrasound video images: correlation 
with histology in diffuse liver disease. 
Invest Radiol 2000;35(5):319-324.
 37. Lin SC, Heba E, Wolfson T, Ang B, Gamst 
A, Han A, Erdman JW, Jr., O’Brien WD, 
Jr., Andre MP, Sirlin CB, Loomba R. Non-
invasive Diagnosis of Nonalcoholic Fatty 
Liver Disease and Quantification of Liver 
Fat Using a New Quantitative Ultrasound 
Technique. Clinical gastroenterology and 
hepatology : the official clinical practice 
journal of the American Gastroenterolog-
ical Association 2015;13(7):1337-1345 
e6.
 38. Sasso M, Beaugrand M, de Ledinghen V, 
Douvin C, Marcellin P, Poupon R, San-
drin L, Miette V. Controlled attenuation 
parameter (CAP): a novel VCTE guided 
ultrasonic attenuation measurement for 
the evaluation of hepatic steatosis: pre-
liminary study and validation in a cohort 
of patients with chronic liver disease from 
various causes. Ultrasound in medicine & 
biology 2010;36(11):1825-35.
 39. Sasso M, Miette V, Sandrin L, Beaugrand 
M. The controlled attenuation parameter 
(CAP): a novel tool for the non-invasive 
evaluation of steatosis using Fibroscan. 
Clinics and research in hepatology and 
gastroenterology 2012;36(1):13-20.
 40. Sasso M, Tengher-Barna I, Ziol M, Miette 
V, Fournier C, Sandrin L, Poupon R, 
Cardoso AC, Marcellin P, Douvin C, de 
Ledinghen V, Trinchet JC, Beaugrand M. 
Novel controlled attenuation parameter 
for noninvasive assessment of steatosis 
using Fibroscan((R)): validation in chron-
ic hepatitis C. Journal of viral hepatitis 
2012;19(4):244-53.
 41. Park CC, Nguyen P, Hernandez C, Betten-
court R, Ramirez K, Fortney L, Hooker J, 
Sy E, Savides MT, Alquiraish MH, Valasek 
MA, Rizo E, Richards L, Brenner D, Sirlin 
CB, Loomba R. Magnetic Resonance 
Elastography vs Transient Elastography 
in Detection of Fibrosis and Noninvasive 
Measurement of Steatosis in Patients 
With Biopsy-Proven Nonalcoholic 
Fatty Liver Disease. Gastroenterology 
2017;152(3):598-607 e2.
 42. Caussy C, Alquiraish MH, Nguyen P, Her-
nandez C, Cepin S, Fortney LE, Ajmera V, 
Bettencourt R, Collier S, Hooker J, Sy E, 
Rizo E, Richards L, Sirlin CB, Loomba R. 
Optimal threshold of controlled attenu-
ation parameter with MRI-PDFF as the 
gold standard for the detection of hepatic 
steatosis. Hepatology 2018;67(4):1348-
1359.
 43. Schwenzer NF, Springer F, Schraml C, 
Stefan N, Machann J, Schick F. Non-
invasive assessment and quantification of 
liver steatosis by ultrasound, computed 
162
C
ha
pt
er
 8
 
tomography and magnetic resonance. 
Journal of hepatology 2009;51(3):433-
45.
 44. Cholongitas E, Senzolo M, Standish R, 
Marelli L, Quaglia A, Patch D, Dhillon 
AP, Burroughs AK. 2006. Am J Clin Pathol 
2006;125(5):710-21.
 45. Janiec DJ, Jacobson ER, Freeth A, Spauld-
ing L, Blaszyk H. Histologic variation of 
grade and stage of non-alcoholic fatty 
liver disease in liver biopsies. Obes Surg 
2005;15(4):497-501.
 46. Ratziu V, Charlotte F, Heurtier A, Gombert 
S, Giral P, Bruckert E, Grimaldi A, Cap-
ron F, Poynard T, Group LS. Sampling 
variability of liver biopsy in nonalco-
holic fatty liver disease. Gastroenterology 
2005;128(7):1898-906.
 47. Caussy C, Reeder SB, Sirlin CB, Loomba 
R. Noninvasive, Quantitative Assess-
ment of Liver Fat by MRI-PDFF as an 
Endpoint in NASH Trials. Hepatology 
2018;68(2):763-772.
 48. Noureddin M, Lam J, Peterson MR, 
Middleton M, Hamilton G, Le TA, Bet-
tencourt R, Changchien C, Brenner DA, 
Sirlin C, Loomba R. Utility of magnetic 
resonance imaging versus histology for 
quantifying changes in liver fat in nonal-
coholic fatty liver disease trials. Hepatol-
ogy 2013;58(6):1930-40.
 49. Wagner RF, Smith SW, Sandrik JM, 
Lopez H. Statistics of Speckle in Ul-
trasound B-Scans. Ieee T Son Ultrason 
1983;30(3):156-163.
163
SUPPLEMENTARy METHODS
CAUS protocol summary
Ultrasound B-mode images were pre-processed in order to linearize the gray level look-up 
table to restore the purely logarithmically compressed echo levels; back-scan conver-
sion was performed to obtain a rectangular (polar, R-‐) grid in which beam divergence of 
transmit and receive was removed and depth information was aligned. We corrected for 
attenuation caused by the superficial tissue layers to compensate for inter-patient variation 
of these layers which negatively affects the mean echo-level. A tissue mimicking phantom 
based automatic gain correction (AGC) was applied to compensate for the echo level depth 
dependency caused by the beam-profile (attenuation, focusing and diffraction). Large he-
patic blood vessels and bile-ducts were automatically segmented in a fixed placed region 
of interest (ROI, with a depth-range of 5-14cm, and 70% of full image width, excluding 
the outermost 15% image-lines of the sector). Finally the residual attenuation coefficient 
(RAC) parameter was estimated and corrected for.
Parametric texture estimation
A new parametric approach for estimation of the speckle size and amplitude is introduced 
compared to previous CAUS studies. This approach uses of a moving window technique 
from which the autocovariance functions (ACVF)49 were estimated on multiple positions 
of each image line (axial) and row (lateral) individually (1D), instead of applying single 
downshifting ROI. Another adjustment is that the speckle sizes were estimated at the -3dB 
instead of the -6dB level of the ACVF. The latter is done since the ACVF amplitude often 
didn’t reach the +6dB level, which resulted in large gaps of missing data. ACVF estimations 
are performed on the full ROI without segmentation applied, in order to overcome speckle 
malformations by the segmentation itself. For creation of the parametric texture image, 
only the ACVF’s of the speckle centers, which were found by applying a peak detection 
algorithm to the corresponding ACVF’s (amplitudes > 4dB, peak distance minimally 1 im-
age line/row), were used. As a next step the speckle center ACVF’s were 10x interpolated 
using a cubic interpolated method. From the interpolated data the axial and lateral -3dB 
speckle size (AX and LAT), amplitudes, and full widths were derived using linear interpola-
tion. The values then are placed on the speckle center locations in so called raw texture 
images. This procedure was repeated for every window position axially and laterally until 
the full ROI was analyzed. Finally the segmentation was re-applied to eliminate the bright 
vessel wall reflections and dark blood/bile pool scattering (Figure 3) from the analysis. 
From these resulting raw parametric texture images (Figure 3) the mean axial and lateral 
speckle size (AX & LAT [mm]), as well as the standard deviations of AX and LAT (AXsd, 
LATsd [mm]) were used in this study. For visualization purposes the parametric data was 
filled over the ROI using 2D linear interpolation. Moving window settings (height; width; 
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step size) used for axial and lateral texture parameter estimations respectively were: 5mm; 
full width; 1mm, and full height; 8mm; 2mm. 
Effect of applied CAUS post-processing steps on the correlation with 
histology
We also studied the effect of the applied post-processing steps on the CAUS parameters 
correlations with histology using the QSPA. Since the pre-processing steps ‘look-up-table 
correction’ and ‘back-scan conversion’ are required for CAUS analysis and parameters 
extraction, we started the correlation analysis using these applied steps firstly. All other 
post-processing steps (automatic segmentation; AGC; FATL corr; RAC corr) then were 
consecutively applied. The full table of the CAUS parameter correlations with histology as 
a function of applied post-processing steps was given in supplementary table 1.
Results of the consecutive applied CAUS post-processing steps
Application of ‘automatic segmentation (segm)’ to the pre-processing resulted in gained 
correlations of the SD and SNR parameters to NAS of: 20% and 12% respectively. The AGC 
correction resulted in improved correlation of the RAC by 4% (R=0.73 > 0.77), the SD 
parameter by 11%, and the SNR by 20%. The FATL correction improved the correlation of 
MU with 11%. When applying RAC correction the mean echo level correlation is boosted 
with 0.52 from 0.19 to 0.71, and changed the echo level standard deviation correlation 
from 0.74 to -0.26, while the signal to noise ratio parameter showed the opposite effect 
and changed from -0.47 to 0.69 (See supplementary table 1).
Inter-observer variability and effect of applied CAUS modules on the 
correlations
Inter-observer agreement determined by Intraclass correlation analysis (ICC), revealed 
high and significance values for all CAUS parameters ranging between 87% and 99%. 
Parameters with ICC levels above 0.95 were found MU; RAC; SNR; SNRs; AX; LAT (See 
supplementary table 1). 
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General discussion 
The aims of this thesis were (1) to better understand how several extra-hepatic risk factors 
(i.e. Fontan physiology, smoking and cessation of alcohol) contribute to liver disease and 
(2) to improve current methods for evaluation of liver disease in patients with NAFLD 
or FALD. We did this by means of the studies described in this thesis. In this general 
discussion I will address the outcomes of these studies, focussing on interpretation and 
implications of results, as well as identification of gaps in current literature that could 
serve as possible directions for future research. To guide the discussion, table 1 provides 
an overview of the main findings, implications and limitations presented in this thesis.
Table 1. Main findings, implications and limitations of this thesis
Part I Contribution of extra-hepatic risk-factors to severe liver disease
Chapter Main findings Implications Limitations 
2.  -FALD spectrum includes 
congestion and fibrosis in all 
patients, with severe fibrosis, 
portal hypertension and nodules 
as significant manifestations
-Non-invasive measures do 
not correlate with histological 
fibrosis severity 
-FALD patients are 
potentially at risk for severe 
complications 
-Routine CT, MRI, TE and 
biomarkers have no role in 
diagnosing FALD 
-New non-invasive measures 
should be validated against 
histology
 -No longitudinal data 
to assess clinical course, 
prognosis and value of 
measures in follow-up of 
FALD  
-Small number of patients 
could have hampered 
statistical power 
3. -Patients with advanced fibrosis 
smoked more than patients with 
no or early fibrosis
-Smoking does not correlate 
with disease activity 
(inflammation, steatosis, 
ballooning) 
-Smoking could accelerate 
NAFLD fibrogenesis 
-Cessation of smoking 
should be recommended to 
all NAFLD patients 
-Retrospective small 
cohort
-Indirect assessment 
smoking status 
4. -GGT values, although within 
normal range, decrease 
after one month of alcohol 
abstinence and increase back 
to baseline after resumption of 
alcohol
-Short term alcohol 
abstinence could already 
diminish oxidative liver 
stress in healthy moderate 
consumers 
-GGT might serve as a 
biomarker of alcohol 
abstinence 
-Small groups, differing 
in size
-No correction for 
possible confounders 
-No randomization of 
intervention
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Table 1. Main findings, implications and limitations of this thesis (continued)
Part II Improving evaluation of liver disease
Chapter Main findings Implications Limitations 
5. -There is major inconsistency in 
reporting of histological FALD 
across studies
-Used grading systems to assess 
histological components of 
FALD are very heterogeneous 
-Fibrosis should be reported 
in a uniform manner to 
determine prognosis 
-Identified histological 
components could aid in 
constituting a systematic 
grading system for FALD
-Unable to determine if 
heterogeneity results from 
difference in assessment 
or reporting
-No formal risk of bias 
assessment of included 
studies
6. -Advanced NAFLD fibrosis has 
a distinct ECM profile, with 
increased α-SMA, MMP-2, 
TIMP-1 and TIMP-2
-Only MMP-9 correlates with 
inflammation severity 
- Profiling ECM composition 
may be used to stratify 
patients according to fibrosis 
remodelling capacity and 
find new drug targets
-Only two MMPs 
analysed, many more 
involved in fibrogenesis 
-No correction for 
possible confounders
7. -The steatosis algorithm 
accurately distinguishes 
steatosis from non-steatotic 
tissue and correlates to 
histological NAS grading by the 
pathologist
-The algorithm could 
be incorporated when 
quantification of steatosis 
is warranted (clinical trials, 
liver donor assessment) 
-Algorithm does 
not quantify other 
histological features 
-Histological grading 
performed by one 
pathologist 
8. -CAUS accurately grades and 
quantifies steatosis 
-Incorporation of multiple 
CAUS parameters improves 
diagnostic accuracy
-CAUS could serve as a non-
invasive alternative to screen 
for steatosis in high-risk 
populations 
-Cross-sectional design 
does not allow validation 
of CAUS in follow-up for 
severity of steatosis 
FALD: Fontan-associated liver disease. CT: computer- tomography. MRI: magnetic-resonance imaging. 
TE: transient elastography. NAFLD: non-alcoholic fatty liver disease. GGT: gamma-glutamyl transferase. 
ECM: extracellular matrix. α-SMA: α-smooth muscle actin. MMP: matrix metalloproteinase. TIMP: tis-
sue inhibitor of matrix metalloproteinases. NAS: NAFLD activity score. CAUS: computer-aided ultra-
sound. 
FINDINGS FROM THIS THESIS 
In Chapter 2 we investigated a prospective cohort of 38 patients with a Fontan physi-
ology. We focused on the clinical and histological spectrum of hepatic abnormalities 
and investigated how useful serum and image-based markers are to assess fibrosis in this 
population, compared to liver biopsy as the gold standard. Our most important findings 
were that histological confirmed liver fibrosis is omnipresent in patients with a Fontan 
physiology. Severe liver fibrosis (stage 3 or 4), signs of portal hypertension (mainly varices) 
and hyperenhancing nodules were present in the majority of asymptomatic patients. These 
findings implicate that all patients with a Fontan physiology are at risk for severe liver 
related complications and should be monitored appropriately. The true pathophysiologi-
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cal mechanisms of FALD remain unknown, but chronic congestion is thought to be the 
main driver of fibrogenesis.1 Upon histological examination, this is typically characterised 
by sinusoidal dilatation, presumably resulting from chronic elevated venous pressure. As 
a consequence fibrosis arises, with mainly a sinusoidal pattern. Over time, injury precipi-
tates formation of broad scars, bridging fibrosis and cirrhosis.2 The ubiquitous presence 
of fibrosis in all biopsies examined in this study, underlines the profound impact of the 
Fontan physiology on liver architecture, and contrasts with that in other aetiologies such 
as viral hepatitis, where only a minority of patients will ultimately develop fibrosis.3 
In this study we furthermore demonstrate that the investigated non-invasive diag-
nostic tools did not correlate with histological confirmed fibrosis severity. This suggests 
that fibrosis biomarkers, elastography and routine CT/MRI have no role in diagnosing 
FALD. Ultrasound abnormalities, such as heterogeneous aspect of parenchyma could be 
indicative for severe fibrosis, but absence does not rule out severe FALD. This highlights 
that experiences from patients with other etiologies of liver fibrosis (e.g. alcohol abuse, 
hepatitis B and C) cannot be applied to the Fontan population. Apparently, the effect of 
congestion on the liver architecture is unique.4-6 Since liver biopsy is not an attractive 
technique for follow-up of patients with liver disease, due to its invasive character with 
risk of complications, we acknowledge that alternatives should be sought. Nevertheless, 
before these non-invasive alternatives are adopted in clinical practice, appropriate valida-
tion against histological examination is warranted. 
In Chapter 3 we assessed the relationship between smoking and histological disease 
severity and fibrosis in a retrospective cohort of NAFLD patients. Liver biopsies from 56 real 
world NAFLD patients were collected and fibrosis stage and NAFLD activity score were 
revised and correlated to smoking history, obtained from chart review. This study showed 
that patients with advanced fibrosis smoked significantly more pack years than patients 
with no-early fibrosis, but that smoking did not correlate with inflammation or disease 
activity. Several explanations can be offered for the discovered associations, although our 
cross-sectional study design cannot prove underlying pathomechanisms. Smoking could 
aggravate fibrosis in NAFLD by a direct effect on fibrogenesis, independent of inflamma-
tion. Chronic hypoxia, resulting from smoking, increases pro-fibrogenic cytokine release 
and nicotine stimulates the nicotinic acetylcholine receptors in hepatic stellate cells in 
vitro.7-9 Our results show that the detrimental effects of smoking also include progression 
of NAFLD and emphasize the recommendation to cease smoking for all patients with 
NAFLD. 
In Chapter 4 we investigated whether one month of alcohol abstinence improves 
liver health in 16 moderate consumers. We found that one month of abstinence from 
alcohol resulted in a significant decrease in gamma-glutamyl transpeptidase (GGT) lev-
els. Resumption of moderate alcohol consumption after four weeks resulted in a return 
to baseline values. GGT is an important factor in maintaining high concentrations of 
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glutathione—a strong mitochondrial anti-oxidant—in the liver tissue during oxidative 
stress.10 The decrease in GGT observed in this study, albeit modest in absolute numbers, 
most likely reflects reduced oxidative stress in the liver. Although we used a control group 
of abstainers, who had stable GGT levels throughout the study, this study was limited 
by small numbers and lacked a second control group that did not cease alcohol intake. 
Therefore, future studies with randomized interventions and larger numbers of participants 
are needed to confirm our results. 
Chapter 5 describes a systematic review aiming to identify how FALD histology is 
assessed and which components and grading systems are reported in current literature. 
We found that there is a major inconsistency in reporting of histological FALD across 
studies. More than half of studies do not describe a methodology for histological assess-
ment of FALD. Of the studies that did, the choice of histological components that were 
described differed greatly. Finally, the used grading systems for similar components were 
very heterogeneous among studies. This heterogeneity hampers correct interpretation of, 
and comparison between, studies. Especially for fibrosis, uniform assessment and report-
ing is of utmost importance to compare prevalence, and interpret severity and prognosis 
of FALD. Fibrosis determines prognosis of patients with other chronic liver diseases, 11 but 
to objectively assess if this is also the case for patients with FALD, a consensus should be 
reached on how to assess and stage fibrosis in this population. We propose that overall 
fibrosis and architectural changes are assessed in a standardized way a using one grading 
in future research and practice, complemented by quantitative digital image analysis, to 
diminish subjectivity and variability of scoring. Only then we can truly speak of a gold 
standard to assess prognosis for this new and increasingly recognized chronic liver disease. 
In Chapter 6 we aimed to investigate the proportion of hepatic stellate cells (HSCs) 
and activity of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) 
in human NAFLD liver tissue with respect to severity of inflammation and fibrosis. In a 
cohort of 42 patients we observed that patients with advanced NAFLD-associated fibrosis 
possess a distinct ECM composition, with increased levels of α-SMA, proMMP-2 and both 
TIMP-1 and -2, that furthermore correlate with collagen proportionate area. ProMMP-9 
was the only ECM component increased in inflamed tissue. These results suggest that 
advancing fibrosis in NAFLD is driven by activated HSCs, creating an environment 
which permits inhibition of matrix degradation and contributes to fibrosis accumulation. 
Increased activation of HSCs in the context of severe fibrosis in human NAFLD has been 
reported previously,12 but data on MMP and TIMP activity were lacking. The increase of 
proMMP-2 and to lesser extent of active MMP-2, suggests that there is still active matrix 
turnover in advanced NAFLD fibrosis. These results should be confirmed in longitudinal 
follow-up studies. Profiling the ECM composition of human liver tissue, using not only 
immunohistochemical stains, but also enzymatic activity assays could be used to improve 
172
C
H
A
PT
ER
 9
stratification of patients according to fibrosis remodeling capacity, which could be helpful 
in clinical drug trials. 
Improving assessment of steatosis was the main aim in Chapter 7 and 8. 
Chapter 7 focused on histological assessment of steatosis. Our main research question 
was whether our digital image analysis algorithm accurately and automatically quantifies 
hepatic steatosis on histological whole slide images. We investigated this using 79 NAFLD 
and control biopsies, in which accuracy for correct steatosis classification of the algorithm 
was analysed by logistic regression. The steatosis percentages calculated with the algo-
rithm were subsequently compared to the NAS steatosis grade assessed by a pathologist. 
This study demonstrates that the algorithm has a high accuracy and correlates well with 
the NAS steatosis grading. Interestingly, the steatosis percentages given by the algorithm 
were in all cases lower than those scored by the pathologist. Accurate estimation of total 
steatosis percentages is difficult for pathologists and scoring is prone to inter- and intraob-
server variability.13-16 Automated digital image analysis can overcome these problems. The 
algorithm furthermore benefits from whole slide image analysis, whereas random field 
selection introduces bias caused by the heterogeneous distribution of steatosis.17 When 
quantification of steatosis is warranted, such as in clinical trials, this algorithm could be 
incorporated as an addition to visual examination by pathologists. 
Chapter 8 focused on improvement of non-invasive assessment of steatosis, by describ-
ing the validation of a computer-aided ultrasound technique (CAUS) for quantification of 
steatosis. In a cohort of 196 patients that underwent simultaneous ultrasound and biopsy 
for clinical purposes, we assessed diagnostic accuracy of CAUS, compared to histologi-
cal staging. The results from our study show that CAUS accurately grades and quantifies 
steatosis compared to histology as the reference standard. The high predictive perfor-
mance obtained in this study indicates that CAUS may provide a valuable alternative to 
percutaneous liver biopsies for the detection and grading of steatosis. Compared to other 
recently developed ultrasound and elastography based techniques,18 CAUS benefits from 
incorporation of multiple image parameters, improving diagnostic accuracy for steatosis 
detection. CAUS can be applied to any conventional B-mode image, easing incorporation 
of the technique on existing ultrasound machines, probably reducing costs compared to 
expensive alternatives such as MRI-PDFF.19 Possible implications for CAUS are screening 
and quantification of steatosis in high risk populations such as patients with obesity or 
type 2 Diabetes, and steatosis monitoring in therapeutic drug trials. 
STRENGTHS AND LIMITATIONS 
The major strength of this thesis is the presence of histological confirmation of disease 
severity, by means of liver biopsy data, in almost all patients. When contribution of risk 
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factors to disease severity is assessed or new techniques for evaluation are sought, accu-
rate staging of disease is important for interpretation of results. With digital quantification 
of fibrosis (i.e. Collagen proportionate area) we could even better and more objectively 
assess associations in several studies. In the Fontan study, the use of a prospective and 
consecutively screened cohort of asymptomatic patients warrants generalisability of the 
observed spectrum of FALD.
All studies in this thesis are based on descriptive cross-sectional patient or tissue 
cohorts. The main limitation of a descriptive cohort study is that cause or consequence of 
the observed associations between variables cannot be determined. Most cohort studies 
have access to a limited number of independent variables. Elements such as costs, conve-
nience, burden on patients and availability of technology are important determinants on 
which and how many variables were selected and obtained during the patients clinical 
trajectory. Absence of data that contains relevant confounding factors is certainly possible 
in our cohort studies since the data was recorded in the past. As we lack longitudinal data 
we also need to be careful with the interpretation of predictive value of certain risk-factors 
and the applicability of the investigated diagnostic tools in monitoring and follow-up of 
liver disease.
FUTURE PERSPECTIVES
Results from this thesis could serve as a base for new research initiatives and questions 
that remain to be answered. 
Only recently we are better appreciating the profound impact that the Fontan 
physiology has on other organ systems in the body and not the least on the liver. FALD 
is omnipresent in this population as we and others have shown.20-22 As these patients 
are aging due to better cardiac survival, we should further investigate to what degree 
FALD contributes to mortality and morbidity. We cannot predict the clinical course of 
FALD with cross-sectional research alone, and systematic follow-up of prospective patient 
cohorts is needed. We are monitoring our initial patient cohort at the Radboudumc, with 
at least yearly follow-up visits. The second major issue that remains unanswered is how 
to monitor these patients. Guidelines are lacking and non-invasive imaging is hampered 
by hepatic congestion in initial staging of disease. In future trials we should investigate 
if longitudinal assessment of non-invasive alternatives for liver biopsy bear predictive or 
prognostic value. Follow-up of nodules is also of importance in the Fontan population, 
since characteristic vascular features for HCC are not applicable.23 The value of AFP, 
liver-specific contrast agents, and additional ancillary features for discrimination between 
benign and potentially malignant Fontan nodules should be explored. 
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Pathophysiological mechanisms of FALD remain largely unknown and future studies 
should aim at unravelling these mechanisms.24 Since we lack an appropriate in-vitro or 
animal model for FALD, profiling of the ECM composition as we did in chapter 5, could be 
a first step to learn more on contribution of hepatic stellate cells and fibrosis remodelling 
capacity in FALD. 
Accurate and easy assessment of steatosis is increasingly desired in clinical practice 
(e.g. donor liver assessment and screening of high-risk populations) and in clinical re-
search (e.g. drug trials for NAFLD). We describe two new methods, that seem promising 
to improve and ease evaluation of steatosis assessment, histologically and non-invasively. 
Before incorporation in daily practice these tools should be validated in external and lon-
gitudinal cohorts. NAFLD not only consists of steatosis, and inflammation and fibrosis are 
more important for disease progression.25, 26 Therefore we are aiming to further investigate 
if CAUS can also diagnose and stage NASH and NAFLD-associated fibrosis. 
GENERAL CONCLUSIONS
This thesis focused first on the relationship between several risk-factors and severity of 
liver disease. We found that the Fontan physiology has a profound impact on the liver, 
with severe liver fibrosis in a majority of patients. Smoking contributes to fibrosis severity 
in patients with NAFLD. And alcohol cessation reduces GGT levels in moderate alcohol 
consumers. 
The thesis further aimed to improve evaluation of liver disease. We show that in FALD 
histological assessment is very heterogeneous with multiple grading systems reported in 
literature. And that non-invasive diagnostic tools such as fibrosis biomarkers, MRI, CT and 
elastography do not correlate with histological confirmed fibrosis severity in patients with 
a Fontan physiology.
In NAFLD, advanced fibrosis has a distinct ECM composition, and patients could be 
stratified according to fibrosis remodelling capacity. Accurate steatosis assessment could 
be improved histologically with quantitative digital image analysis of steatosis proportion-
ate area and non-invasively with quantitative computer-aided ultrasound. 
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Summary
The liver, being the biggest solid organ in the human body, plays a central part in many 
important processes, like the degradation of toxins and medication, the production of 
proteins, and the storage of glucose, vitamins and trace minerals. It is also the only organ 
that is able to repair itself after being damaged, which was already appreciated in Greek 
mythology. The titan Prometheus stole fire from supreme god Zeus and gave it to the 
people. He was punished with an everlasting torture. Chained to a rock, his liver was 
being eaten by an eagle. Overnight the liver repaired itself to serve as food day after day 
until eternity.
The liver can thus repair itself after, for instance, the use of medication, infection or 
an incidental night of too much alcohol. However, this regenerative capacity is limited 
and frequent damage will lead to scarring of the liver, which is called liver fibrosis. Severe 
liver disease can be caused by chronic inflammation, excessive fat accumulation, alcohol 
abuse or congenital conditions. When liver fibrosis progresses, it may lead to cirrhosis. 
This end stage of fibrosis may cause different complications, like bleeding, hepatic en-
cephalopathy (intoxication of the brain), and liver cancer. Not surprisingly, patients with 
severe liver disease are at increased risk of dying.
In the first part of this thesis, I studied the influence of different risk factors, such as the 
presence of a Fontan physiology, smoking and cessation of alcohol, on the severity of liver 
disease. In the second part, I investigated how current methods to evaluate the severity of 
liver disease could be improved. The results are summarized below. 
PART I
We describe the influence of Fontan surgery on the development of liver fibrosis in chapter 
2. A small group of patients has a severe congenital heart defect that necessitates different 
radical surgeries. The Fontan procedure is the final step in this process and connects the 
major veins (vena cava superior and inferior) directly to the pulmonary arteries, while 
bypassing the heart. This prevents the mixture of oxygenated with deoxygenated blood in 
the heart and secures oxygen supply to important organs. This connection causes the pres-
sure in the vena cava, that is directly connected to the liver, to rise and in turn increases 
the pressure in the liver. This damages the liver and leads to fibrosis. We used different 
techniques to evaluate the severity of liver fibrosis in 38 patients with a Fontan physiology. 
All patients had liver fibrosis to some degree, with the majority even having severe liver 
disease.
This means that all patients that underwent this procedure are at increased risk of de-
veloping liver-related complications and should be monitored accordingly. Also, we have 
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shown that it is difficult to monitor the severity of liver fibrosis in these patients without 
taking a biopsy. Different techniques, like blood markers, ultrasound, elastography, MRI 
and CT-scan, did not correlate well with biopsy evaluation, the gold standard. This is 
possibly due to the presence of congestion in the liver. 
We study the effect of smoking on Non-Alcoholic Fatty Liver Disease (NAFLD) in chap-
ter 3. The metabolic syndrome is the most important cause for fat accumulation (steatosis) 
in the liver. This may cause inflammation and eventually lead to fibrosis, a process that 
can be accelerated by smoking. We have linked the severity of steatosis, inflammation and 
fibrosis to smoking behaviour in 56 patients. We indeed found that patients with severe 
liver fibrosis smoked significantly more than those with no to mild fibrosis, but we saw no 
effect on steatosis or inflammation. Smoking therefore seems to directly stimulate fibrosis 
progression. This indicates that smoking directly contributes to liver damage and supports 
the recommendation that patients with liver disease (NAFLD) should stop smoking.
In chapter 4, we assess whether alcohol abstinence for a month benefits the liver of 
moderate drinkers. We all know that prolonged alcohol abuse causes severe liver damage, 
but the effect of moderate alcohol intake on the liver is unknown. We measured several 
aspects of the liver before and after alcohol cessation, and repeated these measurements 
four weeks after alcohol use was resumed. The control group consisted of nine abstainers. 
Gamma-GT decreased significantly in the intervention group, and rose after resuming 
alcohol intake, while it remained stable in the control group. We found no differences in 
steatosis or fibrosis. The decrease in gamma-GT could be indicative of reduced oxidative 
stress in the liver. 
PART II
Chapter 5 consists of a systematic literature review concerning methods for histological 
evaluation of Fontan-associated liver disease. Histological evaluation (of a liver biopsy) 
is the gold standard to assess the degree of liver disease, but our review shows that there 
is great variety in the methods and scoring systems that are being used. It is important 
to use a standardized method to facilitate proper assessment and comparison of sever-
ity, prevalence, and prognosis between patients and trials. A standardized method could 
consist of one of the in this review identified fibrosis scoring systems with the addition of 
digital scoring to reduce inter-observer variability. 
The formation and degradation of fibrosis is a dynamic process that, irrespective of the 
cause, is regulated on a cellular level by a complex interplay of extracellular matrix (ECM) 
components. The composition of these components determines fibrosis progression. In 
chapter 6 we measured several of the ECM components in 42 NAFLD liver biopsies. We 
found a distinct ECM composition in severe fibrosis with many fibrosis promoting cells, 
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but also components that degrade fibrosis. Studies with follow-up biopsies are needed 
to show whether this ECM composition may indeed lead to stagnation or regression of 
fibrosis. Measuring ECM composition may help to determine whether liver fibrosis is still 
reversible. 
The aim of chapter 7 and 8 is to improve the evaluation of steatosis. Where chapter 
7 focusses on the histologic grading of steatosis, chapter 8 addresses how non-invasive 
techniques can contribute.
Visual inspection of liver biopsies by a pathologist using a 4-point scoring system is 
most commonly used to determine the estimate the percentage of fat cells. A disadvantage 
of this and other semi-quantitative approaches is the great intra- and interobserver vari-
ability. In chapter 7 we developed an algorithm to automatically quantify steatosis on 
digitally scanned liver biopsies and found that it is accurate and correlates well with 
the pathologists score. Digital assessment may help to exactly measure the amount of 
steatosis and provide a method to follow steatosis over time, which can be helpful when 
conducting research with new NAFLD therapies.
Obtaining a liver biopsy is the gold standard to assess liver disease, but may cause 
bleeding or pain. In addition, only the architecture of the obtained sample can be judged, 
which is very small and may not be representative for the entire liver. A greater proportion 
of the liver can be visualized by ultrasound, but this modality can only asses the presence, 
and not the quantity, of steatosis. In chapter 8 we investigate whether quantification is 
possible by ‘computer-aided ultrasound’ (CAUS), a method developed in our hospital. 
We found a strong correlation between parameters analyzed by CAUS and the amount of 
steatosis measured in 196 liver biopsies. By means of logistic and linear regression, we 
identified a combination of CAUS parameters that best predict the amount of steatosis. 
CAUS can possibly serve as a non-invasive alternative to indentify and follow patients at 
risk for steatosis. 
CONCLUSION
This thesis firstly investigated the effect of multiple risk factors on the development of liver 
disease. We found that Fontan surgery causes severe liver fibrosis in the majority of our 
cohort. Smoking directly contributes to the degree of fibrosis in NAFLD patients, while 
alcohol abstinence in moderate drinkers has a beneficial effect on gamma-GT. 
Secondly, we aimed to improve the assessment of liver disease. We found that the 
histological evaluation of Fontan-associated liver disease is very heterogenous and uses 
different scoring systems. Current non-invasive alternatives do not seem appropriate 
to grade the severity of fibrosis in this specific population. Also, severe liver fibrosis in 
NAFLD is accompanied by a specific extracellular matrix composition. Lastly, we showed 
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that histological evaluation can be improved by incorporating quantitative and digital 
analysis of these biopsies, and that computer assistance facilitates the quantification of 
fibrosis in routine ultrasound images. 
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NEDERLANDSE SAMENVATTING
Samenvatting 
De lever is het grootste solide orgaan in het menselijk lichaam en heeft een centrale rol 
in veel belangrijke processen, zoals de afbraak van toxische stoffen en medicijnen, pro-
ductie van eiwitten en enzymen, en opslag van glucose, vitamines en sporenelementen. 
De lever is ook het enige orgaan dat zichzelf kan herstellen na beschadiging. In de oude 
Griekse mythologie werd dit fenomeen al onderkend en geromantiseerd in de mythe van 
Prometheus. Deze titaan die oppergod Zeus tartte door het vuur te stelen om het aan de 
mensen te geven werd gestraft met een eeuwig durende marteling. Geketend aan een rots 
at een adelaar van zijn lever, welke vervolgens ’s nachts weer aangroeide, om de volgende 
dag opnieuw als voedsel te dienen. 
De lever kan dus herstellen na kortdurende beschadiging zoals bijvoorbeeld na 
gebruik van medicatie, een infectie, of af en toe een avondje teveel alcohol. Als de le-
ver echter frequent beschadigd raakt, dan is dit niet omkeerbaar en zal verlittekening 
optreden, ook wel lever fibrose genoemd. Er zijn verschillende oorzaken van chronische 
ernstige leverziekte, zoals langdurige ontsteking of vervetting, overmatig alcoholgebruik, 
of aangeboren afwijkingen.
Als fibrose verergerd kan het uiteindelijk overgaan in cirrose, het eindstadium van 
fibrose. Een cirrotische lever functioneert niet goed meer en kan leiden tot complicaties, 
zoals bloedingen, hepatische encefalopathie (vergiftiging van de hersenen) en leverkanker. 
Mensen met ernstige leverziekte hebben dan ook een verhoogd risico om te overlijden. 
In het eerste deel van dit proefschrift heb ik onderzocht welke invloed verschillende 
oorzaken, zoals het ondergaan van een Fontan operatie bij aangeboren hartafwijkingen, 
roken, en het stoppen met drinken van alcohol, hebben op de ernst van leverziekte. In 
het tweede deel heb ik gekeken hoe de huidige methodes om de ernst van de leverziekte 
te evalueren verbeterd kunnen worden. Hieronder volgt een samenvatting van de bevin-
dingen. 
DEEL I 
In hoofdstuk 2 beschrijven we welke invloed het ondergaan van een Fontan operatie 
heeft op het ontstaan van lever fibrose. Een kleine groep patiënten heeft een zo ernstige 
aangeboren hartafwijking dat zij op jonge leeftijd meerdere ingrijpende operaties moe-
ten ondergaan. De Fontan ingreep is de laatste operatie in dit proces en sluit de grote 
terugvoerende lichaamsvaten (vena cava inferior en superior), buiten het hart om, direct 
aan op de longslagaders. Hiermee voorkomt men dat zuurstofarm bloed zich vermengt 
met zuurstofrijk bloed in het hart, waardoor de zuurstoftoevoer naar belangrijke organen 
gewaarborgd blijft. Als een gevolg hiervan wordt de druk in de vena cava echter veel 
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hoger. Dit vat staat in directe verbinding met de lever, waardoor ook de druk in de lever 
veel hoger wordt en de lever beschadigd kan raken, met fibrose als gevolg.
Bij 38 patiënten die deze Fontan operatie hebben ondergaan, hebben we de ernst van 
lever fibrose met verschillende technieken onderzocht. Alle patiënten hadden enige mate 
van lever fibrose. Bij de meerderheid was er zelfs sprake van ernstige leverziekte. Dit 
betekent dat alle patiënten die een dergelijke operatie hebben ondergaan een verhoogd 
risico hebben op leverziekte gerelateerde complicaties en hiervoor vervolgd moeten 
worden. In dit onderzoek toonden we ook aan dat de ernst van lever fibrose lastig te 
beoordelen is bij deze patiënten zonder een biopt van de lever te nemen. De inschatting 
met andere technieken kwam namelijk niet overeen met de metingen in een leverbiopt, 
wat de gouden standaard is. Ons onderzoek suggereert dan ook dat bloed markers, echo-
grafie, elastografie, MRI en CT-scan minder betrouwbaar zijn om de ernst van leverfibrose 
in te schatten bij patiënten met een Fontan circulatie. Mogelijk is dit te wijten aan de 
aanwezigheid van stuwing in de lever. 
In hoofdstuk 3 bestuderen we het effect van roken op de ernst van leverziekte in 
patiënten met niet-alcoholische leververvettingsziekte (NAFLD; Non-Alcoholic Fatty Liver 
Disease). Als gevolg van met name het metabool syndroom kan er vervetting (steatose) 
van de lever ontstaan. Dit kan uiteindelijk tot ontsteking (inflammatie) en zelfs fibrose 
leiden. Roken kan dit proces versterken. In dit hoofdstuk hebben we de ernst van steatose, 
inflammatie en fibrose in leverbiopten van 56 patiënten vergeleken met hun rookgedrag. 
We vonden dat mensen met ernstige fibrose significant meer hadden gerookt dan mensen 
met geen tot milde fibrose. We zagen geen effect van roken op de ernst van steatose 
of inflammatie. Mogelijk heeft roken een direct effect op het ontstaan van fibrose, door 
verschillende cellulaire processen die aanzetten tot fibrose vorming. Onze resultaten 
laten zien dat de schadelijke effecten van roken ook tot de lever reiken en ondersteunen 
de aanbeveling dat patiënten die al een leverziekte (NAFLD) hebben moeten stoppen met 
roken.
In hoofdstuk 4 onderzoeken we of een maand geen alcohol drinken een gunstig ef-
fect heeft op de lever van mensen met een gematigde alcoholinname. Het is bekend dat 
langdurig overmatig alcoholgebruik kan leiden tot ernstige leverziekte, maar het effect 
van gematigde alcoholinname op de lever is onbekend. Bij zestien proefpersonen heb-
ben we levermetingen verricht voor en na het staken van hun alcoholinname gedurende 
een maand en deze nogmaals herhaald vier weken na het hervatten van alcohol. De 
controlegroep bestond uit negen geheelonthouders. Het gamma-GT daalde significant bij 
de proefpersonen en steeg weer na hervatting. In de controle groep bleef het gamma-GT 
stabiel. Beeldvorming liet geen verschillen zien in ernst van steatose of fibrose. De daling 
van gamma-GT kan een eerste uiting zijn van verminderde oxidatieve stress in de lever.
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DEEL II 
Hoofdstuk 5 bestaat uit een systematische review van de in de literatuur gebruikte me-
thodes voor histologische beoordeling van Fontan-geassocieerde leverziekte. Histologie 
(bijvoorbeeld door middel van een leverbiopt) is de gouden standaard om de ernst van 
leverziekte te onderzoeken. Uit onze review blijkt echter dat er zeer veel verschillende 
methodes en scores voor histologische beoordeling van leverziekte worden gebruikt bij 
Fontan patiënten. Een uniforme methode is van belang om de ernst van de fibrose goed te 
evalueren, zodat de prevalentie, ernst en prognose beter ingeschat en vergeleken kunnen 
worden tussen patiënten en studies. Een dergelijke uniforme methode zou kunnen bestaan 
uit een van de gespecificeerde scores voor fibrose die wij in dit review geïdentificeerd 
hebben, aangevuld met de digitale beoordeling van een biopt om variabiliteit tussen 
beoordelaars te verminderen. 
De opbouw en afbraak van fibrose is een dynamisch proces dat, onafhankelijk van 
de onderliggende oorzaak, op celniveau gereguleerd wordt door een samenspel van 
extracellulaire matrix (ECM) componenten. De balans tussen deze componenten bepaalt 
de progressie van fibrose. In hoofdstuk 6 hebben we enkele van deze ECM componenten 
gemeten in leverbiopten van 42 patiënten met NAFLD. We zagen dat er bij ernstige fibrose 
een bepaalde samenstelling van de ECM is met veel cellen die fibrose aanmaken, maar 
ook met componenten die wijzen op actieve afbraak van fibrose. In studies met follow-up 
biopten kan onderzocht worden of de aanwezigheid van deze afbraak componenten ook 
leidt tot vermindering of stagnatie van ernstige fibrose. Het meten van de ECM samenstel-
ling kan helpen om in te schatten of fibrose nog omkeerbaar is. 
Het doel van de onderzoeken in hoofdstuk 7 en 8 is het verbeteren van de beoordeling 
van steatose.
Hoofdstuk 7 richt zich op de histologische beoordeling van steatose. De meest ge-
bruikte methode voor een patholoog om steatose in een leverbiopt te beoordelen is met 
een 4-punts score waarbij de patholoog visueel het percentage vetcellen inschat. Het 
nadeel van deze en andere semi-kwantitatieve scores is de variatie in uitkomsten tussen 
verschillende en zelfs binnen dezelfde pathologen. Wij hebben onderzocht of een door 
ons ontwikkeld algoritme voor automatische digitale steatose kwantificatie op gescande 
leverbiopten accuraat is. Dit was het geval en het algoritme correleerde tevens goed met 
de pathologische score. Een dergelijke digitale beoordeling van het steatose percentage is 
behulpzaam in onderzoek waarin het belangrijk is om precies te weten hoeveel steatose 
er is en hoeveel dit toe- of afneemt, bijvoorbeeld in onderzoek naar nieuwe NAFLD 
behandelingen. 
Hoofdstuk 8 richt zich op de niet-invasieve beoordeling van steatose. Het leverbiopt is 
de gouden standaard, maar brengt complicatie risico’s met zich mee, zoals een bloeding 
of pijn na een biopt. Ook wordt met een biopt maar een heel klein deel van de lever 
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architectuur beoordeeld, welke mogelijk niet representatief is voor de gehele lever. Met 
behulp van echografie kan door de radioloog een inschatting worden gemaakt van de 
aanwezigheid van steatose, maar nog niet bepaald worden hoeveel steatose er precies 
is. In dit laatste hoofdstuk hebben wij onderzocht of een in dit ziekenhuis ontwikkelde 
computer-gestuurde methode voor het analyseren van echobeelden (CAUS; computer-
aided ultrasound) in staat is om steatose te kwantificeren. Van 196 patiënten zijn echo-
beelden en de bijbehorende leverbiopten geanalyseerd. We zagen een sterke correlatie 
tussen de met CAUS geanalyseerde parameters van de echobeelden en de hoeveelheid 
steatose in het leverbiopt. We hebben door middel van logistische en lineaire regressie 
een combinatie van CAUS parameters geïdentificeerd die de best voorspellende waarde 
had voor het stadieren van steatose. Mogelijk kan CAUS in de toekomst dienen als niet-
invasief alternatief voor het identificeren en vervolgen van patiënten met een verhoogd 
risico op steatose. 
CONCLUSIE
Dit proefschrift beschrijft ten eerste meerdere onderzoeken gericht op de het vaststellen 
van de bijdrage van bepaalde risico factoren op het ontstaan van ernstige leverziekte. We 
vonden dat de Fontan operatie een groot effect heeft op de lever, met ernstige lever fibrose 
in een meerderheid van de patiënten. Roken draagt ook bij aan de ernst van fibrose in 
patiënten met NAFLD, terwijl een maand alcoholabstinentie juist een gunstig effect heeft 
op het gamma-GT in gematigde drinkers. 
Ten tweede stelden we ons ten doel de beoordeling van leverziekte te verbeteren. 
We toonden aan dat in Fontan-geassocieerde leverziekte histologische beoordeling zeer 
heterogeen is met gebruik van verschillende scores. Ook lijken huidige niet-invasieve al-
ternatieven niet geschikt om de ernst van fibrose vast te stellen in deze patiëntencategorie. 
In NAFLD lijkt ernstige lever fibrose samen te gaan met een specifieke samenstelling 
van extracellulaire matrix componenten. Voor steatose toonden we aan dat histologische 
beoordeling verbeterd kan worden met behulp van kwantitatieve en automatische digitale 
analyse van in gescande leverbiopten en dat kwantitatieve beoordeling van steatose op 
normale echobeelden mogelijk is. 
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DANKWOORD 
Dankwoord
Hier ligt het dan, mijn proefschrift! Het eind resultaat van een bijna vier jaar durende 
leerweg. Naast het feit dat ik ontzettend trots ben, besef ik me ook heel goed dat dit niet 
was gelukt zonder de hulp van veel mensen. Dit hoofdstuk is uiteindelijk langer geworden 
dan mijn discussie, maar er zijn dan ook heel veel mensen die ik graag persoonlijk wil 
bedanken (en kort van stof ben ik nooit geweest).  
Allereerst; beste Eric, mijn promotie begon met jouw enthousiasme en hoofd vol ideeën, 
die zaten te springen om tot uitvoer gebracht te worden. En daar kwam ik, om dat klusje 
eens even te klaren. We begonnen aan een heel aantal projecten, en over de tijd bleek het 
niet altijd even makkelijk om alle ballen in de lucht te houden. Maar jouw vindingrijkheid, 
vertrouwen in mij én de goede afloop maakten dat ook ik, na een overleg, weer vol goede 
moed en zin verder kon. Dank ook voor al die uren waarin je echt met me naar de data 
en manuscripten hebt gekeken. Dit heeft onze artikelen zoveel beter gemaakt! Ik hoop 
dat we, ondanks dat mijn promotie nu afgerond is, in de toekomst nog veel wervelende 
brainstormsessies mogen hebben! 
Beste Joost, in het begin van mijn promotie was jij vooral op papier mijn promotor, maar 
nog niet heel erg betrokken in de dagelijkse begeleiding. Maar toen er richting het eind 
nog een flinke eindsprint gemaakt moest worden wist jij daar wel raad mee. Je had nog 
wel een kamertje vrij, ver weg van de af- en verleidingen van de onderzoekersgroep. Ik 
denk dat het concept St®afgang zijn effectiviteit wel heeft bewezen en voor herhaling 
vatbaar is. Dank dat je me zo hebt geholpen en ik vind het bewonderenswaardig hoe je 
voor al je promovendi klaar staat op de momenten dat het er echt toedoet.
Dank aan de manuscriptcommissie en coronaleden voor de tijdsinvestering en jullie 
aanwezigheid bij mijn verdediging. 
Tevens wil ik alle patiënten bedanken die hebben bijgedragen aan de onderzoeken in dit 
proefschrift. Heel veel dank ook aan de proefpersonen van het Droge maand onderzoek. 
Jullie hebben een groot deel van jullie vrije tijd, en een maand alcohol, opgegeven om 
deel te nemen aan dit onderzoek. Ook alle medewerkers van de Kennis van Nu, en in het 
bijzonder Anne Martens, bedankt! Wat een spannende, maar uiteindelijk ook leuke ervar-
ing was het om een onderzoek te doen voor een tv programma. Jullie hebben gemaakt dat 
het zo’n mooi item is geworden. 
Door de verschillende onderwerpen in mijn boekje heb ik ook met veel mensen kunnen 
samenwerken de afgelopen jaren. Deze interactie, het uitwisselen van ideeën, het maken 
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van nieuwe plannen en een kijkje in andermans keuken krijgen, heb ik als een van de 
leukste aspecten van mijn promotie ervaren! 
Toon en Arie, met jullie begon het plan om patiënten na een Fontan operatie te gaan 
screenen op leverziekte. En wat een mooi project is het geworden, met als kers op de 
taart onze publicatie in European Heart Journal! Dank voor jullie inzet in de grote lo-
gistiek die er bij kwam kijken om deze patiënten prospectief te vervolgen. Toon, dank 
ook voor je hulp bij de data-invoer, al die verschillende aangeboren hartafwijkingen, de 
ene anatomische variant nog ingewikkelder dan de andere, had ik anders nooit kunnen 
categoriseren. 
Floris en Ronald, de kindercardiologie schoof iets later aan, maar ik denk dat met jullie 
toevoeging het Fontan onderzoek in het Radboud naar een nog hoger plan getild kan 
worden. Ik hoop dat we ons cohort kunnen blijven vervolgen en uitbreiden, want we zijn 
eigenlijk pas net begonnen en er komen alleen maar vragen bij. Floris, dank ook voor je 
ontzettende enthousiasme, dit heeft me erg gemotiveerd tijdens de laatste loodjes. 
Dames van het MDL en cardio secretariaat, specifiek Rina en Marieke, dank voor het soms 
ingewikkelde planwerk om de patiënten op dezelfde dag bij cardioloog en hepatoloog te 
krijgen.
Dear Maxime, thanks so much for reviewing all those scans and interpreting the, for me 
difficult, radiological reviewer comments to our Fontan article. I hope we will continue 
to collaborate!
Dear Tim, I am really grateful that you were so enthusiastic to collaborate when we (total 
strangers) approached you via email. Thank you for your valuable input in many of my 
articles. Also, I’m honoured that you are participating in my opposition committee. Al-
though I advocate digital pathological assessment in my articles, I am happy we are finally 
meeting face to face and can toast to a successful collaboration. 
Carolien, ook van jou heb ik ontzettend veel geleerd over beoordeling van lever histolo-
gie, wat me ook in mijn klinische loopbaan goed van pas zal komen. Je wist ook altijd een 
uurtje (of twee) voor me vrij te maken in je overvolle agenda, om samen in het JBZ coupes 
te beoordelen. Dank hiervoor.
Jeroen en Merijn, dankzij jullie ben ik een beetje wijzer geworden in de wondere wereld 
van digitale pathologie. Merijn, we spraken niet altijd dezelfde taal tijdens onze overleg-
gen, maar we hebben volgehouden en dat stuk is er gekomen: 01000100011000010110
111001101011!
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Zonder leverbiopten helemaal geen data. Mijn dank gaat uit naar iedereen die me bij het 
verkrijgen hiervan heeft geholpen; Beyhan bij het uitzoeken van de coupes, Irene bij het 
inscannen en de dames van het JBZ PA secretariaat bij het digitaal versturen, het is nog 
niet bepaald Whatsapp qua gebruikersgemak! 
Erwin en Mark, dank voor het delen van de NAFLD en roken database die jullie nog 
hadden en jullie input in het eerst gepubliceerde artikel van mijn boekje. Mark, mooi dat 
ik eerder met je heb gepubliceerd dan Erik. Nu nog een keer met z’n drieën? 
Beste prof. Chris Mulder, dank voor je overtuigende aansporing ook buiten de regio 
Amsterdam te zoeken naar een promotieplek (ik was immers nr. 15 op je lijst en zag 
onderzoek naar coeliakie bij paarden toch niet zo zitten). Ik waardeer het dat je daarna 
ook altijd interesse in mijn vorderingen hebt getoond. 
Arnt en Martine, zonder jullie had ik het Droge Maand onderzoek nooit op tijd afgekregen 
voor de tv uitzending. Ik vond het heel leuk ook wat te leren over de psychische kanten 
van alcoholgebruik en abstinentie, misschien toch nog eens bij een (alcoholvrije) borrel 
bespreken of we daar meer mee kunnen? 
Er zijn een aantal mensen die ervoor gezorgd hebben dat ik me uiteindelijk toch best als 
een zebravisje in het water voelde op het lab! Roger en Rene dank voor het eindeloos 
nieuwe gels met én voor me maken als er weer eens helemaal géén bandjes of juist één 
grote streep te zien was. Hennie en Daisy, meedoen aan de rik competitie maakte dat 
ik er echt bij hoorde (maar die regels slaan nog steeds nergens op). Alejandra thanks for 
showing me your zymography skills and for our nice coffee breaks. Dorien, dank dat ik 
zoveel kleuringen mocht doen bij jullie op het lab, je liet me thuis voelen in die grote 
verre RIMLS toren. 
Chris en Gert,de samenwerking met jullie in het CAUS onderzoek was ontzettend prettig. 
Chris, jij was altijd laagdrempelig bereikbaar voor overleg en hakte snel en effectief de 
knopen door die doorgehakt moesten worden, dank hiervoor. Gert, als technicus, bekeek 
je dingen vaak van een hele andere kant dan ik, wat tot nieuwe (en soms betere) inzichten 
leidde. Daarnaast ben je ook gewoon een hele aardige en goede vent, wat maakte dat ik 
het ontzettend leuk vond om met je samen te werken!
Wietske, dank voor je hulp waar nodig, maar vooral ook voor je gezelligheid buiten werk! 
Stafleden, AIOS en secretariaat, dank voor de fijne sfeer op de afdeling. Research-unit; 
Chantal, Sonja en Cynthia, dank dat jullie zoveel (praktische) kennis voor ons beschikbaar 
hebben gemaakt. 
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Wat een grote bijdrage hebben een aantal studenten ook geleverd aan mijn stukken. 
Nawel, Madalina en Jole, heel erg bedankt voor jullie monnikenwerk. Ik hoop jullie nog 
eens tegen te komen. Same goes for all inspiring colleagues I met at conferences. Meeting 
new people and networking (with a beer) is one of the benefits of doing research. Hope 
to see you again! 
Een groot deel van je promotie ben je heel solistisch achter je computer aan het werk. 
Jullie, arts-onderzoekers, hebben gemaakt dat het nooit eenzaam heeft gevoeld. Alle lief 
en leed die we met elkaar hebben gedeeld zullen me meer bijblijven dan mijn opgedane 
SPSS skills. 
Daarover gesproken, Vince, dank voor je bevlogen uiteenzettingen over propensity score 
matching, maar met een T-toets kom je er ook wel (zie hier het resultaat). Floor, dank voor 
al je goede adviezen, en Hedwig voor je masterclass efficiënt werken. Myrte, Lauranne 
en Dorian, dank voor jullie vriendschap en alle leuke etentjes, bij wie en wanneer de 
volgende keer? Titus, dank dat je zo’n hipster avant la lettre bent en dat je mijn vent nog 
harder laat fietsen. Marten, dank voor je personificatie van Captain Jack, er aan denken 
doet me alweer lachen. Mark, dank voor je oprechte interesse. Govert, dank voor al je 
belletjes. Anna, voor je gezelligheid, jammer dat je geen MDL-arts wordt, maar als ik ooit 
aan de botox ga (belangrijke overweging boven de 30) kom ik bij jou. Jos en Edgar, dank 
dat jullie echt labratten-werk deden waardoor ik mijn testjes wel weer vond meevallen. 
Michelle, voor een internist pas je verrassend goed tussen al die MDL-ers, dank dat je 
voor ons koos. Lisa, jij staat altijd voor iedereen klaar, dank daarvoor. Xavier, dank voor 
je kamervullende aanwezigheid, daardoor viel het niet eens op dat je de helft van de 
tijd er niet was. Ayla, dank voor het overnemen van de lief- en leedpot. En Marleen 
het TTT project, dit gaf me ruimte voor andere dringende deadlines, zoals promoveren. 
Vera, dank voor je tegengeluid tussen al die dokters. Judith, Kelly, Yonne, Elsa, Liyanne en 
Suzanne, ik proost graag een lekkere genotskathedraal met jullie op m’n feestje! Bram, 
dank voor het laten zien dat pragmatisch meestal beter (en sneller) is. Ali, bravo voor 
het met zelfvertrouwen in de lucht houden van nog meer projecten dan ik. En Yannick, 
mooi dat jij je door niemand van de wijs laat brengen. Lucas, dank dat je af en toe nog 
zo’n heerlijke student bent. Michiel, fijn dat er van jou zoveel geschikte close-ups voor 
de groepsafbeelding van de MDL-app zijn. Angelique, dank voor je onverwacht lompe 
grappen tijdens de EASL. Rene, dank voor ze dan net nog iets vunziger maken. Simon, 
jij hebt me laten inzien dat Nijmegen best hip is, ook al ligt het niet binnen de ring. En 
Rene en Simon, ouwe ….rupsen, nog eentje dan straks op het feest ;)? Yasmijn, als je 
huisgenootje hoefde ik niet alleen wat minder te reizen, maar had ik ook gewoon een 
hele fijne en gezellige plek om thuis te komen. Dank, ook aan Frank, dat ik een tijd lang 
jullie derde wiel in de woonkamer mocht zijn! En tot slot, lieve Kaatje. Je haat het als 
ik je naam uitsprak als KArina, maar toch zijn we beste maatjes geworden. Helaas was 
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onze geografische afstemming binnen NL iets minder geslaagd, maar dat gaat ons niet 
weerhouden om elkaar nog veel te blijven zien! Ik ben mega trots dat ook jouw boekje 
ingeleverd is en dat je vandaag als mijn paranimf naast me staat.  
Oud-collega’s van het toenmalige Kennemer, nu Spaarne Gasthuis. Bij jullie begon 
ik alweer meer dan vijf jaar geleden aan mijn eerste echte baan als dokter. Alle oud 
arts-assistenten, dank voor de ontzettende leuke tijd, op de werkvloer maar zeker ook 
daarbuiten. Ik denk nog regelmatig terug aan onze nachtjes films kijken op de CCU, 
de mooie borrels en de wintersport. Is vijf jaar geen mooi moment voor een reünie KG 
assistenten 2013-2014?! 
Ik heb ontzettend veel geleerd in die 1.5 jaar, waarvoor dank aan alle stafleden van de vak-
groepen interne, MDL, cardiologie, longziekten en IC. Een paar wil ik specifiek noemen: 
René van der Hulst, bij jou begon ik mijn onderzoekscarrière nog voordat ik afgestuurd 
was. Je gaf me de mogelijkheid om een echte RCT op te zetten en uit te voeren. Toen dat 
gelukt was binnen 6 maanden, met ook nog een mooi artikel als resultaat, dacht ik hoe 
moeilijk kan dat promoveren zijn? Misschien een beetje onderschat, maar ik ben heel blij 
dat je me geholpen hebt mijn carrière binnen de MDL op te starten. Johan Kuijvenhoven, 
dank voor het delen van je proefschrift en leuk dat we nu allebei onderzoek naar MMPs 
gedaan hebben. Pim de Ronde, dank voor je aanbeveling bij Joost Drenth toen ik daar 
solliciteerde voor een promotieplek. Wim van Dorp, dank voor het beste niet-medische 
advies wat ik in mijn KG tijd heb gekregen.
Nieuwe collega’s van het Rijnstate, dank voor het warme bad waarin ik terecht ben geko-
men als nieuwe AIOS. Hoe goed het hier geregeld is, jullie gezelligheid en collegialiteit 
heeft gemaakt dat ik de laatste loodjes van mijn promotie kon voltooien naast deze nieuwe 
uitdaging. Ik heb zin in de komende tijd bij de interne en straks de MDL!
Anja, dank voor het laten inzien dat 70% vaak ook goed genoeg is. En Marieke, thanks 
voor de prachtige kaft van mijn boekje! 
Lieve vriendjes en vriendinnetjes, dank voor jullie steun en de afleiding die jullie me 
boden als ik af en toe genoeg had van die promotie. Fauve en Chantal, ben heel blij dat 
ik bij jullie in het juco-groepje terecht kwam. Onze avondjes en weekendjes met wijn, 
grappen, maar ook een luisterend oor en goede raad zijn me dierbaar. Lieve Chantie, 
het zijn van elkaars paranimf was iets waar we al vroeg in onze promoties over spraken. 
Filosoferen over wat we zouden gaan dragen hield ons echter meer bezig dan fibroseren 
over ons onderzoek! Ik hoop dat je de 22e naast me staat, maar ik zal voor de zekerheid 
een niet-hoogzwangere stand-in achter de hand houden. 
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Dushi gang, Nereus vrinden en jullie knappe aanhang, fijn  dat ik na al die jaren nog 
steeds zo’n gezellig cluppie mensen om me heen heb. Helaas sinds kort wat verder weg. 
Maar we hebben hier één ding wat ze in Amsterdam niet hebben: ruimte voor meerdere 
logés, dus ik hoop dat jullie langs blijven komen! Kirst en Nien, ik leg de stinkkaas vast 
klaar! Pien, een speciale dank voor al je poepgrappen, ze wisten me op te meuren wan-
neer het nodig was. En ik hoop dat we nog lang als bimbo en bambi de wereld rond 
blijven reizen. Als dit avontuur is afgerond samen maar weer eens een nieuwe plannen?! 
Lieve Gelliebellie, jij bent ondertussen bijna familie, zolang kennen we elkaar al. Ik ben 
trots dat ik al suikertante van Pien ben en straks een echte meter van jullie nieuwe hum-
meltje (hopelijk wel pas na de 22e zodat jij met bolle buik gewoon nog bij mij in de zaal 
zit). Dank voor je hulp met mijn boekje en al je goede adviezen op afstand. Ik denk dat er 
tussen ons magie in het spel is.  
Lieve ooms en tantes, neven en nichten, dank voor jullie oprechte interesse in wat ik 
allemaal doe. We zien elkaar misschien niet heel vaak, maar ik hoop dat jullie er vandaag 
bij zijn om dit samen te vieren. 
En dan de van Bommels, lieve gratis bonusfamilie. Harrie en Annemiek, ik ben heel blij 
met jullie als schoonouders. Dank ook voor alle hulp de laatste weken, toen Erik zich 
noodgedwongen op de bank lag te vervelen en ik toch nog wat last-minute promotie stress 
had. Harrie, je hebt het goede voorbeeld gegeven hoe je van je verdediging een college 
maakt, ik ga proberen hier wat van mee te nemen. Marion, Frans en Pepijn, ik bewonder 
hoe jullie samen een gezinnetje vormen en ondanks dat het een moeilijk jaar was zo 
positief blijven. Mark en Kim, ik vind het heel leuk om te zien hoe actief en ondernemend 
jullie zijn, met al jullie mooie projecten en wereldplannen naast werk en studie!   
Lieve opa en oma, dank jullie wel voor jullie onvoorwaardelijke liefde. Wat ben ik ontzet-
tend blij dat jullie er vandaag op 88-jarige leeftijd in goede gezondheid bij kunnen zijn. Ik 
zal proberen tijdens de verdediging niet zo snel te praten als ik normaal doe, zodat jullie 
alles kunnen volgen. 
Lieve Machteld, ik ben heel blij dat jij mijn kleine zusje bent. Dank je wel voor je gezel-
ligheid, je steun, de mogelijkheid om af en toe lekker te kibbelen, en alle mooie schoenen 
die je over de jaren voor me hebt weten te fixen. 
Lieve papa en mama, dank jullie wel voor al jullie steun. Ik besef me steeds meer dat jullie 
altijd alles in het werk gesteld om voor ons het allerbeste te creëren. Jullie verwenden 
ons enorm, we konden jaren studeren en ernaast nog genoeg leuke dingen doen. Maar 
jullie motiveerden ons ook altijd om ons goedbedeelde stel hersenen zo goed mogelijk te 
gebruiken. Pap, je veelgehoorde wijze les zal ik niet snel vergeten: ‘zorg maar dat je jezelf 
eerst kan bedruipen, en zoek dan een rijke vent’. Het belangrijkste deel van het advies is 
in ieder geval al gelukt. Ik hou van jullie. 
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En tot slot; Erik. Met jou begon en eindigt dit hoofdstuk in mijn leven. In het KG werd het 
na een gedeelde boterham (die jij je niet meer kan herinneren), via een stiekeme romance, 
uiteindelijk echte verkering (had je in eerste instantie ook niet helemaal door). En nu 
bijna 5 jaar later wonen we eindelijk echt elke dag samen in een echt huis in Nijmegen. 
Het was de laatste tijd niet altijd even makkelijk voor ons, maar tussen ons was het nooit 
moeilijk. Je laat me lachen (en lacht vooral hard om mij als ik halverwege mijn eigen grap 
alweer dubbel lig), verveelt me nooit (je bent ook niet snel stil) en bent er gewoon voor me 
als het nodig is. Dank je wel. Ik ben trots dat je na de verdediging, hopelijk weer stevig op 
twee benen, naast me staat. Weet dat ik er ook voor jou in die laatste loodjes zal zijn. En ik 
kijk vooral uit naar daarna! Man, wat een tijd zal er over zijn om, zoals het twee geleerde 
personen betaamt, lekker te gaan netflix bingewatchen. 
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Biografie
Isabelle Munsterman werd op 27 oktober 1987 geboren te 
Amstelveen en is de oudste dochter van Winnifred en Bob 
Munsterman. Twee jaar later maakte haar kleine zus Machteld 
het gezin compleet. Tot en met 1995 ging ze naar school in 
Mijdrecht. Hierna verhuisde het gezin naar Apeldoorn, waar 
Isabelle na haar basisschool het stedelijk gymnasium bezocht. 
In 2005 behaalde ze daar haar diploma en besteedde zij een 
‘tussenjaar’ aan de studie ‘Internationale Organisaties en 
Betrekkingen’ te Groningen. In 2006 startte zij haar studie 
geneeskunde aan de Vrije Universiteit te Amsterdam. Dit werd gedurende enkele weken op 
een laag pitje gezet voor vrijwilligerswerk in Nepal, maar in maart 2013 behaalde zij haar 
artsenbul. In juni 2013 begon zij als ANIOS Interne Geneeskunde in het toenmalige Ken-
nemer (nu Spaarne) Gasthuis te Haarlem, waar zij haar vriend Erik van Bommel ontmoette. 
Per 1 juni 2015 ging startte ze haar promotietraject onder leiding van dr. Eric Tjwa en prof. 
dr. Joost Drenth in het Radboudumc. In juli 2018 is zij begonnen met de specialisatie tot 
maag-, darm-, leverarts . Momenteel werkt ze als arts-assistent in het Rijnstate Ziekenhuis 
te Arnhem, waar ze haar vooropleiding interne geneeskunde doet (opleider dr. Louis Rei-
chert). Het is deze stap die zorgde dat zij het Amsterdamse verliet en samen met Erik een 
grote-mensen-huis kocht in het mooie Nijmegen. 
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completed the family. Until 1995 she visited primary school in Mijdrecht, after which 
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